Poročilo RR št. 47 Report No. 47 LJUBLJANA 2008 ISSN 1318-2471 EPIDEMIOLOGIJA IN REGISTER RAKA EPIDEMIOLOGY AND CANCER REGISTRY REGISTER RAKA ZA SLOVENIJO CANCER REGISTRY OF SLOVENIA INCIDENCA RAKA V SLOVENIJI CANCER INCIDENCE IN SLOVENIA REGISTER RAKA ZA SLOVENIJO CANCER REGISTRY OF SLOVENIA EPIDEMIOLOGIJA IN REGISTER RAKA EPIDEMIOLOGY AND CANCER REGISTRY INCIDENCA RAKA V SLOVENIJI CANCER INCIDENCE IN SLOVENIA 02 40 Poročilo RR št. 47 Report No. 47 Ljubljana 2008 ISSN 1318-2471 Uredniški odbor / Editorial Board Maja Primic Žakelj, glavna urednica / editor-in-chief Matej Bračko Marko Hočevar Vera Pompe–Kirn Primož Strojan Vesna Zadnik Branko Zakotnik Tina Žagar Računalniška obdelava / EDP analysis Jurij Modic Vesna Zadnik Tina Žagar Priprava za tisk in tisk / Typesetting and printing Tiskarna Pleško d.o.o. Izdajatelj / Published by Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia Naklada / Published in 500 izvodov / 500 copies Nasvet za citiranje / Recommended reference Incidenca raka v Sloveniji 2005. Ljubljana: Onkološki inštitut Ljubljana, Register raka za Slovenijo, 2008. Cancer Incidence in Slovenia 2005. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Slovenia, 2008. Osebje Registra raka / Staff of the Cancer Registry Maja Primic Žakelj, vodja / head Barbara Babuder, Mojca Brus, Andrej Kirn, Andrej Krašovec, Neža Milčič, Darja Strle, Fani Škrlec, Nataša Šturm, Julij Vertačnik in Tina Žagar Naslov / Correspondence to Register raka za Slovenijo / Cancer Registry of Slovenia Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija Telefon / Phone: + 386 1 5879 450 E-pošta / E-mail: register@onko-i.si Spletna stran / Web site: http://www.onko-i.si/rrs/ http://www.onko-i.si/crs/ Cancer incidence in Slovenia 2005 3 Institute of Oncology Ljubljana, Cancer Registry of Slovenia VSEBINSKO KAZALO / CONTENTS Stran / Page Uvod in pojasnila / Introduction and Comments .......................................................................................................................... 5 Tabela A Breme raka – Slovenija 2005 Table A Cancer burden – Slovenia 2005 .........................................................................................................................................16 Tabela B Prevalenca glede na obdobje opazovanja – Slovenija, 31. 12. 2005 Table B Prevalence by period of observation – Slovenia, December 31, 2005 ........................................................16 Tabela C Stabilnost podatkov – število in odstotek novih primerov raka, prijavljenih po izdaji letnega poročila, po obdobju – Slovenija, 1965–2004 Table C Data stability – number and percentage of new cases reported after the publication of annual reports by time period – Slovenia, 1965–2004 ......................................16 Tabela D Opazovana in napovedana incidenca raka – Slovenija, 1996–2005 in 2008 Table D Observed and predicted cancer incidence – Slovenia, 1996–2005 and 2008 .......................................17 Slike / Figures 1 Najpogostejše lokacije raka po spolu in pri obeh spolih skupaj – Slovenija 2005 The leading cancer sites by sex and for both sexes together – Slovenia, 2005 .......................................18 2 Odstotni delež vseh rakov po starostnih skupinah in spolu – Slovenija 2005 Percentage distribution of all cancer sites by age groups and by sex – Slovenia 2005 .....................19 3 Najpogostejše rakave bolezni po starostnih skupinah in spolu – Slovenija 2001–2005 The leading cancer sites by age groups and by sex – Slovenia 2001–2005 ............................................. 20 4 Groba in kumulativna letna incidenčna stopnja vseh rakov po spolu – Slovenija 1950–2005 Crude and cumulative annual cancer incidence rate for all sites by sex – Slovenia 1950–2005 ................................................................................................................................................................... 22 5 Groba letna incidenčna stopnja izbranih rakov po spolu – Slovenija 1950–2005 Crude annual cancer incidence rate for selected primary sites by sex – Slovenia 1950–2005 ................................................................................................................................................................... 23 6 Vsi raki (C00–C96), moški – Slovenija, 2001–2005 All sites (C00–C96), males – Slovenia, 2001–2005 ......................................................................................................24 7 Vsi raki (C00–C96), ženske – Slovenija, 2001–2005 All sites (C00–C96), females – Slovenia, 2001–2005 ................................................................................................. 25 8 Vsi raki brez nemelanomskih kožnih rakov (C00–C96 brez C44), moški – Slovenija, 2001–2005 All sites, non-melanoma skin cancer excluded (C00–C96, C44 excluded), males – Slovenia, 2001–2005 .................................................................................................................................................................. 26 9 Vsi raki brez nemelanomskih kožnih rakov (C00–C96 brez C44), ženske – Slovenija, 2001–2005 All sites, non-melanoma skin cancer excluded (C00–C96, C44 excluded), females – Slovenia, 2001–2005 ...................................................................................................................................................................27 10 Kumulativno tveganje izbranih rakov do starosti 64 let, 74 let in doživljenjsko po spolu – Slovenija, 2001–2005 Cumulative risk of developing selected cancers till the age 64, 74 and over the entire life-span by sex – Slovenia, 2001–2005............................................................................................................................ 28 11 Pet-letno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 1995–1999 in 2001–2005 po spolu Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 1995–1999 and 2001–2005 by sex ............................................................. 30 4 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabele / Tables 1 Prebivalstvo po starosti in spolu – Slovenija, 30. 06. 2005* Population by age and by sex – Slovenia, June 30, 2005* ................................................................................ 32 2 Prebivalstvo po statističnih regijah in spolu – Slovenija, 30. 06. 2005* Population by statistical regions and by sex – Slovenia, June 30, 2005* ..................................................... 33 3 Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu – Slovenija 2005 Cancer incidence according to basis of diagnosis by site and by sex – Slovenia 2005 ................... 34 4a Incidenca raka po lokaciji (MKB-10), spolu in starosti – Slovenija 2005 Cancer incidence by site (ICD-10), by sex and by age – Slovenia 2005 .................................................... 40 4b Incidenca raka po lokaciji (MKB-8), spolu in starosti – Slovenija 2005 Cancer incidence by site (ICD-8), by sex and by age – Slovenia 2005 ...................................................... 44 5 Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu – Slovenija 2005 Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex – Slovenia 2005 ....................................................................................................................................47 6a Incidenca najpogostejših lokacij raka po statističnih regijah in spolu – Slovenija 2005 Incidence of most frequent cancer sites by statistical regions and by sex – Slovenia 2005 ............ 54 6b Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu – Slovenija 2005 Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex – Slovenia 2005 .................................................................................................................................................. 55 7 Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji – Slovenija 2005 Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site – Slovenia 2005 ..................................................................................................... 56 8 Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti – Slovenija 2005 Incidence of non-Hodgkin´s malignant lymphomas* by site, by sex and by age – Slovenia 2005 ............................................................................................................................................................................... 65 9 Incidenca raka po bolnišnicah ugotovitve diagnoze ter število in odstotek* primerov, napotenih na Onkološki inštitut Ljubljana (OI) – Slovenija 2005 Cancer incidence by reporting hospitals, and number and percentage* of cases referred to the Institute of Oncology Ljubljana (IO) – Slovenia 2005 ................................................................................ 66 10 Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu – Slovenija 2005 Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex – Slovenia 2005 ................................................................................................................................... 68 11 Umrljivost za rakom po lokaciji, spolu in starosti – Slovenija 2005* Mortality by site, by sex and by age – Slovenia 2005* ........................................................................................... 72 12 Prevalenca po spolu in izbrani primarni lokaciji – Slovenija, 31. 12. 2005 Prevalence of cancer patients by sex and by selected primary site – Slovenia, December 31, 2005 ....................................................................................................................................................................77 Izbor publikacij / Selected publications .......................................................................................................................................... 78 Cancer incidence in Slovenia 2005 5 Institute of Oncology Ljubljana, Cancer Registry of Slovenia UVOD Register raka za Slovenijo (Register) je eden najstarejših populacijskih registrov v Evropi. Ustanovljen je bil leta 1950 na Onkološkem inštitutu v Ljubljani kot posebna služba za zbi- ranje in obdelavo podatkov o incidenci raka in preživetju bolnikov z rakom. Pred letom 1950 so bili populacijski registri raka le v Hamburgu, na Danskem in v Veliki Britaniji. Od ustanovitve do leta 1975 je Register vodila pokojna profe- sorica dr. Božena Ravnihar, dolgoletna direkto- rica Onkološkega inštituta. Njeno delo je nato prevzela profesorica dr. Vera Pompe Kirn, ki je do leta 2003 skrbela za nadaljnje uveljavljanje Registra v domačem in mednarodnem merilu. Tega leta je Onkološki inštitut dobil nov statut, ki je združil Register z Enoto za epidemiologijo v enotno službo Epidemiologija in register raka. V njej so poleg Registra še bolnišnični register Onkološkega inštituta, oddelek za epidemio- logijo, kjer tečejo epidemiološke raziskave, in Register organiziranega presejanja za raka materničnega vratu (ZORA) s koordinacijo tega presejalnega programa. Prijavljanje raka je v Republiki Sloveniji obvez- no in zakonsko predpisano že od ustanovitve Registra (Ur. l. SRS, št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS, št. 9/92 in št. 65/00). Zbrani podatki so podlaga za ocenje vanje bremena rakavih bolezni v državi, za načrtovanje in ocenjevanje onkološkega var stva na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabili- tacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvla dovanje rakavih bo- lezni (osebje, medicinska oprema, posteljne zmogljivosti), ter za klinične in epidemiološke raziskave v Sloveniji in v sklopu širših medna- rodnih raziskav. Populacijski register raka opravičuje svoj obstoj, če se zbrani podatki tudi redno obdelujejo, objavljajo in uporabljajo. Ena izmed stalnih oblik vračanja obdelanih informacij so letna poročila. Ker je virov informacij več, je čas, potreben za dokončanje zbirke, povezavo in objavo podatkov pri nas in po svetu daljši, običajno 2 do 3 leta. Sedanje poročilo prikazuje podatke o novih primerih, registriranih v letu INTRODUCTION The Cancer Registry of Slovenia (Registry) is one of the oldest population based registries in Europe. It was founded in 1950 at the Institute of Oncology Ljubljana (Institute) as a special service for collecting and processing data on cancer incidence and cancer patients’ survival. Before 1950, population based regis- tries existed only in Hamburg, Denmark and in Great Britain. From its foundation and until 1975, the Registry was headed by the late Pro- fessor Božena Ravnihar who was also director general of the Institute for almost 20 years. At the Registry she was succeeded by Professor Vera Pompe-Kirn, who carried on her work until 2003 and contributed a lot to the further development of the Registry as well as its recognition at the national and international level. In 2003, a new Statue was adopted by the Institute that enacted the merging of the Reg- istry and Epidemiology Unit in a single service, Epidemiology and Cancer Registry. The new service comprises, besides Cancer Registry of Slovenia, also the hospital-based Cancer Registry of the Institute, Epidemiology Unit for epidemiologic studies and Cervical Cancer Screening Registry (ZORA), a unit that is also in charge of coordinating the nationally organ- ised cervical cancer screening programme. Notification of cancer has been compulsory in Slovenia since the foundation of the Registry and prescribed by law (Official Gazette of SRS, No. 10/50, No. 29/50, No. 14/65, No. 1/80, No. 45/82, No. 42/85; Official Gazette of RS, No. 9/92 and No. 65/00). The data collected serve as the basis for assessing the cancer burden in the country, for programming and evaluating primary prevention, diagnosis, treatment and rehabilitation, planning facilities and fund- ing needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies. The existence of a population-based cancer registry is justified only by regular processing, publishing and using the data collected. The Registry’s Annual Reports are one of the regular ways of disseminating information. Because 6 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo 2005. Za osnovno informacijo o tem, kakšno incidenco pričakujemo leta 2008, dodajamo s posebno statistično metodo ocenjeno napo- ved za leto 2008. Register je prva letna poročila izdajal že v letih 1953–1957 za leta 1951–1955. Prva anali- za podatkov za leto 1950 je bila objavljena v Zdravstvenem vestniku leta 1951. Podatki za leta 1957–1971 so bili objavljani v periodičnih publikacijah Svetovne zdravstvene organizacije Epidemiological and Vital Statistics in v World Health Statistics Report. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom Rak v Sloveniji (1965–1977) in Incidenca raka v Sloveniji (1978–2003), in sicer v slovenskem in angleškem jeziku. Za vsebino publikacije skrbi uredniški odbor, v katerem smo zbrani specialisti raznih vej onkologije. Glede na želje in pripombe uporabnikov letna poročila iz leta v leto dopolnjujemo, hkrati pa poskrbimo, da ostajajo objavljeni podatki primerljivi. Incidenca raka je po svetu zelo različna, za raziskovanje teh razlik pa so ključni kakovostni podatki. Prav zato so bili in so naši podatki o incidenci raka zanimivi tudi za svet. Leta 1957 je izšlo prvo obsežnejše poročilo za leta 1950–1955 v angleščini. Podatke za leta 1956–60, 1961–65, 1968–72, 1973–76, 1978–81, 1982–87, 1988–92 in 1993–97 so objavili tudi v vseh osmih zvezkih knjige Cancer Incidence in Five Continents, ki jo izdaja Mednarodna agencija za raziskovanje raka. Podatki o incidenci in umrljivosti za rakom so vključeni tudi v mednarodne podatkovne baze EUROCIM, GLOBOCAN, ACCIS, preživetje slovenskih bolnikov pa je obdelano v medna- rodnih študijah EUROCARE II, EUROCARE III in EUROCARE IV. Zbrane podatke v Registru obdelujemo in pojasnjujemo v skladu s trenutno perečo pro- blematiko v Sloveniji, z lastnim raziskovalnim programom in s predlogi uporabnikov. Izsledke objavljamo v člankih v domačem in tujem strokovnem in poljudnem tisku. Izdane so tudi tri knjige: Zemljevidi incidence raka v Slove- niji 1978–1987, Preživetje bolnikov z rakom v Sloveniji 1963–1990 in Preživetje bolnikov z rakom v Sloveniji 1983–1997. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila. of a variety of data sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usu- ally takes two to three years. As preliminary information on expected incidence in 2008, predicted numbers and rates are presented in this report. The first annual reports of the Registry for the period 1951−1955 were issued during the years 1953−1957. The first data analysis for the year 1950 was published in Zdravstveni vestnik in 1951. The data for the period 1957−1971 were appearing in the periodicals Epidemiological and Vital Statistics Report and World Health Statistics Report, both edited by World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi- lingual (Slovene-English) annual reports, first en- titled Cancer in Slovenia (1965−1977), and then Cancer Incidence in Slovenia (1978−2003). The editorial board, responsible for the contents of the report, consists of experts of different specialties in oncology. Our endeavours have always been directed towards further improve- ment of these publications, by taking into ac- count as much the requests and comments of the users as the comparability of the data from year to year. There are great differences in cancer inci- dence among different populations and to evaluate them, good quality data are needed from different parts of the world. That is why our data on cancer incidence have always been interesting also for professional public abroad. In 1957, the first comprehensive report, cover- ing the period 1950−1955, was issued in English under the title Cancer in Slovenia 1955. The data for the periods 1956−60, 1961−65, 1968−72, 1973−76, 1978−81, 1982−87, 1988−92 and 1993−97 were published in all eight volumes of the Cancer Incidence in Five Continents issued by International Agency for Research on Cancer. The data on cancer incidence and mortality are also included in international databases EUROCIM, GLOBOCAN, ACCIS. The survival of Slovenian cancer patients is analysed in the international studies EUROCARE II, EUROCARE III and EUROCARE IV. The data collected have been processed in accordance with the current problems in Cancer incidence in Slovenia 2005 7 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Letošnje poročilo je v celoti dostopno v elektron- ski obliki na spletni strani Onkološkega inštituta Ljubljana: http://www.onko-i.si/rrs. GRADIVO IN METODE Osnovni vir podatkov so prijavnice rakave bolezni. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordina- cij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje. Dodatni vir po- datkov so zdravniška poročila o vzroku smrti in obdukcijski zapisniki z diagnozo maligne bolezni. Zbiranje podatkov za to letno poročilo smo zaključili 15. februarja 2008. Zanesljivost podatkov osvetljujeta dva kazal- ca: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež raka, registriranega samo iz zdravniških poročil o vzroku smrti (tabela 3). Majhen delež primerov, prijavljenih po izdaji letnega poročila v raznih časovnih obdobjih kaže, da do izdaje poročila registriramo večino novih primerov raka (tabela C). Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrira- le le spremembe, označene v tabelah s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepiteljiske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1995 registriramo tudi prijavljene intraepi- telijske karcinome mehurja in maligne mela- nome Clark I. Za razvrščanje neoplazem po lokacijah Register od leta 1997 uporablja 10. revizijo Mednarodne Slovenia, as well as with respect to our research program and suggestions from our users. These data are published in national and foreign medical literature and as publications for lay readers. Three special publications are Atlas of Cancer Incidence in Slovenia 1978−1987, Cancer Patients’ Survival in Slovenia 1963−1990 and Cancer Patients’ Survival in Slovenia 1983−1997. The list of other relevant publications in last five years is at the end of this report. The current annual report is available in pdf format on website of the Institute of Oncology Ljubljana: http://www.onko-i.si/crs. MATERIAL AND METHODS The main sources of data are notifications gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the pa- tient was not referred for further diagnostic investigations and/or treatment. This informa- tion is completed by death certificates and autopsy protocols stating cancer diagnosis. The collection of data for the current report was completed on February 15, 2008. The reliability of information can be assessed by two parameters: the percentage of mi- croscopically (histologically or cytologically) confirmed cases and by the percentage of cancer cases registered on the basis of death certificates only (Table 3). The small and sta- ble proportion of cases registered after the publication of annual reports shows that the majority of cases are reported to the Registry by the time of the publication of annual re- ports (Table C). In 1993, compulsory registration of all cervical intraepithelial dysplasias classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961−1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1995, the number of all reported intraepithelial carcinomas of the bladder and all malignant melanomas Clark I have been registered. 8 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo klasifikacije bolezni, poškodb in vzrokov smrti, do takrat pa je uporabljal osmo. Za vse, ki želijo primerjati podatke iz prejšnjih poročil, je dodana tabela 4b. Klasifikaciji različno uvrščata bolezni med maligne, zato število novih primerov raka po obeh klasifikacijah ni enako. Prav pri uvrščanju med maligne bolezni je tre- ba opozoriti še na klasifikacijo za morfologijo neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onko- logijo, od poročila za leto 2001 tretjo izdajo. V tej izdaji je spet nekaj sprememb, tudi katere histološke vrste sodijo med maligne. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7). V skla- du z novimi pravili tudi mejno malignih ovarijskih tumorjev ne uvrščamo več v kategorijo C56, pač pa v D39.1. Opozarjamo še, da so v tabeli 7 histološke vrste razvrščene po tretji reviziji morfološkega dela Mednarodne klasifikacije bolezni za onkologijo in združene v drugačne skupine kot v poročilih za leto 2000 in leta pred njim. V tabeli 6 smo do letnega poročila 2002 prika- zovali podatke po devetih zdravstvenih regijah. V skladu z Uredbo o standardni klasifikaciji te- ritorialnih enot – SKTE, ki predpisuje sistematiko členitve ozemlja Slovenije na 11 ravneh, smo se odločili, da v tej tabeli in regijskih primerjavah uporabimo raven SKTE-3, 12 statističnih regij. Podatke pa še vedno lahko preuredimo do ravni upravnih enot. Za napoved incidence v letu 2008 je uporablje- na metoda po Dybi in Hakulinenu, ki je primerna za oceno incidence v krajšem časovnem ob- dobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih pa je treba upoštevati tudi vpliv rojstne kohorte. DEFINICIJE Incidenca pomeni število vseh v enem koledar- skem letu na novo ugotovljenih primerov raka v točno določeni populaciji. V incidenco ne Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related health Problems (ICD-10); before, the 8th revision was used (ICD-8). As in earlier reports, Table 4b contains also the data coded according to the 8th revision in order to allow the comparison with the earlier reports. There are differences in coding neoplasms as malignant or benign according to both classifications, so, accord- ing to the two classifications, the number of new cancer cases is not equal. When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology is used in the current annual report. In this edition, some changes were introduced in terms of morphology and behaviour code. According to this classifica- tion, chronic myeloproliferative disorders and myelodisplastic syndromes are classified as malignant (topography code C96.7), while ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). It should be noted that in Table 7 the morphol- ogy codes are grouped in different catego- ries as in reports 2000 and previous and are adapted to the third revision of morphology part of International Classification of Diseases for Oncology. Till Annual Report 2002, the data in Table 6 have been presented by 9 health regions. The new law on regional division of Slovenia introduced the system of eleven levels. So, 12 statistical regions have been chosen to present the data in Table 6. The method by Dyba and Hakulinen was used for predictions of incidence in 2008. It is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long- term predictions the cohort effect should be included also. DEFINITIONS Incidence is the number of newly diagnosed cancer cases in a defined population, reported to the Registry for a given calendar year. New Cancer incidence in Slovenia 2005 9 Institute of Oncology Ljubljana, Cancer Registry of Slovenia štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije, ne glede na to, kje so bili ti bolniki zdravljeni. Prevalenca je število vseh živih bolnikov z rakom na določen datum ne glede na leto dia gnoze. Groba incidenčna stopnja je število novih pri- merov na 100.000 oseb opazovane populacije; starostno specifična stopnja pove to relativno število v posamezni petletni starostni skupini. Če analiziramo incidenco v daljšem časovnem obdobju (če se starostna struktura prebivalstva v času spreminja) ali če primerjamo incidenco med populacijami z različno starostno struktu- ro, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije enaka starostni strukturi v standardni populaciji. Na slikah 6 do 9 smo za verodostojnejšo primerjavo incidenčnih in umrljivostnih stopenj z državami v Evropi ali po svetu pri neposredni metodi starostne standar- dizacije uporabili svetovni standard, v tabeli 6b pa je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami za standard uporabljena starostna struktura prebivalcev Slovenije ob popisu leta 2002. Kumulativna incidenčna stopnja (KS) (v za- dnjem stolpcu tabele 5) je petkratna vsota starostno specifičnih incidenčnih stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je pose- ben primer neposredne starostne standardi- zacije, kjer je standardna populacija v vseh starostnih skupinah enaka, zato vrednost ni odvisna od izbora standarda. Kumulativno incidenčno stopnjo smo uporabili tudi za prikaz časovnega trenda incidence v spodnjem delu slike 4. Primerjava z obliko krivulje grobe incidenčne stopnje (zgornji del slike 4) kaže, da povečevanja incidence raka ne moremo primary cancers of the same histology in paired organs, e. g. on the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology ap- pearing in the same organ, e.g. multiple lesions of the colon. The incidence includes only the data on patients with permanent residence in Slovenia, regardless of the place of treatment. Prevalence is the number of all surviving cancer patients, irrespective of the year of diagnosis. Crude incidence rate is the number of new cases per 100,000 population, while the age specific rate expresses this relative number in an individual five-year age group. When analysing the incidence rate within longer time period (if the age structure of popu- lation changes) or comparing the incidence between populations with different age struc- ture, age standardisation is needed to adjust the rate for the effect of age. The age-stand- ardised rate is a theoretical incidence rate as- suming that the age structure in the observed population is the same as in the standard population. In Figures 6−9, the World standard population was used in direct standardisation for better comparison of Slovenian data with those from other countries in the World, while in Table 6b the standard is age structure of Slovenian 2002 census population. The cumulative incidence rate (the last column in Table 5) is five times the sum of the age- specific incidence rates over five-year age groups up to the age of 74 years, calculated per 100 population. The cumulative rate can be interpreted as a form of direct age-stand- ardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4. The comparison to the curves of crude incidence per 100,000 popu- lation (upper part of Figure 4) indicates that the increasing cancer incidence rate in both sexes cannot be attributed only to the aging of Slovenian population, but also to additional risk factors. The cumulative risk (presented on Figures 6-10) is the risk an individual would have of develop- 10 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo pripisati le staranju prebivalstva v Sloveniji, ampak da k rasti incidence prispevajo še drugi nevarnostni dejavniki. Kumulativno tveganje (KT) (prikazano na slikah 6 do 10) je verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je kumulativna incidenčna stopnja manjša kot 10/100, jo lahko uporabi- mo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: KT = 100 (1 – e-KS/100). Kumulativno incidenčno stopnjo raka dojk pri ženskah 7,1/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 7,1–odstotno. To pomeni oceno, da bo 7,1 % deklic, rojenih leta 2005, (ali približno ena od 14) do 74. leta starosti verjetno zbolelo za rakom dojk. Relativno preživetje pomeni razmerje med opazovanim preživetjem proučevane skupine in preživetjem, ki bi ga pričakovali pri enako stari skupini istega spola v slovenski populaciji. Je približek preživetja bolnikov v primeru, da bi upoštevali kot vzrok smrti samo izbranega raka. Izračunano je s paketom relsurv v programu R. POJASNILA Tabeli A, B in slika 1 prikazujejo osnovne po- datke o bremenu raka v Sloveniji: število vseh zbolelih in umrlih za rakom v letu 2005, pre- valenco in najpogostejše rakave bolezni po spolu in pri obeh spolih skupaj. V letu 2005 je pri moških prvič doslej največ raka prostate in ne več pljučnega. V tabeli D je prikazana incidenca in povprečna letna incidenčna stopnja vseh in izbranih rakov v dveh 5-letnih obdobjih 1996–2000 in 2001–2005. Pomemb- ne so napovedane vrednosti za leto 2008 s 95-odstotnim napovednim intervalom. Sliki 2 in 3 opozarjata na različno breme raka v raznih življenjskih obdobjih. Rak je skoraj izjema pri mladih do 19 let; če pa zbolijo, najpogosteje zbolijo za levkemijo. Manj kot 3 % vseh rakov je med 20. in 34. letom starosti, ko je pri moških ing the disease in question during a certain age period if no other causes of death were in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated according to the following formula: CR = 100 (1 – e-KS/100). For example, the cumulative risk (0−74) of 7.1/100 for breast cancer in females means that 7.1% of women born in 2005 (approximately each l4th woman) are expected to develop breast cancer by their age of 75 in the absence of any other cause of death. Relative survival is the ratio of the observed actual survival and the survival in same obser- vation period, expected in general population of Slovenia with respect to age and sex. It is approximation of cancer cause specific sur- vival. It has been calculated with the package relsurv in the programme R. COMMENTS Tables A and B and Figure 1 present the ba- sic data on cancer burden in Slovenia: the number of new, deceased and prevalent cancer patients in 2005 and the most frequent cancer sites by sex and both sexes combined. In Table D, incidence and average crude inci- dence rate in two 5-year periods (1996−2000 and 2001−2005) is presented together with predicted values for 2008 with 95% predic- tion interval. Figures 2 and 3 point to the different propor- tion of cancer in different age groups; cancer is more an exception till the age of 19, with leukaemia being the most frequent cancer. Less than 3% of all cancer is in the age group 20−34, where the most frequent is testicular cancer in males and cervical in females. Lung Cancer incidence in Slovenia 2005 11 Institute of Oncology Ljubljana, Cancer Registry of Slovenia najpogostejši rak mod, pri ženskah pa rak materničnega vratu. Pljučni rak pri moških in rak dojk pri ženskah sta na prvem mestu med 35. in 69. letom starosti, po 70. letu pa pri moških vodi rak prostate, pri ženskah pa kožni rak. Več kot tri četrtine vseh rakov je pri bolnikih, starejših od 50 let. Medtem ko med 35. in 49. letom zboli za rakom nekaj več žensk kot moških, se med 50. in 74. letom to razmerje obrne; delež zbolelih je spet večji med ženskami po 75. letu starosti, tudi zato, ker je njihova pričakovana življenjska doba daljša. Sliki 4 in 5 kažeta trend incidence vseh in iz- branih rakov po spolu. Pri grafičnih prikazih so v eno skupino združeni rak debelega črevesa in danke in v drugo rak ust, žrela in grla (glava in vrat). Na slikah 6 in 7 so pomembnejši epidemiološki podatki o vseh rakavih boleznih skupaj, ločeno za moške in ženske. Za verodostojnejšo pri- merjavo incidenčnih in umrljivostnih stopenj z državami v Evropi ali po svetu smo pri neposre- dni metodi starostne standardizacije uporabili svetovni standard. Ker je v tem standardu delež starejšega prebivalstva relativno manjši kot v slo- venskem prebivalstvu, so te stopnje večinoma manjše od grobih. Za razliko od lanskega let- nega poročila smo tokrat namesto kumulativ- ne stopnje objavili kumulativno tveganje. Na slikah 8 in 9 smo prikazali iste epidemiološke podatke o raku, vendar brez nemelanomskih kožnih rakov (C44 po MKB-10), da je lažja pri- merjava s tistimi registri raka, ki tega raka ne registrirajo. Razlike so predvsem pri relativnem 5-letnem preživetju, ki je v tem primeru manjše, saj ne upoštevamo bolnikov z nemelanomskim kožnim rakom, pri katerih je bolezen večinoma odkrita v omejenem stadiju. Slika 10 prikazuje kumulativno tveganje izbra- nih rakov do starosti 64 let, 74 let in dosmrtno, ločeno za moške in ženske. Da je rak izrazito bolezen starejših, lahko vidimo že na sliki 2. Skoraj 17 % moških bo verjetno zbolelo za eno od rakavih bolezni do 64. leta starosti in kar 54 % do konca svojega življenja. Pri ženskah je ogroženost malo manjša; dobrih 15 % jih bo verjetno zbolelo do 64. leta starosti in 38 % do konca svojega življenja. Razlike so tudi med posameznimi raki; kumulativno tveganje raka in males and breast in females are the most frequent cancer sites in the age group 35−69; after the age of 70, in males prostate is the most frequent cancer site while non-melanoma skin is in females. More than three quarters of all cancer cases occur in patients older than 50 years. The proportion of new cancer patients is a bit higher among females in the age group 35−49, while this ratio is reversed between the age of 50−74 years. After the age of 75, there is again a higher proportion of cancer among females, also because of their longer life expectancy. Figures 4 and 5 show the incidence trends for all and selected cancers by sex. In graphical presentations, colon and rectal cancers are grouped in one category as colorectal, as well as oral, pharyngeal and laryngeal cancers as head and neck. Figures 6 and 7 show some important epide- miological data on all cancers combined. In these figures, direct age standardization using the World standard population was applied for valid comparison of incidence and mortality rates with other countries. As in this standard, the proportion of older population is relatively smaller as in Slovenian population, these rates are in general lower than the crude ones. there Cumulative risks and not rates are presented this year. In Figures 8 and 9 there is the same epidemiological summary for all sites with non-melanoma skin cancer excluded (C44 according to ICD-10) for easier comparison with those cancer registries who do not register non-melanoma skin cancer at all. 5-year rela- tive survival is much lower in this case which is mainly due to the difference in survival of non-melanoma skin cancer patients since their illness is generally discovered in localized stage having good prognosis. Figure 10 shows cumulative risk of developing selected cancers between the ages of 0-64, 0-74 and over the entire life-span. One can see already from Figure 2 that cancer is a disease of the elderly. About 17% of all men are at risk of being diagnosed with cancer before their 65 birthday but almost 54% during their entire life-span. Females have somehow lower probabilities; more than 15% are at risk of being diagnosed with cancer till their age 12 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo prostate in nemelanomskega kožnega raka (oba spola) se veča s starostjo, medtem ko se kumulativno tveganje ne spreminja veliko po 65. letu starosti pri raku mod in raku materničnega vratu. Slika 11 prikazuje relativno 5-letno preživetje bolnikov z vsemi in izbranimi raki, zbolelih v letih 2001–2005. Za primerjavo so dodani po- datki o bolnikih, zbolelih v letih 1995–1999. Pri moških se je skupno preživetje povečalo za 9 %, delno tudi na račun boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je pri tej bolezni preživetje navidezno večje kar za 16 %. Za 11 % boljše preživetje bolnikov z rakom debelega črevesa je gotovo realno in je posledica boljšega odkri- vanja bolezni, večje kakovosti zdravljenja in več sistemskega zdravljenja. Pri ženskah je skupno preživetje večje za 5 %. Tudi pri njih je za 9 % boljše preživetje pri bolnicah z rakom debelega črevesa, za 8 % pa se je izboljšalo preživetje bolnic z rakom dojk. Tabele prikazujejo podatke o prebivalcih in incidenci raka v Sloveniji leta 2005 po spolu, starosti, lokaciji, histološki vrsti in stadiju bolezni ob diagnozi, o incidenci po statističnih regijah ter podatke o številu novih primerov raka, ugo- tovljenih v tem letu po posameznih bolnišnicah, število smrti za rakom po spolu, starosti in lokaciji ter prevalenco najpogostejših rakov. V tabeli 3 prikazujemo, na kakšen način je bila postavljena diagnoza pri registriranih novih primerih raka. Od 10.720 leta 2005 na novo registriranih primerov raka je bila pri 93,5 % diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,8 % z drugimi preiskavami, 0,7 % primerov pa smo registrirali samo na osnovi zdravniškega poročila o vzroku smrti. Ta, zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Kakšna je bila morfološka slika malignomov pri 10.024 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže tabela 7. V njej so posebej primeri, ki so potrjeni histološko (91,5 %), in tisti, ki so bili potrjeni samo citološko (8,5 %). Po 8. reviziji MKB, po kateri so raki razvrščeni v tabeli 4b, je novih primerov raka 10.612. Razlika of 64 and 38% in their entire life. However, there are big differences between cancer sites; cumulative risk is increasing with age for prostate and non-melanoma skin cancer (in both sexes), but cumulative risk is not changing much after 65 year of age for testicular and cervical cancer. In Figure 11, 5-year relative survival of all and selected cancer sites in patients diagnosed in 2001−2005 is presented along with the same survival in patients, diagnosed in 1995−1999. In all male cancer patients the relative five-year survival increased for 9%, partially also due to better registration of prostate cancer cases with less advanced stage at diagnosis, who have better prognosis; in these patients the 5-year relative survival increased (spuriously) for 16 %. 11% better 5-year relative survival of colorectal cancer patients is real, reflecting earlier diagnosis and better surgical and medi- cal oncology treatment. In all female cancer patients the 5-year relative survival increased for 5%. In colon cancer patients the relative survival increased for 9% and in breast cancer patients for 8%. Tables show the data on population and on cancer incidence in Slovenia in 2005 by sex, age, primary site, histology, stage of the disease at diagnosis, on the incidence in the individual statistical regions, and on new cancer cases diagnosed in the current year in different hospi- tals in Slovenia, on deaths and on prevalence of most frequent cancer sites. In Table 3, data on basis of diagnosis of new cancer cases that were registered in 2005 are presented. From 10,720 new cancer cases, in 93.5% the diagnosis was confirmed microscopi- cally (by histology or cytology), in 5.8% with other investigations and 0.7% was registered from death certificate only. This letter percent- age has been similar for several years and rep- resents those patients that, due to advanced age or disease have not been treated in the hospital. The morphology of tumours in 10,024 cases, diagnosed microscopically, is presented in Table 7. In this table, cases confirmed by histology (91.5%) and by cytology only (8.5%) are presented separately. In Table 4b, the diagnoses are coded accord- ing to the 8th revision of International Classifica- Cancer incidence in Slovenia 2005 13 Institute of Oncology Ljubljana, Cancer Registry of Slovenia 108 primerov je posledica novega razvrščanja neoplazem glede na tretjo izdajo morfološkega dela Mednarodne klasifikacije bolezni za onko- logijo. Tabela 5 prikazuje grobo in starostno specifično incidenčno stopnjo na 100.000 prebivalcev ter kumulativno stopnjo na 100. Število vseh novih primerov raka iz leta 2005 je preračunano na število prebivalcev Republike Slovenije na dan 30. junija 2005. V tabeli 6a je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Te številke so pomembne za načrtovanje zdra- vstvenih zmogljivosti. Starostno standardizirane incidenčne stopnje (tabela 6b) kažejo, da je velik del razlik med regijami posledica različne starostne strukture njihovih prebivalcev, pred- vsem v različnem deležu starejših. Tabela 8 kaže starostno porazdelitev ekstra- nodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekstranodal- nih lokacij majhno, so prikazane le absolutne številke. Iz tabele 9 je razvidno, kje vse so bolnikom postavili diagnozo. Tako kot že vrsto let polo- vica vseh bolnikov z rakom, ki jim diagnozo postavijo v slovenskih bolnišnicah ali jih tam tudi začnejo zdraviti, v nadaljnjem poteku bolezni pride na posvet ali zdravljenje na Onkološki inštitut Ljubljana. Tabela 10 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Upo- rabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo; če bolnik ni bil poprej zdravljen, tudi obdukcijo. Uporabljamo in navajamo jo zato, ker so podatki o stadiju bolezni po klasifika- ciji TNM na prijavnicah pogosto pomanjkljivi. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je razvrščena bolezen, kjer je tumor označen kot Tl in T2 (razen pri dojki, ma- lignem melanomu in ščitnici, kjer so vključeni tudi tumorji T3, in materničnem vratu, telesu in sarkomih, kjer so vključeni le tumorji T1) in pri kateri niso prizadete regionalne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je bolezen, kjer je tion of Diseases. According to this classification, 10,612 new cancer cases were registered. The difference of 108 cases is due to new morphology classification of the third revision of International Classification of Diseases for Oncology. Table 5 shows crude and age specific incidence rate per 100,000 population and cumulative rate per 100. For calculation of crude rate, the Slo- venian population on June 30, 2005 was used. In Table 6a, the number of new cases of all and selected cancer sites by different statisti- cal regions is presented. While these data are important for planning health care facilities, the age standardised rates in Table 6b indi- cate, that the majority of these differences are due to different age structure of population in these regions. Age distribution of extranodal and nodal sites of non-Hodgkin malignant lymphomas is pre- sented in Table 8. Owing to a small number of extranodal sites, only the absolute numbers are given. From Table 9 it is evident, in which hospitals cancer cases are diagnosed. Observations of many years show that half of the patients diagnosed or initially treated in regional hos- pitals are later on referred to the Institute of Oncology Ljubljana. A simplified definition of stages at diagnosis is presented in Table 10. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is consid- ered as well. The simplified stage definition is used because, in cancer notification forms, the data on stage according to TNM Classifi- cation System are often lacking. However in solid tumours, the simplified stage definition often follows the TNM Classification. Localised stage includes all cancers where the tumour has been classified as T1 and T2 (except in breast, malignant melanoma and thyroid cancer, where T3 is also included, and uterine cervix, uterine corpus and sarcomas, where T1 only is included), where neither regional node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (exceptions 14 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo tumor opredeljen kot T3 in T4 (razen v omenje- nih izjemah) in/ali so prizadete tudi regionalne bezgavke (N1), zasevkov v oddaljenih bezga- vkah in organih pa ni (M0). V stadiju oddaljene razširitve pa je tista bolezen, pri kateri so zasevki že v oddaljenih bezgavkah ali organih (M1). Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor. V tabeli 11 so uradni podatki o umrljivosti za rakom v letu 2005. Tabelo so pripravili na Inštitutu za varovanje zdravja RS. Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2005. ZAHVALA Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdrav- stvenih ustanov so Registru pošiljali prijavnice s podatki o novih bolnikih z rakom in njihovi nadaljnji usodi ter nam pomagali dopolniti prijave z manjkajočimi informacijami. Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič. Naše delo bi bilo bistveno težje brez dolgo- letnega sodelovanja s Centralnim registrom prebivalstva RS, Inštitutom za varovanje zdravja RS in Statističnim uradom RS. Vsem imenovanim in tudi drugim, ki so kakorko- li prispevali k temu poročilu, se najlepše zahvaljujemo. Uredniški odbor already mentioned) and/or regional node metastases (N1), if no metastases in distant lymph nodes or organs (M0) are found. The disease with metastases in distant nodes or organs is classified as the remote stage (M1). Malignant lymphomas are classified accord- ing to Ann-Arbor System. Official data on cancer mortality in 2005 are given in Table 11. The table has been prepared at the Institute of Public Health of the Republic of Slovenia. Data on prevalence of all and most frequent cancers on December 31, 2005 are presented in Table 12. ACKNOWLEDGEMENT Physicians, nurses, and administrative staff from Slovenian hospitals and other health institu- tions have provided the data on new cancer patients and their medical history as well as helped us in obtaining additional information when needed. Our co-workers at the Hospital Registry of the Institute of Oncology Ljubljana, Ana Dotzauer and Maruška Ferjančič have contributed at least a half of the information presented in this report. The long-term collaboration with the Population Registry of the Republic of Slovenia, the Institute of Public Health of the Republic of Slovenia and the Statistical Office of the Republic of Slovenia is indispensable for our work. We thank all of them as well as to all others who have contributed and enabled us to present the results of our work in this report. Editors Cancer incidence in Slovenia 2005 15 Institute of Oncology Ljubljana, Cancer Registry of Slovenia – Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. Zdrav Vestn 1951; 20: 264–77. – Epidemiological and Vital Statistics Report. Geneva: World Health Organization, 1961–1966. – World Health Statistics Report. Geneva: World Health Organization, 1970–1974. – Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980. – Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onko loški inštitut, Register raka za Slovenijo, 1981–2004. – Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966. – Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970. – Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15). – Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42). – Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88). – Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120). – Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143). – Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155). – European Network of Cancer Registries. EUROCIM version 4.0. European incidence database V2.4, ICD- 10 dictionary (2003), Lyon 2001. – Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence world- wide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press, 2004. – Steliarova-Foucher E, Berrino F, Coebergh JW et al. ACCISpass 1.01 software for analysis and presenta- tion of data on incidence and survival of children and adolescents in Europe. Lyon: ENCR, 2002. – Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCARE-2 study. Lyon: International Agency for Research on Cancer, 1999. – Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003: 14 (Suppl 5). – Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCARE-IV Study. Lancet Oncol 2007; 8: 773–83. – Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of Cancer Incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992. – Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer Patients’ Survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995. – Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolni- kov z rakom v Sloveniji 1983–1997 (Cancer Patients’ Survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003. – Savezni zavod za zdravstvenu zaštitu. Međunarodna klasifikacija bolesti, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstvenu zaštitu, 1970. – Inštitut za varovanje zdravja RS. Mednarodna klasi- fikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International Statistical Classification of Diseaseses and Related health Problems). Ljubljana: Inštitut za varovanje zdrav ja, 1995. – World Health Organisation. International Calssification of Diseases for Oncology. Geneva: World Health Organisation, 2000. – Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000. – Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751–66. – Jensen OM, Parkin M et al, eds. Cancer registration principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95). – Statistični letopis republike Slovenije 2004. Ljubljana: Statistični urad Republike Slovenije, 2005. – Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Monogr Natl Cancer Inst 1961; 6: 101–21. – Hakulinen T. Cancer survival corrected for hetero- geneity in patient withdrawal. Biometrics 1982; 38: 933–42. – Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272–8. REFERENCE / References 16 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela A. Breme raka – Slovenija 2005 Table A. Cancer burden – Slovenia 2005 Skupaj Moški Ženske Total Males Females Incidenca 10720 5455 5265 Incidence Umrljivost 5119 2814 2305 Mortality Prevalenca 63561 25550 38011 Prevalence Tabela B. Prevalenca glede na obdobje opazovanja – Slovenija, 31. 12. 2005 Table B. Prevalence by period of observation – Slovenia, December 31, 2005 Od tega izgubljenih Lost to follow-up Obdobje Število bolnikov Število Odstotek Period Number of patients Number Percentage 1950–2005 63558 1977 3,1 1966–2005 61895 1053 1,7 1976–2005 59727 588 1,0 1986–2005 59568 184 0,3 1996–2005 41990 53 0,1 Tabela C. Stabilnost podatkov – število in odstotek novih primerov raka, prijavljenih po izdaji letnega poročila, po obdobju – Slovenija, 1965–2004 Table C. Data stability – number and percentage of new cases reported after the publication of annual reports by time period – Slovenia, 1965–2004 Naknadno prijavljeni Subsequently registered Obdobje Letno poročilo 25. 2. 2008 Število Odstotek Period Annual report 25 February 2008 Number Percentage 1965–68 14696 14842 146 1,0 1969–72 15719 16170 451 2,9 1973–76 17711 18276 565 3,2 1977–80 19176 19896 720 3,7 1981–84 20701 21416 715 3,4 1985–88 22715 23379 664 2,9 1989–92 25973 26709 736 2,8 1993–96 29141 30467 1326 4,5 1997–00 33859 35377 1518 4,5 2001–04 39036 40416 1380 3,5 Cancer incidence in Slovenia 2005 17 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela D. Opazovana in napovedana incidenca raka – Slovenija, 1996–2005 in 2008 Table D. Observed and predicted cancer incidence – Slovenia, 1996–2005 and 2008 Šifra MKB Primarna lokacija Spol Povprečne letne opazovane vrednosti 1996–2000 Povprečne letne opazovane vrednosti 2001–2005 Napoved za 2008 Število Incidenčna stopnja na 100.000 Število Incidenčna stopnja na 100.000 Število (95 % napovedni interval) Incidenčna stopnja na 100.000 (95 % napovedni interval) ICD code Primary site Sex Average ann. observed values 1996–2000 Average ann. observed values 2001–2005 Prediction for 2008 Number Incidence rate per 100,000 Number Incidence rate per 100,000 Number (95% prediction interval) Incidence rate per 100,000 (95% prediction interval) C00 – C96 Vse lokacije All sites M + Ž 8631 435,4 10227 512,2 11738 11335–12141 582 562–602 M 4387 456,5 5243 536,7 6075 5869–6282 611 590–631 Ž 4244 415,6 4984 488,8 5663 5467–5860 553 534–572 C00 Usta in žrelo M 265 27,5 255 26,2 245 204–286 25 21–29 –C14 Mouth and pharynx Ž 48 4,7 63 6,2 79 57–102 8 6–10 C15 Požiralnik M 75 7,8 77 7,9 75 52–98 8 5–10 Oesophagus Ž 16 1,5 18 1,7 19 7–31 2 1–3 C16 Želodec M 294 30,6 293 30,0 291 246–337 29 25–34 Stomach Ž 191 18,7 184 18,1 181 145–217 18 14–21 C18 Debelo črevo M 293 30,5 364 37,3 430 375–484 43 38–39 Colon Ž 261 25,5 308 30,2 336 288–384 33 28–38 C19 Rektum in rektosigmoidna zveza M 261 27,2 317 32,4 362 311–413 36 31–42 –C20 Rectum and rectosigmoid junction Ž 200 19,6 222 21,7 243 202–285 24 20–28 C22 Jetra in intrahepatični vodi M 71 7,4 92 9,4 112 83–141 11 8–14 Liver and intrahepatic bile ducts Ž 36 3,5 41 4,0 48 9–87 5 1–9 C23 Žolčnik in žolčevodi M 48 5,0 52 5,3 66 45–88 7 5–9 –C24 Gallbladder and billiary tract Ž 82 8,1 82 8,0 92 65–118 9 6–12 C25 Trebušna slinavka M 99 10,3 122 12,5 137 106–168 14 11–17 Pancreas Ž 115 11,3 137 13,5 148 117–180 15 11–18 C32 Grlo M 100 10,4 97 9,9 93 68–119 9 7–12 Larynx Ž 11 1,0 12 1,1 13 3–23 1 0–2 C33 Sapnik, sapnici in pljuča M 824 85,7 851 87,0 874 794–954 88 80–96 –C34 Trachea, bronchus and lung Ž 208 20,4 281 27,6 346 299–394 34 29–38 C43 Maligni melanom kože M 106 11,0 142 14,5 179 144–213 18 15–22 Malignant melanoma of skin Ž 120 11,8 166 16,3 208 172–244 20 17–24 C44 Druge maligne neoplazme kože M 491 51,1 696 71,3 941 862–1020 95 87–103 Skin, other malignomas Ž 543 53,1 781 76,6 1040 958–1122 102 94–110 C48 Vezivno in mehko tkivo M 22 2,3 30 3,0 28 17–39 3 2–4 –C49 Connective and soft tissue Ž 28 2,7 30 2,9 38 22–56 4 2–5 C50 Dojka M 7 0,7 9 1,0 13 3–23 1 0–2 Breast Ž 937 91,8 1060 104,0 1164 1075–1253 114 105–122 C53 Maternični vrat M – – – – – – – – Cervix uteri Ž 214 21,0 196 19,2 182 147–218 18 14–21 C54 Maternično telo M – – – – – – – – Corpus uteri Ž 266 26,1 299 29,3 329 282–377 32 28–37 C56 Jajčnik M – – – – – – – – Ovary Ž 184 18,1 177 17,3 175 139–210 17 14–21 C61 Prostata M 490 51,0 741 75,9 988 908–1068 99 91–107 Prostate Ž – – – – – – – – C62 Modo M 77 8,0 93 9,5 103 77–130 10 8–13 Testis Ž – – – – – – – – C64 Ledvica z ledvičnim mehom M 128 13,4 159 16,3 182 147–218 18 15–22 –C65 Kidney with renal pelvis Ž 82 8,0 90 8,8 107 81–134 11 8–13 C67 Sečni mehur M 156 16,2 186 19,0 232 192–273 23 19–27 Bladder Ž 52 5,1 67 6,5 80 57–103 8 6–10 C70 Centralni in avtonomni živčni sistem M 60 6,3 73 7,5 82 59–106 8 6–11 –C72 Central and autonomic nervous system Ž 49 4,8 65 6,4 76 52–101 8 5–10 C73 Ščitnica M 21 2,2 26 2,7 42 22–62 4 2–6 Thyroid gland Ž 60 5,9 91 9,0 125 98–153 12 10–15 C81 Hodgkinova bolezen M 20 2,1 26 2,6 29 15–43 3 2–4 Hodgkin’s disease Ž 19 1,8 23 2,3 28 11–44 3 1–4 C82 Ne-Hodgkinovi limfomi M 96 10,0 114 11,7 126 96–156 13 10–16 –C85 Non-Hodgkin’s lymphoma Ž 105 10,3 129 12,7 149 118–181 15 12–18 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov M 35 3,7 40 4,1 51 32–70 5 3–7 Multiple myeloma and malignant plasma cell neoplasms Ž 44 4,3 48 4,7 53 34–73 5 3–7 C91 Levkemije M 102 10,6 99 10,1 99 73–126 10 7–13 –C95 Leukaemias Ž 79 7,8 86 8,5 90 62–118 9 6–12 18 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Slika 1. Najpogostejše lokacije raka po spolu in pri obeh spolih skupaj – Slovenija 2005 Figure 1. The leading cancer sites by sex and for both sexes together – Slovenia, 2005 * Pojasnilo – Explanation Debelo črevo in danka – Colorectum (C18–C20) Glava in vrat – Head and neck (C00–C14, C30–C32) NHL: ne-Hodgkinovi limfomi – non-Hodgkin’s lymphoma (C82–C85) Prostata Prostate Pljuča Lung Koža, razen melanoma Skin, non-melanoma Debelo črevo in danka* Colorectum* Glava in vrat* Head and neck* Želodec Stomach Mehur Bladder Ledvica Kidney NHL* NHL* Trebušna slinavka Pancreas Ostalo Other 15,7 15,5 14,2 12,5 6,1 5,4 3,9 3,4 2,3 2,1 18,8 Dojka Breast Koža, razen melanoma Skin, non-melanoma Debelo črevo in danka* Colorectum* Maternično telo Corpus uteri Pljuča Lung Jajčnik Ovary Želodec Stomach Koža, melanom Skin, melanoma Maternični vrat Cervix uteri Trebušna slinavka Pancreas Ostalo Other 20,6 15,8 10,1 6,2 5,8 3,7 3,5 3,4 3,4 3,2 24,2 MOŠKI – MALES ŽENSKE – FEMALES Cancer incidence in Slovenia 2005 19 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Slika 2. Odstotni delež vseh rakov po starostnih skupinah in spolu – Slovenija 2005 Figure 2. Percentage distribution of all cancer sites by age groups and by sex – Slovenia 2005 Slika 3. Najpogostejše rakave bolezni po starostnih skupinah in spolu – Slovenija 2001–2005 Figure 3. The leading cancer sites by age groups and by sex – Slovenia 2001–2005 nadaljevanje / cont’d 4 20 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Slika 3. – Figure 3. Nadaljevanje – Continued MOŠKI – MALES 20–34 let/years ŽENSKE – FEMALES Modo Testis Koža, melanom Skin, melanoma Hodgkinova bolezen Hodgkin’s disease Koža, razen melanoma Skin, non-melanoma ne-Hodgkinovi limfomi* non-Hodgkin’s lymphoma* Levkemije* Leukaemias* Centralni in avtonomni živčni sistem* Central and autonomic nervous system* Vezivno in mehko tkivo* Connective and soft tissue* Debelo črevo in danka* Colorectum* Ščitnica Thyroid gland Ostalo Other Maternični vrat Cervix uteri Dojka Breast Koža, melanom Skin, melanoma Ščitnica Thyroid gland Koža, razen melanoma Skin, non-melanoma Hodgkinova bolezen Hodgkin’s disease ne-Hodgkinovi limfomi* non-Hodgkin’s lymphoma* Jajčnik Ovary Centralni in avtonomni živčni sistem* Central and autonomic nervous system* Levkemije* Leukaemias* Ostalo Other 42,5 7,8 7,6 6,5 5,8 5,2 3,9 3,6 2,4 2,4 12,3N = 617 N = 672 21,6 14,1 13,4 10,4 7,0 6,5 3,9 3,7 3,3 2,4 13,7 MOŠKI – MALES 35–49 let/years ŽENSKE – FEMALES Glava in vrat* Head and neck* Sapnik, sapnici in pljuča* Trachea, bronchus and lung* Koža, razen melanoma Skin, non-melanoma Debelo črevo in danka* Colorectum* Modo Testis Koža, melanom Skin, melanoma Želodec Stomach Ledvica z ledvičnim mehom* Kidney with renal pelvis* ne-Hodgkinovi limfomi* non-Hodgkin’s lymphoma* Centralni in avtonomni živčni sistem* Central and autonomic nervous system* Ostalo Other 14,7 13,0 10,6 9,2 7,5 6,9 4,7 4,6 4,0 3,0 21,8N = 2207 N = 3240 33,1 12,7 9,0 5,9 4,7 4,5 4,3 4,0 3,5 2,2 16,2 Dojka Breast Maternični vrat Cervix uteri Koža, razen melanoma Skin, non-melanoma Koža, melanom Skin, melanoma Sapnik, sapnici in pljuča* Trachea, bronchus and lung* Jajčnik Ovary Debelo črevo in danka* Colorectum* Ščitnica Thyroid gland Maternično telo Corpus uteri Želodec Stomach Ostalo Other nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 21 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Slika 3. – Figure 3. Nadaljevanje – Continued MOŠKI – MALES 50–69 let/years ŽENSKE – FEMALES Dojka Breast Koža, razen melanoma Skin, non-melanoma Debelo črevo in danka* Colorectum* Maternično telo Corpus uteri Sapnik, sapnici in pljuča* Trachea, bronchus and lung* Jajčnik Ovary Koža, melanom Skin, melanoma Maternični vrat Cervix uteri Želodec Stomach ne-Hodgkinovi limfomi* non-Hodgkin’s lymphoma* Ostalo Other Sapnik, sapnici in pljuča* Trachea, bronchus and lung* Prostata Prostate Debelo črevo in danka* Colorectum* Koža, razen melanoma Skin, non-melanoma Glava in vrat* Head and neck* Želodec Stomach Ledvica z ledvičnim mehom* Kidney with renal pelvis* Sečni mehur Bladder Koža, melanom Skin, melanoma Trebušna slinavka Pancreas Ostalo Other 18,3 13,9 13,6 12,0 8,9 5,2 3,2 3,2 2,6 2,3 16,8N = 12686 N = 9659 25,3 13,4 10,3 8,6 6,5 4,5 3,1 2,9 2,6 2,3 20,5 MOŠKI – MALES 70 + let/years ŽENSKE – FEMALES Prostata Prostate Koža, razen melanoma Skin, non-melanoma Sapnik, sapnici in pljuča* Trachea, bronchus and lung* Debelo črevo in danka* Colorectum* Želodec Stomach Sečni mehur Bladder Glava in vrat* Head and neck* Ledvica z ledvičnim mehom* Kidney with renal pelvis* Trebušna slinavka Pancreas ne-Hodgkinovi limfomi* non-Hodgkin’s lymphoma* Ostalo Other 18,2 16,0 15,5 13,9 6,6 4,6 3,3 2,6 2,4 1,9 15,0 Koža, razen melanoma Skin, non-melanoma Dojka Breast Debelo črevo in danka* Colorectum* Sapnik, sapnici in pljuča* Trachea, bronchus and lung* Želodec Stomach Maternično telo Corpus uteri Trebušna slinavka Pancreas ne-Hodgkinovi limfomi* non-Hodgkin’s lymphoma* Žolčnik in žolčevodi Gallbladder and billiary tract Jajčnik Ovary Ostalo Other 20,3 15,1 13,5 5,5 5,3 4,9 3,9 2,9 2,5 2,4 23,9N = 10517 N = 11194 22 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Slika 4. Groba in kumulativna letna incidenčna stopnja vseh rakov po spolu – Slovenija 1950–2005 Figure 4. Crude and cumulative annual cancer incidence rate for all sites by sex – Slovenia 1950–2005 Cancer incidence in Slovenia 2005 23 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Slika 5. Groba letna incidenčna stopnja izbranih rakov po spolu – Slovenija 1950–2005 Figure 5. Crude annual cancer incidence rate for selected primary sites by sex – Slovenia 1950–2005 24 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Br em e ra ka Po vp re čn o le tn o št ev ilo p rim er ov G ro b a s to p nj a na 1 00 .0 00 SS S* na 1 00 .0 00 KT ** (% ) In ci d en ca 52 43 53 6, 7 35 8, 5 34 ,6 U m rlj iv o st 27 91 28 5, 7 18 5, 4 18 ,8 Ra zm er je in ci d en ca /u m rlj iv o st 1, 9 N a či n ug o to vi tv e (le tn o p ov p re čj e) M ik ro sk o p sk o p o trj en i p rim er i 48 28 U g o to vl je ni z d ru g im i p re is ka va m i 35 8 Re g is tri ra ni s a m o iz z d ra vn iš ki h p o ro či l o v zr o ku s m rt i 58 D el ež (% ) h is to lo šk o a li ci to lo šk o p o trj en ih p rim er ov A d en o ka rc in o m 42 ,7 Pl o šč a to ce lič ni k a rc in o m 17 ,4 Ba za ln o ce lič ni k a rc in o m 11 ,5 D ru g i i n ne o p re d el je ni k a rc in o m i 13 ,1 M a lig ni m el a no m 3, 2 Le vk em ije in d ru g e he m a to p o et sk e ne o p la zm e 3, 8 Li m fo m i 2, 9 O st a lo 5 ,4 Sl ik e 6. V si ra ki (C 00 –C 96 ), m o šk i – S lo ve ni ja , 2 00 1– 20 05 Fi g ur es 6 . A ll sit e s (C 00 –C 96 ), m a le s – Sl ov e ni a , 2 00 1– 20 05 Re la tiv no p re ži ve tje (9 5 % in te rv a l z a up a nj a ) 1- le tn o 3- le tn o 5- le tn o 68 ,3 (6 7,6 –6 8, 9) 55 ,4 (5 4, 6– 56 ,1 ) 51 ,2 (5 0, 3– 52 ,1 ) Kr iv ul ja re la tiv ne g a p re ži ve tja p o s ta d iju G ro b e in s ta ro st no s ta nd a rd iz ira ne in ci d en čn e in u m rlj iv o st ne s to p nj e Po vp re čn a le tn a s ta ro st no s p ec ifi čn a in ci d en ca Po vp re čn a le tn a s ta ro st no s p ec ifi čn a u m rlj iv o st 10 0 80 60 40 20 0 0 1 2 3 4 5 Č a s v le tih Relativno preživetje (%) St a d ij (N ; 5 -le tn o p re ži ve tje ) O m e je n (1 07 64 ; 8 2, 0 % ) Ra zš irj e n (7 48 8; 4 2, 2 % ) Ra zs e ja n (6 11 6; 1 3, 0 % ) N e zn a n (1 20 3; 2 3, 8 % ) Cancer incidence in Slovenia 2005 25 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C a nc er b ur d en A ve ra g e a nn ua l nu m b er o f c a se s C ru d e ra te p er 10 0, 00 0 A SR * p er 10 0, 00 0 C R* * (% ) In ci d en ce 49 84 48 8, 8 26 4, 2 25 ,5 M o rt a lit y 22 18 21 7, 5 98 ,1 10 ,3 In ci d en ce /m o rt a lit y ra tio 2, 2 Ba si s o f d ia g no si s (a ve ra g e a nn ua l n um b er ) M ic ro sc o p ic a lly c o nf irm ed c a se s 46 34 C o nf irm ed b y o th er in ve st ig a tio ns 28 4 Re g is te re d fr o m d ea th c er tif ic a te s o nl y 66 Pe rc en ta g e (% ) o f h is to lo g ic a lly o r c yt o lo g ic a lly c o m fir m ed c a se s A d en o ca rc in o m a 52 ,5 Sq ua m o us c el l c a rc in o m a 10 ,3 Ba sa l c el l c a rc in o m a 13 ,4 O th er a nd u ns p ec ifi ed c a rc in o m a s 9, 1 M a lig na nt m el a no m a 3, 9 Le uk em ia s a nd o th er h a em a to p o et ic n eo p la sm s 3, 9 Ly m p ho m a s 3, 3 O th er 3, 6 Sl ik e 7. V si ra ki (C 00 –C 96 ), že ns ke – S lo ve ni ja , 2 00 1– 20 05 Fi g ur es 7 . A ll sit e s (C 00 –C 96 ), fe m a le s – Sl ov e ni a , 2 00 1– 20 05 Re la tiv e su rv iv a l ( 95 % c o nf id en ce in te rv a l) 1- ye a r 3- ye a r 5- ye a r 78 ,3 (7 7, 7– 78 ,8 ) 68 ,6 (6 7, 9– 69 ,3 ) 64 ,9 (6 4, 0– 65 ,7 ) Re la tiv e su rv iv a l b y st a g e C ru d e a nd a g e st a nd a rd iz ed in ci d en ce a nd m o rt a lit y ra te s A ve ra g e a nn ua l a g e sp ec ifi c in ci d en ce A ve ra g e a nn ua l a g e sp ec ifi c m o rt a lit y 10 0 80 60 40 20 0 Relative survival (%) St a g e ( N ; 5 -y e a r s ur vi va l) Lo ca liz e d (1 16 61 ; 9 0. 5 % ) Re g io na l (6 73 3; 5 7. 5 % ) D ist a nt (5 12 7; 2 1, 3 % ) U nk no w n (8 40 ; 2 3. 3 % ) 0 1 2 3 4 5 Ti m e in y e a rs 26 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Sl ik e 8. V si ra ki b re z ne m el a no m sk ih k ož ni h ra ko v (C 00 –C 96 b re z C 44 ), m o šk i – S lo ve ni ja , 2 00 1– 20 05 Fi g ur es 8 . A ll sit e s, no n- m e la no m a s ki n ca nc e r e xc lu d e d ( C 00 –C 96 , C 44 e xc lu d e d ), m a le s – Sl ov e ni a , 2 00 1– 20 05 Br em e ra ka Po vp re čn o le tn o št ev ilo p rim er ov G ro b a s to p nj a na 1 00 .0 00 SS S* na 1 00 .0 00 KT ** (% ) In ci d en ca 45 47 46 5, 5 31 2, 2 31 ,1 U m rlj iv o st 27 84 28 5, 0 18 5, 0 18 ,8 Ra zm er je in ci d en ca /u m rlj iv o st 1, 6 N a či n ug o to vi tv e (le tn o p ov p re čj e) M ik ro sk o p sk o p o trj en i p rim er i 41 38 U g o to vl je ni z d ru g im i p re is ka va m i 35 1 Re g is tri ra ni s a m o iz z d ra vn iš ki h p o ro či l o v zr o ku s m rt i 56 D el ež (% ) h is to lo šk o a li ci to lo šk o p o trj en ih p rim er ov A d en o ka rc in o m 49 ,7 Pl o šč a to ce lič ni k a rc in o m 17 ,3 D ru g i i n ne o p re d el je ni k a rc in o m i 15 ,3 M a lig ni m el a no m 3, 7 Le vk em ije in d ru g e he m a to p o et sk e ne o p la zm e 4, 5 Li m fo m i 3, 4 O st a lo 6, 2 Re la tiv no p re ži ve tje (9 5 % in te rv a l z a up a nj a ) 1- le tn o 3- le tn o 5- le tn o 63 ,2 (6 2, 6– 63 ,9 ) 48 ,4 (4 7, 6– 49 ,1 ) 43 ,7 (4 2, 8– 44 ,6 ) Kr iv ul ja re la tiv ne g a p re ži ve tja p o s ta d iju G ro b e in s ta ro st no s ta nd a rd iz ira ne in ci d en čn e in u m rlj iv o st ne s to p nj e Po vp re čn a le tn a s ta ro st no s p ec ifi čn a in ci d en ca Po vp re čn a le tn a s ta ro st no s p ec ifi čn a u m rlj iv o st 10 0 80 60 40 20 0 0 1 2 3 4 5 Č a s v le tih Relativno preživetje (%) St a d ij (N ; 5 -le tn o p re ži ve tje ) O m e je n (7 35 3; 7 3, 3 % ) Ra zš irj e n (7 43 0; 4 1, 9 % ) Ra zs e ja n (6 11 1; 1 3, 0 % ) N e zn a n (1 19 9; 2 3, 8 % ) Cancer incidence in Slovenia 2005 27 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Sl ik e 9. V si ra ki b re z ne m el a no m sk ih k ož ni h ra ko v (C 00 –C 96 b re z C 44 ), že ns ke – S lo ve ni ja , 2 00 1– 20 05 Fi g ur es 9 . A ll sit e s, no n- m e la no m a s ki n ca nc e r e xc lu d e d ( C 00 –C 96 , C 44 e xc lu d e d ), fe m a le s – Sl ov e ni a , 2 00 1– 20 05 C a nc er b ur d en A ve ra g e a nn ua l nu m b er o f c a se s C ru d e ra te p er 10 0, 00 0 A SR * p er 10 0, 00 0 C R* * (% ) In ci d en ce 42 02 41 2, 1 22 8, 6 22 ,5 M o rt a lit y 22 07 21 6, 4 97 ,7 10 ,2 In ci d en ce /m o rt a lit y ra tio 1, 9 Ba si s o f d ia g no si s (a ve ra g e a nn ua l n um b er ) M ic ro sc o p ic a lly c o nf irm ed c a se s 38 59 C o nf irm ed b y o th er in ve st ig a tio ns 27 8 Re g is te re d fr o m d ea th c er tif ic a te s o nl y 65 Pe rc en ta g e (% ) o f h is to lo g ic a lly o r c yt o lo g ic a lly c o m fir m ed c a se s A d en o ca rc in o m a 62 ,9 Sq ua m o us c el l c a rc in o m a 8 ,7 O th er a nd u ns p ec ifi ed c a rc in o m a s 10 ,8 M a lig na nt m el a no m a 4, 7 Le uk em ia s a nd o th er h a em a to p o et ic n eo p la sm s 4, 7 Ly m p ho m a s 4, 0 O th er 4, 3 Re la tiv e su rv iv a l ( 95 % c o nf id en ce in te rv a l) 1- ye a r 3- ye a r 5- ye a r 7 4 ,2 (7 3, 5– 74 ,8 ) 62 ,8 (6 2, 1– 63 ,6 ) 58 ,7 (5 7, 8– 59 ,6 ) Re la tiv e su rv iv a l b y st a g e C ru d e a nd a g e st a nd a rd iz ed in ci d en ce a nd m o rt a lit y ra te s A ve ra g e a nn ua l a g e sp ec ifi c in ci d en ce A ve ra g e a nn ua l a g e sp ec ifi c m o rt a lit y 10 0 80 60 40 20 0 ˝Relative survival (%) St a g e ( N ; 5 -y e a r s ur vi va l) Lo ca liz e d (7 84 6; 8 6. 0 % ) Re g io na l (6 66 4; 5 7. 5 % ) D ist a nt (5 12 4; 2 1. 2 % ) U nk no w n (8 31 ; 2 3. 0 % ) 0 1 2 3 4 5 Ti m e in y e a rs 28 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Slika 10. Kumulativno tveganje izbranih rakov do starosti 64 let, 74 let in doživljenjsko po spolu – Slovenija, 2001–2005 Figure 10. Cumulative risk of developing selected cancers till the age 64, 74 and over the entire life-span by sex – Slovenia, 2001–2005 Cancer incidence in Slovenia 2005 29 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Slika 10. – Figure 10. Nadaljevanje – Continued 30 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Slika 11. Pet-letno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 1995–1999 in 2001–2005 po spolu Figure 11. Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 1995–1999 and 2001–2005 by sex Cancer incidence in Slovenia 2005 31 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Slika 11. – Figure 11. Nadaljevanje – Continued 32 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela1. Prebivalstvo po starosti in spolu – Slovenija, 30. 06. 2005* Table 1. Population by age and by sex – Slovenia, June 30, 2005* Starost Skupaj Moški Ženske Age Total Males Females 0–4 89351 45900 43451 5–9 92568 47778 44790 10–14 102957 52777 50180 15–19 123507 63419 60088 20–24 141356 72515 68841 25–29 153502 79417 74085 30–34 145499 74883 70616 35–39 149973 75993 73980 40–44 155302 78677 76625 45–49 156060 79846 76214 50–54 155623 80214 75409 55–59 122423 61325 61098 60–64 103456 49543 53913 65–69 95847 43800 52047 70–74 85872 34939 50933 75–79 65759 22914 42845 80+ 62059 16130 45929 Vse starosti 2001114 980070 1021044 All ages *Vir: Statistični urad Republike Slovenije Source: Statistical Office of the Republic of Slovenia Cancer incidence in Slovenia 2005 33 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Statistična regija Skupaj Moški Ženske Statistical region Total Males Females Pomurska 122483 59278 63205 Podravska 319282 155876 163406 Koroška 73905 36885 37020 Savinjska 257525 126852 130673 Zasavska 45468 22141 23327 Spodnjeposavska 69940 34647 35293 JV Slovenija 139434 69158 70276 Osrednjeslovenska 498378 241736 256642 Gorenjska 198713 97129 101584 Notranjsko-kraška 51132 25369 25763 Goriška 119541 59037 60504 Obalno-kraška 105313 51962 53351 Slovenija Slovenia Skupaj Total 2001114 980070 1021044 *Vir: Statistični urad Republike Slovenije Source: Statistical Office of the Republic of Slovenia Tabela 2. Prebivalstvo po statističnih regijah in spolu – Slovenija, 30. 06. 2005* Table 2. Population by statistical regions and by sex – Slovenia, June 30, 2005* SPODNJEPOSAVSKA JUGOVZHODNA SLOVENIJA OBALNO- KRAŠKA NOTRANJSKO- KRAŠKA 34 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 3. Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu – Slovenija 2005 Table 3. Cancer incidence according to basis of diagnosis by site and by sex – Slovenia 2005 Šifra MKB* Primarna lokacija Spol Število novih primerov Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdrav- niških poročil o vzroku smrti Število %** Število %** Število %** ICD code* Primary site Sex Number of new cases Microscopically confirmed cases Confirmed by other investigations Registered from death certificates only Number %** Number %** Number %** C00 Vse lokacije M+Ž 10720 10024 93,5 624 5,8 72 0,7 – M 5455 5101 93,5 330 6,1 24 0,4 C96 All sites Ž 5265 4923 93,5 294 5,6 48 0,9 C00 Ustnica M 14 14 – 0 – 0 – Lip Ž 12 12 – 0 – 0 – C01 Baza jezika M 21 21 100,0 0 0,0 0 0,0 Base of tongue Ž 1 1 – 0 – 0 – C02 Jezik, drugi deli M 27 27 100,0 0 0,0 0 0,0 Tongue, other & unspecified parts Ž 6 6 – 0 – 0 – C03 Dlesen M 2 2 – 0 – 0 – Gum Ž 4 4 – 0 – 0 – C04 Ustno dno M 28 28 100,0 0 0,0 0 0,0 Floor of mouth Ž 6 6 – 0 – 0 – C05 Nebo M 15 15 – 0 – 0 – Palate Ž 4 4 – 0 – 0 – C06 Usta, drugi deli M 13 13 – 0 – 0 – Mouth, other & unspecified parts Ž 14 13 – 0 – 1 – C07 Parotidna žleza M 9 9 – 0 – 0 – Parotid gland Ž 8 8 – 0 – 0 – C08 Druge in neopredeljene velike žleze slinavke M 0 0 – 0 – 0 – Other & unspecified major salivary glands Ž 1 1 – 0 – 0 – C09 Tonzila M 23 23 100,0 0 0,0 0 0,0 Tonsil Ž 5 5 – 0 – 0 – C10 Orofarinks M 46 46 100,0 0 0,0 0 0,0 Oropharynx Ž 5 5 – 0 – 0 – C11 Nazofarinks M 3 3 – 0 – 0 – Nasopharynx Ž 4 4 – 0 – 0 – C12 Piriformni sinus M 21 20 95,2 1 4,8 0 0,0 Pyriform sinus Ž 3 3 – 0 – 0 – C13 Hipofarinks M 26 24 92,3 2 7,7 0 0,0 Hypopharynx Ž 3 3 – 0 – 0 – C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu M 0 0 – 0 – 0 – Other and ill–defined sites in the lip, oral cavity and pharynx Ž 0 0 – 0 – 0 – nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 35 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 3. – Table 3. Nadaljevanje – Continued nadaljevanje / cont’d 4 C15 Požiralnik M 74 69 93,2 4 5,4 1 1,4 Oesophagus Ž 17 15 88,2 2 11,8 0 0,0 C16 Želodec M 296 286 96,6 9 3,0 1 0,3 Stomach Ž 186 172 92,5 8 4,3 6 3,2 C17 Tanko črevo M 14 14 – 0 – 0 – Small intestine Ž 15 14 – 1 – 0 – C18 Debelo črevo M 381 366 96,1 12 3,1 3 0,8 Colon Ž 311 299 96,1 9 2,9 3 1,0 C19 Rektosigmoidna zveza M 67 65 97,0 0 0,0 2 3,0 Rectosigmoid junction Ž 46 44 95,7 1 2,2 1 2,2 C20 Rektum M 236 229 97,0 5 2,1 2 0,8 Rectum Ž 176 168 95,5 4 2,3 4 2,3 C21 Anus in analni kanal M 12 12 – 0 – 0 – Anus and anal canal Ž 6 6 – 0 – 0 – C22 Jetra in intrahepatični vodi M 99 64 64,6 34 34,3 1 1,0 Liver and intrahepatic bile ducts Ž 32 10 31,3 18 56,3 4 12,5 C23 Žolčnik M 21 12 57,1 9 42,9 0 0,0 Gallbladder Ž 70 46 65,7 24 34,3 0 0,0 C24 Drugi in neopredeljeni deli biliarnega trakta M 38 29 76,3 9 23,7 0 0,0 Billiary tract, other and unspecified parts Ž 46 27 58,7 19 41,3 0 0,0 C25 Trebušna slinavka M 114 70 61,4 44 38,6 0 0,0 Pancreas Ž 171 90 52,6 76 44,4 5 2,9 C26 Druga in slabo opredeljena mesta v prebavnih organih M 3 1 – 1 – 1 – Other and ill-defined digestive organs Ž 5 2 – 2 – 1 – C30 Nosna votlina in srednje uho M 5 5 – 0 – 0 – Nasal cavity and middle ear Ž 3 3 – 0 – 0 – C31 Obnosni sinusi M 5 5 – 0 – 0 – Accessory sinuses Ž 4 4 – 0 – 0 – C32 Grlo M 76 75 98,7 1 1,3 0 0,0 Larynx Ž 13 13 – 0 – 0 – C33 Sapnik M 1 1 – 0 – 0 – Trachea Ž 4 4 – 0 – 0 – C34 Sapnica in pljuča M 846 781 92,3 60 7,1 5 0,6 Bronchus and lung Ž 299 268 89,6 28 9,4 3 1,0 C37 Timus M 3 3 – 0 – 0 – Thymus Ž 1 1 – 0 – 0 – Šifra MKB* Primarna lokacija Spol Število novih primerov Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdrav- niških poročil o vzroku smrti Število %** Število %** Število %** ICD code* Primary site Sex Number of new cases Microscopically confirmed cases Confirmed by other investigations Registered from death certificates only Number %** Number %** Number %** 36 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 3. – Table 3. Nadaljevanje – Continued Šifra MKB* Primarna lokacija Spol Število novih primerov Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdrav- niških poročil o vzroku smrti Število %** Število %** Število %** ICD code* Primary site Sex Number of new cases Microscopically confirmed cases Confirmed by other investigations Registered from death certificates only Number %** Number %** Number %** C38 Srce, mediastinum, plevra M 6 4 – 2 – 0 – Heart, mediastinum, pleura Ž 1 1 – 0 – 0 – C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih M 0 0 – 0 – 0 – Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 0 0 – 0 – 0 – C40 Kosti, sklepni hrustanec udov M 0 0 – 0 – 0 – Bone and articular cartilage of limbs Ž 2 2 – 0 – 0 – C41 Kosti, sklepni hrustanec, drugje M 3 3 – 0 – 0 – Bone and articular cartilage of other and unspecified parts Ž 6 6 – 0 – 0 – C43 Maligni melanom kože M 126 126 100,0 0 0,0 0 0,0 Malignant melanoma of skin Ž 181 181 100,0 0 0,0 0 0,0 C44 Druge maligne neoplazme kože M 772 767 99,4 5 0,6 0 0,0 Skin, other malignomas Ž 834 831 99,6 1 0,1 2 0,2 C45 Mezoteliom M 20 20 100,0 0 0,0 0 0,0 Mesothelioma Ž 4 4 – 0 – 0 – C46 Kaposijev sarkom M 2 2 – 0 – 0 – Kaposi’s sarcoma Ž 0 0 – 0 – 0 – C47 Periferni živci in avtonomno živčevje M 1 1 – 0 – 0 – Peripheral nerves and autonomic nervous system Ž 1 1 – 0 – 0 – C48 Peritonej in retroperitonej M 3 3 – 0 – 0 – Retroperitoneum and peritoneum Ž 13 13 – 0 – 0 – C49 Drugo vezivno in mehko tkivo M 23 22 95,7 1 4,3 0 0,0 Other connective and soft tissue Ž 21 20 95,2 1 4,8 0 0,0 C50 Dojka M 9 9 – 0 – 0 – Breast Ž 1082 1064 98,3 12 1,1 6 0,6 C51 Žensko zunanje spolovilo M – – – – – – – Vulva Ž 41 41 100,0 0 0,0 0 0,0 C52 Nožnica M – – – – – – – Vagina Ž 4 4 – 0 – 0 – C53 Maternični vrat M – – – – – – – Cervix uteri Ž 180 178 98,9 2 1,1 0 0,0 C54 Maternično telo M – – – – – – – Corpus uteri Ž 326 323 99,1 3 0,9 0 0,0 C55 Maternica, neopredeljeno M – – – – – – – Uterus, unspecified Ž 9 7 – 1 – 1 – C56 Jajčnik M – – – – – – – Ovary Ž 197 187 94,9 7 3,6 3 1,5 nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 37 Institute of Oncology Ljubljana, Cancer Registry of Slovenia nadaljevanje / cont’d 4 Tabela 3. – Table 3. Nadaljevanje – Continued C57 Drugi in neopredeljeni ženski spolni organi M – – – – – – – Other and unspecified parts of female genital organs Ž 9 9 – 0 – 0 – C58 Posteljica M – – – – – – – Placenta Ž 0 0 – 0 – 0 – C60 Penis M 6 6 – 0 – 0 – Penis Ž – – – – – – – C61 Prostata M 859 803 93,5 52 6,1 4 0,5 Prostate Ž – – – – – – – C62 Modo M 79 79 100,0 0 0,0 0 0,0 Testis Ž – – – – – – – C63 Drugi in neopredeljeni moški spolni organi M 4 3 – 0 – 1 – Other and unspecified male genital organs Ž – – – – – – – C64 Ledvica razen meha M 172 153 89,0 19 11,0 0 0,0 Kidney, except renal pelvis Ž 89 74 83,1 15 16,9 0 0,0 C65 Ledvični meh M 14 14 – 0 – 0 – Renal pelvis Ž 14 13 – 1 – 0 – C66 Sečevod M 9 9 – 0 – 0 – Ureter Ž 6 6 – 0 – 0 – C67 Sečni mehur M 211 202 95,7 9 4,3 0 0,0 Bladder Ž 64 60 93,8 4 6,3 0 0,0 C68 Drugi in neopredeljeni sečni organi M 2 2 – 0 – 0 – Other and unspecified urinary organs Ž 0 0 – 0 – 0 – C69 Oko in očesni adneksi M 14 14 – 0 – 0 – Eye and adnexa Ž 5 5 – 0 – 0 – C70 Meninge M 1 1 – 0 – 0 – Meninges Ž 2 2 – 0 – 0 – C71 Možgani M 66 64 97,0 2 3,0 0 0,0 Brain Ž 64 51 79,7 12 18,8 1 1,6 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS M 0 0 – 0 – 0 – Spinal cord, cranial nerves and other parts of CNS Ž 1 1 – 0 – 0 – C73 Ščitnica M 31 31 100,0 0 0,0 0 0,0 Thyroid gland Ž 117 117 100,0 0 0,0 0 0,0 C74 Nadledvična žleza M 1 1 – 0 – 0 – Adrenal gland Ž 2 2 – 0 – 0 – C75 Druge endokrine žleze in sorodne strukture M 0 0 – 0 – 0 – Other endocrine glands and related structures Ž 2 1 – 1 – 0 – Šifra MKB* Primarna lokacija Spol Število novih primerov Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdrav- niških poročil o vzroku smrti Število %** Število %** Število %** ICD code* Primary site Sex Number of new cases Microscopically confirmed cases Confirmed by other investigations Registered from death certificates only Number %** Number %** Number %** 38 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 3. – Table 3. Nadaljevanje – Continued C76 Druga in slabo opredeljena mesta M 7 5 – 2 – 0 – Other and ill-defined sites Ž 23 15 65,2 6 26,1 2 8,7 C77 Metastaza in neopredeljena maligna neoplazma bezgavk M 24 23 95,8 1 4,2 0 0,0 Metastasis and unspecified malignant neoplasm of lymph nodes Ž 12 11 – 1 – 0 – C78 Metastaze dihal in prebavil M 43 20 46,5 21 48,8 2 4,7 Metastases of respiratory and digestive organs Ž 51 28 54,9 21 41,2 2 3,9 C79 Metastaze, drugje M 22 11 50,0 11 50,0 0 0,0 Metastases of other sites Ž 9 4 – 5 – 0 – C80 Maligna neoplazma brez opredeljenega mesta M 43 28 65,1 14 32,6 1 2,3 Malignant neoplasm without specification of site Ž 40 29 72,5 8 20,0 3 7,5 C81 Hodgkinova bolezen M 26 26 100,0 0 0,0 0 0,0 Hodgkin’s disease Ž 19 19 100,0 0 0,0 0 0,0 C82 Folikularni ne-Hodgkinov limfom M 26 26 100,0 0 0,0 0 0,0 Follicular non-Hodgkin’s lymphoma Ž 39 39 100,0 0 0,0 0 0,0 C83 Difuzni ne-Hodgkinov limfom M 68 68 100,0 0 0,0 0 0,0 Diffuse non-Hodgkin’s lymphoma Ž 77 77 100,0 0 0,0 0 0,0 C84 Limfomi celic T in kožni limfom celic T M 15 15 – 0 – 0 – Peripheral and cutaneous T–cell lymphomas Ž 14 14 – 0 – 0 – C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma M 7 7 – 0 – 0 – Other and unspecified types of non–Hodgkin’s lymphoma Ž 8 8 – 0 – 0 – C88 Maligne imunoproliferativne bolezni M 1 1 – 0 – 0 – Malignant immunoproliferative diseases Ž 0 0 – 0 – 0 – C90 Difuzni plazmocitom in maligne neoplazme plazmocitov M 45 45 100,0 0 0,0 0 0,0 Multiple myeloma and malignant plasma cell neoplasms Ž 56 55 98,2 1 1,8 0 0,0 C91.0 Limfatična levkemija, akutna M 9 9 – 0 – 0 – Lymphoblastic leukaemia, acute Ž 8 8 – 0 – 0 – C91.1 – Limfatična levkemija, druga M 46 46 100,0 0 0,0 0 0,0 C91.9 Lymphoid leukaemia, other Ž 34 34 100,0 0 0,0 0 0,0 C92 Mieloična levkemija M 31 31 100,0 0 0,0 0 0,0 Myeloid leukaemia Ž 47 47 100,0 0 0,0 0 0,0 C93 Monocitna levkemija M 3 3 – 0 – 0 – Monocytic leukaemia Ž 3 3 – 0 – 0 – Šifra MKB* Primarna lokacija Spol Število novih primerov Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdrav- niških poročil o vzroku smrti Število %** Število %** Število %** ICD code* Primary site Sex Number of new cases Microscopically confirmed cases Confirmed by other investigations Registered from death certificates only Number %** Number %** Number %** nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 39 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 3. – Table 3. Nadaljevanje – Continued C94 Druge opredeljene levkemije M 0 0 – 0 – 0 – Other leukaemias of specified cells Ž 2 2 – 0 – 0 – C95 Levkemija z neopredeljenim celičnim tipom M 0 0 – 0 – 0 – Leukaemia, unspecified cell type Ž 1 1 – 0 – 0 – C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva M 66 66 100,0 0 0,0 0 0,0 Other and unspecified malignant neo- plasms of lymphoid, haematopoietic and related tissue Ž 64 64 100,0 0 0,0 0 0,0 Zgoraj neupoštevani Not included above D03 Melanom, in situ M 16 16 100,0 0 0,0 0 0,0 Melanoma, in situ Ž 13 13 – 0 – 0 – D05 Dojka, in situ M 2 2 – 0 – 0 – Breast, in situ Ž 90 90 100,0 0 0,0 0 0,0 D06 Maternični vrat, CIN III M – – – – – – – Cervix uteri, in situ Ž 1093 1093 100,0 0 0,0 0 0,0 D09.0 Sečni mehur, in situ M 107 107 100,0 0 0,0 0 0,0 Bladder, in situ Ž 38 38 100,0 0 0,0 0 0,0 D32.0 Meninge, benigna neoplazma M 21 17 81,0 4 6,0 0 0,0 Benign neoplasm of meninges Ž 43 42 97,7 1 2,3 0 0,0 D33.0 Možgani, benigna neoplazma M 0 0 – 0 – 0 – –D33.2 Benign neopasm of brain Ž 1 1 – 0 – 0 – D39.1 Jajčnik, neopl. negotovega značaja M – – – – – – – Ovary, neopl. of uncertain behavior Ž 30 30 100,0 0 0,0 0 0,0 D43.0 Možgani, neopredeljeno M 6 2 – 4 – 0 – –D43.2 CNS, uncertain or unknown Ž 11 4 – 6 – 1 – Šifra MKB* Primarna lokacija Spol Število novih primerov Mikroskopsko potrjeni primeri Ugotovljeni z drugimi preiskavami Registrirani samo iz zdrav- niških poročil o vzroku smrti Število %** Število %** Število %** ICD *code Primary site Sex Number of new cases Microscopically confirmed cases Confirmed by other investigations Registered from death certificates only Number %** Number %** Number %** ** MKB – Mednarodna klasifikacija bolezni, deseta revizija, 1995 ICD – International Classification of Diseases, Tenth Revision, 1995 ** Odstotki niso računani, če je število novih primerov manjše od 15 Percentages are not calculated when number of new cases is less than 15 40 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo C00 Vse lokacije M+Ž 10720 15 9 6 21 50 81 115 203 336 544 898 1058 1242 1521 1665 1453 1503 – M 5455 7 6 5 12 23 34 40 70 121 240 444 599 715 919 945 736 539 C96 All sites Ž 5265 8 3 1 9 27 47 75 133 215 304 454 459 527 602 720 717 964 C00 Ustnica M 14 0 0 0 0 0 0 0 0 0 1 0 1 2 2 2 5 1 Lip Ž 12 0 0 0 0 0 0 0 0 0 0 0 1 0 3 2 1 5 C01 Baza jezika M 21 0 0 0 0 0 0 0 1 0 4 6 2 2 4 1 1 0 Base of tongue Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C02 Jezik, drugi deli M 27 0 0 0 0 0 0 0 1 3 4 6 4 3 3 2 1 0Tongue, other & unspecified parts Ž 6 0 0 0 0 1 0 0 0 0 0 0 0 2 2 0 1 0 C03 Dlesen M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 Gum Ž 4 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 C04 Ustno dno M 28 0 0 0 0 0 0 0 1 2 4 6 8 2 2 1 2 0 Floor of mouth Ž 6 0 0 0 0 0 0 0 0 0 1 1 0 0 2 1 1 0 C05 Nebo M 15 0 0 0 0 0 0 0 0 0 2 1 4 4 2 2 0 0 Palate Ž 4 0 0 0 0 1 0 0 1 1 0 0 1 0 0 0 0 0 C06 Usta, drugi deli M 13 0 0 0 0 0 0 0 0 0 1 1 3 2 3 2 1 0 Mouth, other & unspecified parts Ž 14 0 0 0 0 0 0 0 1 2 0 1 1 2 0 4 1 2 C07 Parotidna žleza M 9 0 0 0 0 0 0 0 1 1 2 0 1 1 0 1 1 1 Parotid gland Ž 8 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 3 C08 Druge in neopredeljene velike žleze slinavke M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other & unspecified major salivary glands Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 C09 Tonzila M 23 0 0 0 0 0 0 0 1 1 3 1 4 5 2 3 2 1 Tonsil Ž 5 0 0 0 0 0 0 0 0 0 2 1 0 1 0 0 1 0 C10 Orofarinks M 46 0 0 0 0 0 0 0 1 3 9 8 5 10 5 4 1 0 Oropharynx Ž 5 0 0 0 0 0 0 0 0 0 0 0 0 3 0 1 1 0 C11 Nazofarinks M 3 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 Nasopharynx Ž 4 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 1 0 C12 Piriformni sinus M 21 0 0 0 0 0 0 0 0 0 1 2 3 4 7 2 2 0 Pyriform sinus Ž 3 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 C13 Hipofarinks M 26 0 0 0 0 0 0 0 0 0 2 4 9 4 5 1 1 0 Hypopharynx Ž 3 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 C14 Druga in slabo oprede- ljena mesta na ustnici, v ustni votlini in farinksu M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other and ill-defined sites in the lip, oral cavity and pharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C15 Požiralnik M 74 0 0 0 0 0 0 0 0 1 1 4 16 19 11 14 4 4 Oesophagus Ž 17 0 0 0 0 0 0 0 0 0 0 1 2 3 1 4 2 4 C16 Želodec M 296 0 0 0 0 0 1 1 1 11 14 21 25 35 54 46 50 37 Stomach Ž 186 0 0 0 0 0 0 4 2 3 8 4 8 10 19 34 37 57 C17 Tanko črevo M 14 0 0 0 0 0 0 0 0 0 1 4 1 1 1 2 0 4 Small intestine Ž 15 0 0 0 0 0 0 0 1 0 0 1 1 0 5 2 3 2 C18 Debelo črevo M 381 0 0 0 0 0 1 0 1 8 10 22 37 46 80 72 65 39 Colon Ž 311 0 0 0 0 0 0 1 1 8 4 19 17 34 34 57 56 80 C19 Rektosigmoidna zveza M 67 0 0 0 0 0 0 0 0 2 4 3 10 9 11 13 8 7 Rectosigmoid junction Ž 46 0 0 0 0 1 0 0 0 0 1 2 1 8 9 4 8 12 C20 Rektum M 236 0 0 0 0 0 1 1 2 3 9 17 35 30 41 44 35 18 Rectum Ž 176 0 0 0 0 0 1 0 1 3 4 8 12 14 25 24 39 45 C21 Anus in analni kanal M 12 0 0 0 0 0 0 0 0 1 2 2 1 3 1 1 1 0 Anus and anal canal Ž 6 0 0 0 0 0 0 0 0 0 1 0 2 0 1 1 0 1 C22 Jetra in intrahepatični vodi M 99 0 0 0 0 0 0 0 0 0 5 10 11 12 23 16 11 11 Liver and intrahepatic bile ducts Ž 32 0 0 0 0 0 0 0 0 0 0 0 1 0 7 3 7 14 C23 Žolčnik M 21 0 0 0 0 0 0 0 1 0 1 0 1 3 4 2 4 5 Gallbladder Ž 70 0 0 0 0 0 0 0 0 0 0 7 6 3 5 9 21 19 C24 Drugi in neopredeljeni deli biliarnega trakta M 38 0 0 0 0 0 0 0 0 1 3 1 3 5 7 11 3 4 Billiary tract, other and unspecified parts Ž 46 0 0 0 0 0 0 0 0 1 1 2 3 3 4 5 10 17 C25 Trebušna slinavka M 114 0 0 0 0 0 0 1 0 6 4 9 12 22 15 15 18 12 Pancreas Ž 171 0 0 0 0 0 0 0 1 2 7 10 10 18 20 38 26 39 Tabela 4a. Incidenca raka po lokaciji (MKB-10), spolu in starosti – Slovenija 2005 Table 4a. Cancer incidence by site (ICD-10), by sex and by age – Slovenia 2005 Šifra MKB Lokacija Spol Vse starosti S t a r o s t ICD Site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 41 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 4a. – Table 4a. Nadaljevanje – Continued Šifra MKB Lokacija Spol Vse starosti S t a r o s t ICD Site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 C26 Druga in slabo opredeljena mesta v prebavnih organih M 3 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 Other and ill-defined digestive organs Ž 5 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 2 C30 Nosna votlina in srednje uho M 5 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 2 0 Nasal cavity and middle ear Ž 3 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 C31 Obnosni sinusi M 5 0 0 0 0 0 0 0 0 0 1 0 2 0 0 1 1 0 Accessory sinuses Ž 4 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 0 C32 Grlo M 76 0 0 0 0 0 0 0 1 3 8 7 12 10 10 11 9 5 Larynx Ž 13 0 0 0 0 0 0 0 0 1 1 1 2 2 2 0 4 0 C33 Sapnik M 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 Trachea Ž 4 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 1 0 C34 Sapnica in pljuča M 846 0 0 0 0 0 0 2 3 12 37 88 112 113 143 164 110 62 Bronchus and lung Ž 299 0 0 0 0 0 0 0 4 13 17 37 26 33 38 42 39 50 C37 Timus M 3 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0 0 Thymus Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 C38 Srce, mediastinum, plevra M 6 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 3 Heart, mediastinum, pleura Ž 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C39 Druga in slabo opredelje- na mesta v dihalih in prsnih organih M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C40 Kosti, sklepni hrustanec udov M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Bone and articular cartilage of limbs Ž 2 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 C41 Kosti, sklepni hrustanec, drugje M 3 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 0 Bone and articular carti- lage of other and unspeci- fied parts Ž 6 0 0 0 1 1 0 0 1 2 0 0 0 0 0 0 1 0 C43 Maligni melanom kože M 126 0 0 0 0 1 1 4 6 8 9 15 22 12 16 15 5 12 Malignant melanoma of skin Ž 181 0 0 0 0 3 4 8 13 9 19 13 15 16 23 14 12 32 C44 Druge maligne neoplazme kože M 772 0 0 0 0 0 3 3 5 15 24 54 65 92 108 164 125 114 Skin, other malignomas Ž 834 0 0 0 0 0 5 9 8 16 29 53 57 72 98 133 130 224 C45 Mezoteliom M 20 0 0 0 0 0 0 0 0 0 0 4 2 5 3 3 2 1 Mesothelioma Ž 4 0 0 0 0 0 0 0 0 1 0 0 1 0 2 0 0 0 C46 Kaposijev sarkom M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 Kaposi’s sarcoma Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C47 Periferni živci in avto- nomno živčevje M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Peripheral nerves and autonomic nervous system Ž 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 C48 Peritonej in retroperitonej M 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 Retroperitoneum and peritoneum Ž 13 1 0 0 0 0 0 0 1 0 0 0 2 1 5 2 1 0 C49 Drugo vezivno in mehko tkivo M 23 0 0 0 0 1 1 1 3 1 1 5 2 3 3 1 1 0 Other connective and soft tissue Ž 21 0 0 0 0 0 0 1 3 0 2 2 3 1 2 2 4 1 C50 Dojka M 9 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 3 2 Breast Ž 1082 0 0 0 0 0 4 20 37 76 89 135 137 133 119 125 104 103 C51 Žensko zunanje spolovilo M – – – – – – – – – – – – – – – – – – Vulva Ž 41 0 0 0 0 0 0 0 0 2 2 5 3 1 4 6 7 11 C52 Nožnica M – – – – – – – – – – – – – – – – – – Vagina Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 1 C53 Maternični vrat M – – – – – – – – – – – – – – – – – – Cervix uteri Ž 180 0 0 0 0 3 9 17 27 24 32 14 8 6 8 11 9 12 C54 Maternično telo M – – – – – – – – – – – – – – – – – – Corpus uteri Ž 326 0 0 0 0 0 1 0 1 9 13 45 46 38 51 46 42 34 C55 Maternica, neopredeljeno M – – – – – – – – – – – – – – – – – – Uterus, unspecified Ž 9 0 0 0 0 0 0 0 0 1 1 2 0 0 1 1 2 1 C56 Jajčnik M – – – – – – – – – – – – – – – – – – Ovary Ž 197 0 1 0 1 1 4 0 4 5 18 23 23 35 22 23 22 15 42 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 4a. – Table 4a. Nadaljevanje – Continued Šifra MKB Lokacija Spol Vse starosti S t a r o s t ICD Site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 C57 Drugi in neopredeljeni ženski spolni organi M – – – – – – – – – – – – – – – – – – Other and unspecified parts of female genital organs Ž 9 0 0 0 0 0 0 0 1 0 1 1 2 2 1 0 0 1 C58 Posteljica M – – – – – – – – – – – – – – – – – – Placenta Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C60 Penis M 6 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 1 1 Penis Ž – – – – – – – – – – – – – – – – – – C61 Prostata M 859 0 0 0 0 0 0 0 0 1 7 37 76 137 188 174 148 91 Prostate Ž – – – – – – – – – – – – – – – – – – C62 Modo M 79 0 0 0 4 11 16 19 13 7 6 1 2 0 0 0 0 0 Testis Ž – – – – – – – – – – – – – – – – – – C63 Drugi in neopredeljeni moški spolni organi M 4 0 0 0 0 0 0 0 2 0 1 1 0 0 0 0 0 0 Other and unspecified male genital organs Ž – – – – – – – – – – – – – – – – – – C64 Ledvica razen meha M 172 0 0 0 0 1 0 2 7 7 15 13 27 30 25 26 11 8 Kidney, except renal pelvis Ž 89 0 1 0 0 0 0 1 1 4 7 5 3 10 15 17 15 10 C65 Ledvični meh M 14 0 0 0 0 0 0 0 0 0 0 2 0 2 3 2 3 2 Renal pelvis Ž 14 0 0 0 0 0 0 0 0 0 0 1 0 2 4 4 0 3 C66 Sečevod M 9 0 0 0 0 0 0 0 0 0 1 3 1 0 2 1 1 0 Ureter Ž 6 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 3 C67 Sečni mehur M 211 0 0 0 0 0 0 0 0 0 5 19 24 22 33 45 29 34 Bladder Ž 64 0 0 0 0 0 0 0 0 2 4 2 6 2 7 7 16 18 C68 Drugi in neopredeljeni sečni organi M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 Other and unspecified urinary organs Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C69 Oko in očesni adneksi M 14 1 0 0 0 0 0 0 0 1 2 1 1 1 2 2 2 1 Eye and adnexa Ž 5 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 2 C70 Meninge M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Meninges Ž 2 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 C71 Možgani M 66 2 3 1 0 1 1 1 2 4 6 13 5 6 12 4 3 2 Brain Ž 64 2 1 0 0 1 2 0 2 7 4 3 3 10 4 12 5 8 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Spinal cord, cranial nerves and other parts of CNS Ž 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 C73 Ščitnica M 31 0 0 1 1 1 2 0 1 1 3 8 5 5 2 1 0 0 Thyroid gland Ž 117 0 0 0 1 11 8 7 11 13 11 16 7 14 5 5 3 5 C74 Nadledvična žleza M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Adrenal gland Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 C75 Druge endokrine žleze in sorodne strukture M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other endocrine glands and related structures Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 C76 Druga in slabo opredeljena mesta M 7 0 0 0 0 0 1 0 0 0 1 0 0 1 1 1 2 0 Other and ill-defined sites Ž 23 0 0 0 0 0 0 0 0 0 0 0 3 1 3 5 4 7 C77 Metastaza in neopredeljena maligna neoplazma bezgavk M 24 0 0 0 0 0 0 1 0 1 0 5 3 4 4 3 2 1 Metastasis and unspecified malignant neoplasm of lymph nodes Ž 12 0 0 0 0 0 0 0 0 0 1 2 2 1 1 1 1 3 C78 Metastaze dihal in prebavil M 43 0 0 0 0 0 0 0 0 0 1 4 3 4 8 6 9 8 Metastases of respiratory and digestive organs Ž 51 0 0 0 0 0 0 1 0 0 0 2 2 1 5 9 7 24 C79 Metastaze, drugje M 22 0 0 0 0 0 0 0 0 1 0 2 3 6 2 3 3 2 Metastases of other sites Ž 9 0 0 0 0 0 0 0 0 0 1 1 0 1 3 1 1 1 C80 Maligna neoplazma brez opredeljenega mesta M 43 0 0 0 0 0 0 0 1 2 5 4 1 7 4 8 5 6 Malignant neoplasm without specification of site Ž 40 0 0 0 0 0 0 1 0 2 3 2 3 3 3 8 4 11 C81 Hodgkinova bolezen M 26 0 1 2 0 4 3 0 3 2 2 1 2 1 3 1 1 0 Hodgkin’s disease Ž 19 0 0 0 2 2 4 1 1 0 0 1 0 2 1 1 1 3 C82 Folikularni ne-Hodgkinov limfom M 26 0 0 0 0 0 0 1 3 2 0 5 4 2 5 1 2 1 Follicular non-Hodgkin’s lymphoma Ž 39 0 0 0 0 0 0 0 2 1 1 4 6 3 4 5 7 6 Cancer incidence in Slovenia 2005 43 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Šifra MKB Lokacija Spol Vse starosti S t a r o s t ICD Site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ Tabela 4a. – Table 4a. Nadaljevanje – Continued C83 Difuzni ne-Hodgkinov limfom M 68 0 0 1 3 1 1 1 6 2 3 5 5 6 11 8 10 5 Diffuse non-Hodgkin’s lymphoma Ž 77 0 0 0 0 0 1 2 1 0 6 6 7 10 7 15 10 12 C84 Limfomi celic T in kožni limfom celic T M 15 0 0 0 0 1 0 0 0 0 0 0 6 2 3 1 1 1 Peripheral and cutaneous T-cell lymphomas Ž 14 0 0 0 0 1 2 0 1 0 1 3 2 1 1 1 1 0 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma M 7 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 2 1 Other and unspecified types of non-Hodgkin’s lymphoma Ž 8 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 5 C88 Maligne imunopro-liferativne bolezni M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Malignant immunopro- liferative diseases Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov M 45 0 0 0 0 0 0 0 0 3 5 3 5 2 6 11 7 3 Multiple myeloma and malignant plasma cell neoplasms Ž 56 0 0 0 0 0 0 0 0 2 2 5 4 5 5 9 9 15 C91.0 Limfatična levkemija, akutna M 9 3 2 0 2 0 0 1 0 0 1 0 0 0 0 0 0 0 Lymphoblastic leukaemia, acute Ž 8 1 0 1 0 0 0 0 0 0 0 0 1 2 0 2 1 0 C91.– Limfatična levkemija, druga M 46 0 0 0 0 0 0 0 0 2 2 5 3 8 12 3 4 7 C91.9 Lymphoid leukaemia, other Ž 34 0 0 0 0 0 0 0 0 0 2 2 3 5 3 2 8 9 C92 Mieloična levkemija M 31 0 0 0 0 1 1 0 1 1 2 0 1 4 6 5 2 7 Myeloid leukaemia Ž 47 1 0 0 2 0 2 2 0 1 1 1 5 3 7 5 5 12 C93 Monocitna levkemija M 3 0 0 0 1 0 0 0 0 0 1 0 0 0 0 1 0 0 Monocytic leukaemia Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 C94 Druge opredeljene levkemije M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other leukaemias of specified cells Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 C95 Levkemija z neopre-deljenim celičnim tipom M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leukaemia, unspecified cell type Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvor- nega in sorodnega tkiva M 66 0 0 0 0 0 1 0 0 1 3 4 6 3 12 13 11 12 Other and unspecified malignant neoplasms of lymphoid, haemato- poietic and related tissue Ž 64 0 0 0 0 1 0 0 4 1 3 3 3 6 5 7 15 16 Zgoraj neupoštevani Not included above D03 Melanom, in situ M 16 0 0 0 0 0 0 0 0 1 1 1 3 3 3 4 0 0Melanoma, in situ Ž 13 0 0 0 0 0 2 0 0 2 1 1 0 2 1 2 2 0 D05 Dojka, in situ M 2 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0Breast, in situ Ž 90 0 0 0 0 0 0 0 2 2 13 18 15 8 8 13 7 4 D06 Maternični vrat, CIN III M – – – – – – – – – – – – – – – – – –Cervix uteri, in situ Ž 1093 0 0 0 2 88 237 239 163 158 95 40 33 16 9 8 2 3 D09.0 Sečni mehur, in situ M 107 0 0 0 0 0 0 0 1 2 8 12 10 12 14 23 14 11Bladder, in situ Ž 38 0 0 0 0 0 0 0 0 3 0 8 5 6 2 6 5 3 D32.0 Meninge, benigna neoplazma M 21 0 0 1 0 0 2 0 1 0 0 3 1 3 1 5 3 1 Benign neoplasm of meninges Ž 43 0 0 0 0 1 0 0 1 3 3 4 4 5 4 6 7 5 D33.0 Možgani, benigna neoplazma M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 –D33.2 Benign neopasm of brain Ž 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 D39.1 Jajčnik, neopl. negotovega značaja M – – – – – – – – – – – – – – – – – – Ovary, neopl. of uncertain behavior Ž 30 0 0 0 0 1 1 2 5 8 4 3 4 2 0 0 0 0 D43.0 Možgani, neopredeljeno M 6 0 0 0 0 0 1 0 0 2 0 0 0 1 1 0 1 0 –D43.2 CNS, uncertain or unknown Ž 11 0 0 0 0 0 0 0 0 1 0 1 1 0 2 3 1 2 44 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 4b. Incidenca raka po lokaciji (MKB-8), spolu in starosti – Slovenija 2005 Table 4b. Cancer incidence by site (ICD-8), by sex and by age – Slovenia 2005 Šifra MKB-8 Primarna lokacija Spol Vse starosti S t a r o s t ICD-8 Primary site Sex All A g e Site code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ 140 Vse lokacije M + Ž 10612 15 9 6 21 49 80 115 199 334 539 892 1051 1234 1509 1649 1432 1478 – M 5405 7 6 5 12 23 33 40 70 120 238 441 595 712 911 935 728 529 209 All sites Ž 5207 8 3 1 9 26 47 75 129 214 301 451 456 522 598 714 704 949 140 Ustnica M 14 0 0 0 0 0 0 0 0 0 1 0 1 2 2 2 5 1 Lip Ž 12 0 0 0 0 0 0 0 0 0 0 0 1 0 3 2 1 5 141 Jezik M 50 0 0 0 0 0 0 0 2 3 8 12 6 6 7 4 2 0 Tongue Ž 7 0 0 0 0 1 0 0 0 0 0 0 0 2 2 0 1 1 142 Slinavke M 10 0 0 0 0 0 0 0 1 1 2 0 1 2 0 1 1 1 Salivary glands Ž 10 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 2 3 143 Dlesni M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 Gum Ž 4 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 144 Ustno dno M 28 0 0 0 0 0 0 0 1 2 4 6 8 2 2 1 2 0 Floor of mouth Ž 6 0 0 0 0 0 0 0 0 0 1 1 0 0 2 1 1 0 145 Usta, drugo M 28 0 0 0 0 0 0 0 0 0 3 2 7 6 5 4 1 0 Mouth, other parts Ž 18 0 0 0 0 1 0 0 2 3 0 1 2 2 0 4 1 2 146 Orofarinks M 76 0 0 0 0 0 0 0 4 5 12 11 9 15 7 8 4 1 Oropharynx Ž 14 0 0 0 0 0 0 0 0 0 2 1 1 4 0 4 2 0 147 Epifarinks M 4 0 0 0 0 0 0 0 1 0 0 0 2 0 1 0 0 0 Epipharynx Ž 6 0 0 0 0 0 0 0 0 1 0 0 1 0 0 2 2 0 148 Hipofarinks M 47 0 0 0 0 0 0 0 0 0 3 6 12 8 12 3 3 0 Hypopharynx Ž 7 0 0 0 0 0 0 0 0 1 2 1 1 0 0 0 1 1 149 Žrelo, neoznačeno M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Pharynx, not specified Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 150 Požiralnik M 74 0 0 0 0 0 0 0 0 1 1 4 16 19 11 14 4 4 Oesophagus Ž 17 0 0 0 0 0 0 0 0 0 0 1 2 3 1 4 2 4 151 Želodec M 310 0 0 0 0 0 1 1 2 12 14 23 25 37 57 48 51 39 Stomach Ž 203 0 0 0 0 0 0 4 3 3 9 6 10 12 21 37 37 61 152 Tanko črevo M 14 0 0 0 0 0 0 0 0 0 1 4 1 1 1 2 0 4 Small intestine Ž 15 0 0 0 0 0 0 0 1 0 0 1 1 0 5 2 3 2 153 Debelo črevo M 386 0 0 0 1 1 1 0 1 8 10 22 37 46 81 72 67 39 Colon Ž 314 0 0 0 0 0 0 1 1 8 4 19 17 34 34 57 57 82 154 Rektum M 315 0 0 0 0 0 1 1 2 6 15 22 46 42 53 58 44 25 Rectum Ž 228 0 0 0 0 1 1 0 1 3 6 10 15 22 35 29 47 58 155 Jetra M 80 0 0 0 0 0 0 0 0 0 4 7 11 10 19 13 9 7 Liver Ž 18 0 0 0 0 0 0 0 0 0 0 0 1 0 5 2 5 5 156 Žolčnik, žolčni vodi M 59 0 0 0 0 0 0 0 1 1 4 1 4 8 11 13 7 9 Gallbladder, bile ducts Ž 116 0 0 0 0 0 0 0 0 1 1 9 9 6 9 14 31 36 157 Trebušna slinavka M 114 0 0 0 0 0 0 1 0 6 4 9 12 22 15 15 18 12 Pancreas Ž 171 0 0 0 0 0 0 0 1 2 7 10 10 18 20 38 26 39 158 Retro-, peritonej M 6 0 0 0 0 0 0 0 0 0 0 0 1 1 1 2 0 1 Retro, peritoneum Ž 13 1 0 0 0 0 0 0 1 0 0 0 2 1 5 2 1 0 159 Prebavila, drugo M 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 Digestive organs, other Ž 4 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 1 160 Nos, obnosne votline, drugo M 12 1 0 0 0 0 0 0 0 1 1 0 3 0 1 2 3 0 Nose, sinuses, etc. Ž 8 0 0 0 0 0 0 0 0 1 0 1 2 0 1 1 1 1 161 Grlo M 76 0 0 0 0 0 0 0 1 3 8 7 12 10 10 11 9 5 Larynx Ž 14 0 0 0 0 0 0 0 0 1 1 1 3 2 2 0 4 0 162 Sapnik, sapnica, pljuča M 848 0 0 0 0 0 0 2 3 12 37 88 113 113 143 165 110 62 Trachea, bronchus, lung Ž 305 0 0 0 0 0 0 0 4 13 18 37 28 34 38 43 40 50 163 Plevra, mediastinum, drugo M 24 0 0 0 1 0 0 1 1 0 0 4 1 4 3 3 2 4 Pleura, mediastinum, etc. Ž 5 1 0 0 0 0 0 0 0 1 0 0 1 0 2 0 0 0 170 Kosti M 4 0 0 0 0 0 0 0 1 0 0 1 0 0 0 2 0 0 Bone Ž 8 0 0 0 2 1 0 0 1 2 0 0 0 0 0 0 2 0 171 Mehka tkiva M 25 0 0 0 0 1 1 1 3 1 1 5 2 3 5 1 1 0 Soft tissues Ž 22 0 0 0 0 0 0 1 3 0 2 2 4 1 2 2 4 1 172 Koža, maligni melanom M 126 0 0 0 0 1 1 4 6 8 9 15 22 12 16 15 5 12Skin, malignant mela- noma Ž 181 0 0 0 0 3 4 8 13 9 19 13 15 16 23 14 12 32 173 Koža, drugi malignomi M 785 0 0 0 0 0 3 4 7 15 25 55 67 93 110 164 126 116 Skin, other malignancies Ž 839 0 0 0 0 0 7 9 8 16 29 54 57 72 98 133 132 224 174 Dojka M 9 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 3 2 Breast Ž 1086 0 0 0 0 0 4 20 37 76 89 135 137 135 120 125 104 104 nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 45 Institute of Oncology Ljubljana, Cancer Registry of Slovenia 180 Maternica, vrat M – – – – – – – – – – – – – – – – – – Uterus, cervix Ž 180 0 0 0 0 3 9 17 27 24 32 14 8 6 8 11 9 12 181 Horioepiteliom M – – – – – – – – – – – – – – – – – – Chorioepithelioma Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 182 Maternica, telo, drugo M – – – – – – – – – – – – – – – – – – Uterus, corpus, etc. Ž 335 0 0 0 0 0 1 0 1 10 14 47 46 38 52 47 44 35 183 Jajčnik, jajcevod, drugo M – – – – – – – – – – – – – – – – – – Ovary, Fallopian tube, other Ž 204 0 1 0 1 1 4 0 5 5 19 24 25 36 23 23 22 15 184 Nožnica, vulva, drugo M – – – – – – – – – – – – – – – – – – Vagina, vulva, etc. Ž 47 0 0 0 0 0 0 0 0 2 2 5 3 2 4 9 7 13 185 Prostata M 859 0 0 0 0 0 0 0 0 1 7 37 76 137 188 174 148 91 Prostate Ž – – – – – – – – – – – – – – – – – – 186 Modo M 81 0 0 0 4 11 16 19 13 7 6 1 2 0 1 1 0 0 Testis Ž – – – – – – – – – – – – – – – – – – 187 Penis, obmodek, drugo M 7 0 0 0 0 0 0 0 1 1 0 0 0 1 2 0 1 1 Penis, epididymis, etc. Ž – – – – – – – – – – – – – – – – – – 188 Mehur M 212 0 0 0 0 0 0 0 0 0 5 19 24 22 33 45 30 34 Bladder Ž 65 0 0 0 0 0 0 0 1 2 4 2 6 2 7 7 16 18 189 Ledvica, sečevod, drugo M 198 0 0 0 0 1 0 2 7 7 17 18 28 32 30 30 16 10 Kidney, ureter, etc. Ž 110 0 1 0 0 0 0 1 2 4 7 6 3 12 19 23 15 17 190 Oko M 15 1 0 0 0 0 0 0 0 1 2 1 1 1 2 3 2 1 Eye Ž 5 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 2 191 Možgani M 68 2 3 1 0 1 1 1 2 4 6 13 5 7 13 4 3 2 Brain Ž 71 2 1 0 0 1 2 0 2 7 5 5 3 13 4 13 5 8 192 Živčevje, drugo M 2 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 Nervous system, other Ž 4 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 193 Ščitnica M 31 0 0 1 1 1 2 0 1 1 3 8 5 5 2 1 0 0 Thyroid Ž 119 0 0 0 1 11 8 7 11 13 11 16 7 14 5 5 3 7 194 Endokrine žleze, druge M 4 0 0 0 0 0 0 0 0 0 0 3 0 0 1 0 0 0 Endocrine glands, other Ž 6 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 2 1 195 Slabo opredeljene lokacije M 7 0 0 0 0 0 1 0 0 0 1 0 0 1 1 1 2 0 Ill-defined site Ž 23 0 0 0 0 0 0 0 0 0 0 0 3 1 3 5 4 7 196 Metastaze v bezgavkah M 24 0 0 0 0 0 0 1 0 1 0 5 3 4 4 3 2 1 Lymph node metastases Ž 12 0 0 0 0 0 0 0 0 0 1 2 2 1 1 1 1 3 197 Metastaze v dihalih, prebavilih M 62 0 0 0 0 0 0 0 0 0 2 7 3 6 12 9 11 12 Respirative, digestive tract metastases Ž 67 0 0 0 0 0 0 1 0 0 0 2 2 1 7 10 10 34 198 Metastaze, drugje M 22 0 0 0 0 0 0 0 0 1 0 2 3 6 2 3 3 2 Metastases, other Ž 9 0 0 0 0 0 0 0 0 0 1 1 0 1 3 1 1 1 199 Malignomi, neopre- deljeni M 43 0 0 0 0 0 0 0 1 2 5 4 1 7 4 8 5 6 Malignancies, unspeci- fied Ž 40 0 0 0 0 0 0 1 0 2 3 2 3 3 3 8 4 11 200+ Ne-Hodgkinovi limfomi M 70 0 0 1 2 1 1 1 4 3 2 8 12 6 11 4 10 4 202 Non-Hodgkin’s lymphoma Ž 84 0 0 0 0 1 0 2 2 1 6 9 10 7 9 13 13 11 201 Hodgkinov limfom M 26 0 1 2 0 4 3 0 3 2 2 1 2 1 3 1 1 0 Hodgkin’s disease Ž 19 0 0 0 2 2 4 1 1 0 0 1 0 2 1 1 1 3 203 Plazmacitom M 40 0 0 0 0 0 0 0 0 1 5 2 5 2 4 11 7 3 Plasmacytoma Ž 55 0 0 0 0 0 0 0 0 2 2 5 3 5 5 9 9 15 204.0 Levkemija, limfatična, akutna M 9 3 2 0 2 0 0 1 0 0 1 0 0 0 0 0 0 0 Leukaemia, lymphatic, acute Ž 8 1 0 1 0 0 0 0 0 0 0 0 1 2 0 2 1 0 204.1– 204.9 Levkemija, limfatična, drugo M 42 0 0 0 0 0 0 0 0 2 0 5 2 7 12 3 4 7 Leukaemia, lymphatic, other Ž 32 0 0 0 0 0 0 0 0 0 2 2 3 5 3 2 6 9 205 Levkemija, mieloična M 24 0 0 0 1 1 1 0 1 1 2 0 1 2 5 3 1 5 Leukaemia, myeloic Ž 40 1 0 0 2 0 2 2 0 1 1 1 4 3 5 3 4 11 206 Levkemija, monocitna M 10 0 0 0 0 0 0 0 0 0 1 0 0 2 1 3 1 2 Leukaemia, monocytic Ž 11 1 0 0 0 0 0 0 0 0 0 0 1 0 3 2 2 2 207 Levkemije, druge M 4 0 0 0 0 0 0 0 0 0 2 0 1 1 0 0 0 0 Leukaemias, other Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 208 Policitemija, prava M 10 0 0 0 0 0 0 0 0 0 0 0 2 0 3 1 3 1 Polycythemia, other Ž 5 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 209 Mielofibroza M 7 0 0 0 0 0 0 0 0 0 1 1 0 0 1 2 1 1 Myelofibrosis Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Tabela 4b. – Table 4b. Nadaljevanje – Continued Šifra MKB-8 Primarna lokacija Spol Vse starosti S t a r o s t ICD-8 Primary site Sex All A g e Site code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 46 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 4b. – Table 4b. Nadaljevanje – Continued Šifra MKB-8 Primarna lokacija Spol Vse starosti S t a r o s t ICD-8 Primary site Sex All A g e Site code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ Zgoraj neupoštevani Not included above 219+ 234 Maternični vrat, in situ CIN III M – – – – – – – – – – – – – – – – – – Cervix uteri, in situ CIN III Ž 1093 0 0 0 2 88 237 239 163 158 95 40 33 16 9 8 2 3 225.0+ Možgani, benigni tumor M 25 0 0 1 0 0 2 0 1 0 0 3 1 5 2 6 3 1 225.2 Brain, benign tumor Ž 50 0 0 0 0 1 0 0 1 4 3 4 4 7 5 7 8 6 232.2 Maligni melanom, in situ M 16 0 0 0 0 0 0 0 0 1 1 1 3 3 3 4 0 0 Malignant melanoma, in situ Ž 13 0 0 0 0 0 2 0 0 2 1 1 0 2 1 2 2 0 233 Dojka, in situ M 2 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 Breast, in situ Ž 90 0 0 0 0 0 0 0 2 2 13 18 15 8 8 13 7 4 235 Jajčnik, neopl. negoto- vega značaja M – – – – – – – – – – – – – – – – – – Ovary, neopl. of uncer- tain behavior Ž 30 0 0 0 0 1 1 2 5 8 4 3 4 2 0 0 0 0 Sečni mehur, in situ M 107 0 0 0 0 0 0 0 1 2 8 12 10 12 14 23 14 11237.6 Bladder, in situ Ž 38 0 0 0 0 0 0 0 0 3 0 8 5 6 2 6 5 3 238.1 Možgani, neopredeljeno M 6 0 0 0 0 0 1 0 0 2 0 0 0 1 1 0 1 0 Brain, unspecified Ž 11 0 0 0 0 0 0 0 0 1 0 1 1 0 2 3 1 2 Cancer incidence in Slovenia 2005 47 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Ta b el a 5 . G ro b a in s ta ro st no s p ec ifi čn a in ci d en čn a s to p nj a n a 1 00 .0 00 p re b iv a lc ev te r k um ul a tiv na s to p nj a (K S) p o lo ka ci ji in s p o lu – S lo ve ni ja 2 00 5 Ta b le 5 . C ru d e a nd a g e s p e ci fic c a nc e r i nc id e nc e ra te p e r 1 00 ,0 00 a nd c um ul a tiv e ra te ( C R) b y sit e a nd b y se x – Sl ov e ni a 2 00 5 Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 C 00 V se lo ka ci je M + Ž 53 5, 7 16 ,8 9, 7 5, 8 17 ,0 35 ,4 52 ,8 79 ,0 13 5, 4 21 6, 4 34 8, 6 57 7, 0 86 4, 2 12 00 ,5 15 86 ,9 19 38 ,9 22 09 ,6 24 21 ,9 35 ,4 – M 55 6, 6 15 ,3 12 ,6 9, 5 18 ,9 31 ,7 42 ,8 53 ,4 92 ,1 15 3, 8 30 0, 6 55 3, 5 97 6, 8 14 43 ,2 20 98 ,2 27 04 ,7 32 12 ,0 33 41 ,6 42 ,5 C 96 A ll sit e Ž 51 5, 6 18 ,4 6, 7 2, 0 15 ,0 39 ,2 63 ,4 10 6, 2 17 9, 8 28 0, 6 39 8, 9 60 2, 1 75 1, 3 97 7, 5 11 56 ,6 14 13 ,6 16 73 ,5 20 98 ,9 30 ,1 C 00 U st ni ca M 1, 4 0 0 0 0 0 0 0 0 0 1, 3 0 1, 6 4, 0 4, 6 5, 7 21 ,8 6, 2 0, 1 Li p Ž 1, 2 0 0 0 0 0 0 0 0 0 0 0 1, 6 0 5, 8 3, 9 2, 3 10 ,9 0, 1 C 01 Ba za je zi ka M 2, 1 0 0 0 0 0 0 0 1, 3 0 5, 0 7, 5 3, 3 4, 0 9, 1 2, 9 4, 4 0 0, 2 Ba se o f t o ng ue Ž 0, 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 2 0, 0 C 02 Je zi k, d ru g i d el i M 2, 8 0 0 0 0 0 0 0 1, 3 3, 8 5, 0 7, 5 6, 5 6, 1 6, 8 5, 7 4, 4 0 0, 2 To ng ue , o th e r & u ns p e ci - fie d p a rt s Ž 0, 6 0 0 0 0 1, 5 0 0 0 0 0 0 0 3, 7 3, 8 0 2, 3 0 0, 0 C 03 D le se n M 0, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 0 0 6, 2 0, 0 G um Ž 0, 4 0 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 2, 0 4, 7 0 0, 0 C 04 U st no d no M 2, 9 0 0 0 0 0 0 0 1, 3 2, 5 5, 0 7, 5 13 ,0 4, 0 4, 6 2, 9 8, 7 0 0, 2 Fl o o r o f m o ut h Ž 0, 6 0 0 0 0 0 0 0 0 0 1, 3 1, 3 0 0 3, 8 2, 0 2, 3 0 0, 0 C 05 N eb o M 1, 5 0 0 0 0 0 0 0 0 0 2, 5 1, 2 6, 5 8, 1 4, 6 5, 7 0 0 0, 1 Pa la te Ž 0, 4 0 0 0 0 1, 5 0 0 1, 4 1, 3 0 0 1, 6 0 0 0 0 0 0, 0 C 06 U st a , d ru g i d el i M 1, 3 0 0 0 0 0 0 0 0 0 1, 3 1, 2 4, 9 4, 0 6, 8 5, 7 4, 4 0 0, 1 M o ut h, o th e r & u ns p e ci - fie d p a rt s Ž 1, 4 0 0 0 0 0 0 0 1, 4 2, 6 0 1, 3 1, 6 3, 7 0 7, 9 2, 3 4, 4 0, 1 C 07 Pa ro tid na ž le za M 0, 9 0 0 0 0 0 0 0 1, 3 1, 3 2, 5 0 1, 6 2, 0 0 2, 9 4, 4 6, 2 0, 1 Pa ro tid g la nd Ž 0, 8 0 0 0 1, 7 0 0 0 0 0 0 1, 3 0 1, 9 1, 9 2, 0 0 6, 5 0, 0 C 08 D ru g e in n eo p re d el je ne ve lik e žl ez e sl in a vk e M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 O th e r & u ns p e ci fie d m a jo r s a liv a ry g la nd s Ž 0, 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 0 0, 0 C 09 To nz ila M 2, 3 0 0 0 0 0 0 0 1, 3 1, 3 3, 8 1, 2 6, 5 10 ,1 4, 6 8, 6 8, 7 6, 2 0, 2 To ns il Ž 0, 5 0 0 0 0 0 0 0 0 0 2, 6 1, 3 0 1, 9 0 0 2, 3 0 0, 0 C 10 O ro fa rin ks M 4, 7 0 0 0 0 0 0 0 1, 3 3, 8 11 ,3 10 ,0 8, 2 20 ,2 11 ,4 11 ,4 4, 4 0 0, 4 O ro p ha ry nx Ž 0, 5 0 0 0 0 0 0 0 0 0 0 0 0 5, 6 0 2, 0 2, 3 0 0, 0 C 11 N a zo fa rin ks M 0, 3 0 0 0 0 0 0 0 1, 3 0 0 0 3, 3 0 0 0 0 0 0, 0 N a so p ha ry nx Ž 0, 4 0 0 0 0 0 0 0 0 1, 3 0 0 1, 6 0 0 2, 0 2, 3 0 0, 0 na d a lje va nj e / c o nt ’d 4 48 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo C 12 Pi rif o rm ni s in us M 2, 1 0 0 0 0 0 0 0 0 0 1, 3 2, 5 4, 9 8, 1 16 ,0 5, 7 8, 7 0 0, 2 Py rif o rm s in us Ž 0, 3 0 0 0 0 0 0 0 0 0 1, 3 1, 3 1, 6 0 0 0 0 0 0, 0 C 13 H ip o fa rin ks M 2, 7 0 0 0 0 0 0 0 0 0 2, 5 5, 0 14 ,7 8, 1 11 ,4 2, 9 4, 4 0 0, 2 H yp o p ha ry nx Ž 0, 3 0 0 0 0 0 0 0 0 1, 3 1, 3 0 0 0 0 0 2, 3 0 0, 0 C 14 D ru g a in s la b o o p re d e- lje na m es ta n a u st ni ci , v us tn i v o tli ni in fa rin ks u M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 O th e r a nd il l-d e fin e d s ite s in t he li p , o ra l c a vi ty a nd p ha ry nx Ž 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 C 15 Po ži ra ln ik M 7, 6 0 0 0 0 0 0 0 0 1, 3 1, 3 5, 0 26 ,1 38 ,4 25 ,1 40 ,1 17 ,5 24 ,8 0, 7 O e so p ha g us Ž 1, 7 0 0 0 0 0 0 0 0 0 0 1, 3 3, 3 5, 6 1, 9 7, 9 4, 7 8, 7 0, 1 C 16 Že lo d ec M 30 ,2 0 0 0 0 0 1, 3 1, 3 1, 3 14 ,0 17 ,5 26 ,2 40 ,8 70 ,6 12 3, 3 13 1, 7 21 8, 2 22 9, 4 2, 1 St o m a ch Ž 18 ,2 0 0 0 0 0 0 5, 7 2, 7 3, 9 10 ,5 5, 3 13 ,1 18 ,5 36 ,5 66 ,8 86 ,4 12 4, 1 0, 8 C 17 Ta nk o č re vo M 1, 4 0 0 0 0 0 0 0 0 0 1, 3 5, 0 1, 6 2, 0 2, 3 5, 7 0 24 ,8 0, 1 Sm a ll in te st in e Ž 1, 5 0 0 0 0 0 0 0 1, 4 0 0 1, 3 1, 6 0 9, 6 3, 9 7, 0 4, 4 0, 1 C 18 D eb el o č re vo M 38 ,9 0 0 0 0 0 1, 3 0 1, 3 10 ,2 12 ,5 27 ,4 60 ,3 92 ,8 18 2, 6 20 6, 1 28 3, 7 24 1, 8 3, 0 C o lo n Ž 30 ,5 0 0 0 0 0 0 1, 4 1, 4 10 ,4 5, 2 25 ,2 27 ,8 63 ,1 65 ,3 11 1, 9 13 0, 7 17 4, 2 1, 6 C 19 Re kt o si g m o id na z ve za M 6, 8 0 0 0 0 0 0 0 0 2, 5 5, 0 3, 7 16 ,3 18 ,2 25 ,1 37 ,2 34 ,9 43 ,4 0, 5 Re ct o sig m o id ju nc tio n Ž 4, 5 0 0 0 0 1, 5 0 0 0 0 1, 3 2, 7 1, 6 14 ,8 17 ,3 7, 9 18 ,7 26 ,1 0, 2 C 20 Re kt um M 24 ,1 0 0 0 0 0 1, 3 1, 3 2, 6 3, 8 11 ,3 21 ,2 57 ,1 60 ,6 93 ,6 12 5, 9 15 2, 7 11 1, 6 1, 9 Re ct um Ž 17 ,2 0 0 0 0 0 1, 3 0 1, 4 3, 9 5, 2 10 ,6 19 ,6 26 ,0 48 ,0 47 ,1 91 ,0 98 ,0 0, 8 C 21 A nu s in a na ln i k a na l M 1, 2 0 0 0 0 0 0 0 0 1, 3 2, 5 2, 5 1, 6 6, 1 2, 3 2, 9 4, 4 0 0, 1 A nu s a nd a na l c a na l Ž 0, 6 0 0 0 0 0 0 0 0 0 1, 3 0 3, 3 0 1, 9 2, 0 0 2, 2 0, 0 C 22 Je tra in in tra he p a tič ni vo d i M 10 ,1 0 0 0 0 0 0 0 0 0 6, 3 12 ,5 17 ,9 24 ,2 52 ,5 45 ,8 48 ,0 68 ,2 0, 8 Li ve r a nd in tra he p a tic b ile d uc ts Ž 3, 1 0 0 0 0 0 0 0 0 0 0 0 1, 6 0 13 ,4 5, 9 16 ,3 30 ,5 0, 1 C 23 Žo lč ni k M 2, 1 0 0 0 0 0 0 0 1, 3 0 1, 3 0 1, 6 6, 1 9, 1 5, 7 17 ,5 31 ,0 0, 1 G a llb la d d e r Ž 6, 9 0 0 0 0 0 0 0 0 0 0 9, 3 9, 8 5, 6 9, 6 17 ,7 49 ,0 41 ,4 0, 3 C 24 D ru g i i n ne o p re d el je ni d el i b ili a rn eg a tr a kt a M 3, 9 0 0 0 0 0 0 0 0 1, 3 3, 8 1, 2 4, 9 10 ,1 16 ,0 31 ,5 13 ,1 24 ,8 0, 3 Bi lli a ry tr a ct , o th e r a nd un sp e ci fie d p a rt s Ž 4, 5 0 0 0 0 0 0 0 0 1, 3 1, 3 2, 7 4, 9 5, 6 7, 7 9, 8 23 ,3 37 ,0 0, 2 C 25 Tr eb uš na s lin a vk a M 11 ,6 0 0 0 0 0 0 1, 3 0 7, 6 5, 0 11 ,2 19 ,6 44 ,4 34 ,2 42 ,9 78 ,6 74 ,4 0, 8 Pa nc re a s Ž 16 ,7 0 0 0 0 0 0 0 1, 4 2, 6 9, 2 13 ,3 16 ,4 33 ,4 38 ,4 74 ,6 60 ,7 84 ,9 0, 9 C 26 D ru g a in s la b o o p re d el - je na m es ta v p re b a vn ih o rg a ni h M 0, 3 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 0 0 4, 4 6, 2 0, 0 O th e r a nd il l-d e fin e d d ig e st iv e o rg a ns Ž 0, 5 0 0 0 0 0 0 0 0 0 0 1, 3 1, 6 0 1, 9 0 0 4, 4 0, 0 Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 na d a lje va nj e / c o nt ’d 4 Ta b el a 5 . – T a b le 5 . N a d a lje va nj e – C o nt in ue d Cancer incidence in Slovenia 2005 49 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 na d a lje va nj e / c o nt ’d 4 Ta b el a 5 . – T a b le 5 . N a d a lje va nj e – C o nt in ue d C 30 N os na vo tli na in sr ed nj e uh o M 0, 5 2, 2 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 2, 9 8, 7 0 0, 0 N a sa l c a vi ty a nd m id d le e a r Ž 0, 3 0 0 0 0 0 0 0 0 1, 3 0 0 1, 6 0 0 0 2, 3 0 0, 0 C 31 O b no sn i s in us i M 0, 5 0 0 0 0 0 0 0 0 0 1, 3 0 3, 3 0 0 2, 9 4, 4 0 0, 0 A cc e ss o ry s in us e s Ž 0, 4 0 0 0 0 0 0 0 0 0 0 1, 3 1, 6 0 1, 9 2, 0 0 0 0, 0 C 32 G rlo M 7, 8 0 0 0 0 0 0 0 1, 3 3, 8 10 ,0 8, 7 19 ,6 20 ,2 22 ,8 31 ,5 39 ,3 31 ,0 0, 6 La ry nx Ž 1, 3 0 0 0 0 0 0 0 0 1, 3 1, 3 1, 3 3, 3 3, 7 3, 8 0 9, 3 0 0, 1 C 33 Sa p ni k M 0, 1 0 0 0 0 0 0 0 0 0 0 0 1, 6 0 0 0 0 0 0, 0 Tr a ch e a Ž 0, 4 0 0 0 0 0 0 0 0 0 1, 3 0 1, 6 1, 9 0 0 2, 3 0 0, 0 C 34 Sa p ni ca in p lju ča M 86 ,3 0 0 0 0 0 0 2, 7 3, 9 15 ,3 46 ,3 10 9, 7 18 2, 6 22 8, 1 32 6, 5 46 9, 4 48 0, 1 38 4, 4 6, 9 Br o nc hu s a nd lu ng Ž 29 ,3 0 0 0 0 0 0 0 5, 4 17 ,0 22 ,3 49 ,1 42 ,6 61 ,2 73 ,0 82 ,5 91 ,0 10 8, 9 1, 8 C 37 Ti m us M 0, 3 0 0 0 0 0 0 0 0 0 0 2, 5 0 0 2, 3 0 0 0 0, 0 Th ym us Ž 0, 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 0 0, 0 C 38 Sr ce , m ed ia st in um , p le vr a M 0, 6 0 0 0 1, 6 0 0 1, 3 1, 3 0 0 0 0 0 0 0 0 18 ,6 0, 0 H e a rt , m e d ia st in um , p le ur a Ž 0, 1 2, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 C 39 D ru g a in s la b o o p re d el je na m es ta v d ih a lih in p rs ni h o rg a ni h M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 O th e r a nd il l-d e fin e d s ite s in th e re sp ira to ry s ys te m a nd in tra th o ra ci c o rg a ns Ž 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 C 40 Ko st i, sk le p ni h ru st a ne c ud ov M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 Bo ne a nd a rt ic ul a r c a rt i- la g e o f l im b s Ž 0, 2 0 0 0 1, 7 0 0 0 0 0 0 0 0 0 0 0 2, 3 0 0, 0 C 41 Ko st i, sk le p ni h ru st a ne c, d ru g je M 0, 3 0 0 0 0 0 0 0 0 0 0 1, 2 0 0 0 5, 7 0 0 0, 0 Bo ne a nd a rt ic ul a r ca rt ila g e o f o th e r a nd un sp e ci fie d p a rt s Ž 0, 6 0 0 0 1, 7 1, 5 0 0 1, 4 2, 6 0 0 0 0 0 0 2, 3 0 0, 0 C 43 M a lig ni m el a no m k ož e M 12 ,9 0 0 0 0 1, 4 1, 3 5, 3 7, 9 10 ,2 11 ,3 18 ,7 35 ,9 24 ,2 36 ,5 42 ,9 21 ,8 74 ,4 1, 0 M a lig na nt m e la no m a o f s ki n Ž 17 ,7 0 0 0 0 4, 4 5, 4 11 ,3 17 ,6 11 ,7 24 ,9 17 ,2 24 ,6 29 ,7 44 ,2 27 ,5 28 ,0 69 ,7 1, 1 C 44 D ru g e m a lig ne ne o p la zm e ko že M 78 ,8 0 0 0 0 0 3, 8 4, 0 6, 6 19 ,1 30 ,1 67 ,3 10 6, 0 18 5, 7 24 6, 6 46 9, 4 54 5, 5 70 6, 8 5, 7 Sk in , o th e r m a lig no m a s Ž 81 ,7 0 0 0 0 0 6, 7 12 ,7 10 ,8 20 ,9 38 ,1 70 ,3 93 ,3 13 3, 5 18 8, 3 26 1, 1 30 3, 4 48 7, 7 4, 2 C 45 M ez o te lio m M 2, 0 0 0 0 0 0 0 0 0 0 0 5, 0 3, 3 10 ,1 6, 8 8, 6 8, 7 6, 2 0, 2 M e so th e lio m a Ž 0, 4 0 0 0 0 0 0 0 0 1, 3 0 0 1, 6 0 3, 8 0 0 0 0, 0 C 46 Ka p o si je v sa rk o m M 0, 2 0 0 0 0 0 0 0 0 0 0 0 0 2, 0 0 0 0 6, 2 0, 0 Ka p o si’ s sa rc o m a Ž 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 50 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo C 47 Pe rif er ni ž iv ci in a vt o no m no ž iv če vj e M 0, 1 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 0 0 0 0, 0 Pe rip he ra l n e rv e s a nd a u- to no m ic n e rv o us s ys te m Ž 0, 1 0 0 0 0 0 0 0 1, 4 0 0 0 0 0 0 0 0 0 0, 0 C 48 Pe rit o ne j i n re tro p er ito ne j M 0, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 5, 7 0 0 0, 0 Re tro p e rit o ne um a nd p e rit o ne um Ž 1, 3 2, 3 0 0 0 0 0 0 1, 4 0 0 0 3, 3 1, 9 9, 6 3, 9 2, 3 0 0, 1 C 49 D ru g o v ez iv no in m eh ko tk iv o M 2, 3 0 0 0 0 1, 4 1, 3 1, 3 3, 9 1, 3 1, 3 6, 2 3, 3 6, 1 6, 8 2, 9 4, 4 0 0, 2 O th e r c o nn e ct iv e a nd so ft ti ss ue Ž 2, 1 0 0 0 0 0 0 1, 4 4, 1 0 2, 6 2, 7 4, 9 1, 9 3, 8 3, 9 9, 3 2, 2 0, 1 C 50 D o jk a M 0, 9 0 0 0 0 0 0 0 0 0 0 1, 2 0 0 2, 3 5, 7 13 ,1 12 ,4 0, 0 Br ea st Ž 10 6 0 0 0 0 0 5, 4 28 ,3 50 ,0 99 ,2 11 6, 8 17 9 22 4, 2 24 6, 7 22 8, 6 24 5, 4 24 2, 7 22 4, 3 7, 1 C 51 Že ns ko z un a nj e sp o lo vi lo M – – – – – – – – – – – – – – – – – – – V ul va Ž 4, 0 0 0 0 0 0 0 0 0 2, 6 2, 6 6, 6 4, 9 1, 9 7, 7 11 ,8 16 ,3 24 0, 2 C 52 N ož ni ca M – – – – – – – – – – – – – – – – – – – Va g in a Ž 0, 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5, 9 0 2, 2 0, 0 C 53 M a te rn ič ni v ra t M – – – – – – – – – – – – – – – – – – – C e rv ix u te ri Ž 17 ,6 0 0 0 0 4, 4 12 ,1 24 ,1 36 ,5 31 ,3 42 ,0 18 ,6 13 ,1 11 ,1 15 ,4 21 ,6 21 ,0 26 ,1 1, 2 C 54 M a te rn ič no te lo M – – – – – – – – – – – – – – – – – – – C o rp us u te ri Ž 31 ,9 0 0 0 0 0 1, 3 0 1, 4 11 ,7 17 ,1 59 ,7 75 ,3 70 ,5 98 ,0 90 ,3 98 ,0 74 ,0 2, 1 C 55 M at er ni ca , n eo pr ed el je no M – – – – – – – – – – – – – – – – – – – U te ru s, un sp e ci fie d Ž 0, 9 0 0 0 0 0 0 0 0 1, 3 1, 3 2, 7 0 0 1, 9 2, 0 4, 7 2, 2 0, 0 C 56 Ja jč ni k M – – – – – – – – – – – – – – – – – – – O va ry Ž 19 ,3 0 2, 2 0 1, 7 1, 5 5, 4 0 5, 4 6, 5 23 ,6 30 ,5 37 ,6 64 ,9 42 ,3 45 ,2 51 ,3 32 ,7 1, 3 C 57 D ru g i i n ne o p re d el je ni že ns ki s p o ln i o rg a ni M – – – – – – – – – – – – – – – – – – – O th e r a nd u ns p e ci fie d p a rt s o f f e m a le g e ni ta l o rg a ns Ž 0, 9 0 0 0 0 0 0 0 1, 4 0 1, 3 1, 3 3, 3 3, 7 1, 9 0 0 2, 2 0, 1 C 58 Po st el jic a M – – – – – – – – – – – – – – – – – – – Pl a ce nt a Ž 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 C 60 Pe ni s M 0, 6 0 0 0 0 0 0 0 0 1, 3 0 0 0 2, 0 4, 6 0 4, 4 6, 2 0, 0 Pe ni s Ž – – – – – – – – – – – – – – – – – – – C 61 Pr o st a ta M 87 ,6 0 0 0 0 0 0 0 0 1, 3 8, 8 46 ,1 12 3, 9 27 6, 5 42 9, 2 49 8, 0 64 5, 9 56 4, 2 6, 9 Pr o st a te Ž – – – – – – – – – – – – – – – – – – – C 62 M o d o M 8, 1 0 0 0 6, 3 15 ,2 20 ,1 25 ,4 17 ,1 8, 9 7, 5 1, 2 3, 3 0 0 0 0 0 0, 5 Te st is Ž – – – – – – – – – – – – – – – – – – – C 63 D ru g i i n ne o p re d el je ni m o šk i s p o ln i o rg a ni M 0, 4 0 0 0 0 0 0 0 2, 6 0 1, 3 1, 2 0 0 0 0 0 0 0, 0 O th e r a nd u ns p e ci fie d m a le g e ni ta l o rg a ns Ž – – – – – – – – – – – – – – – – – – – na d a lje va nj e / c o nt ’d 4 Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 Ta b el a 5 . – T a b le 5 . N a d a lje va nj e – C o nt in ue d Cancer incidence in Slovenia 2005 51 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C 64 Le d vi ca ra ze n m eh a M 17 ,5 0 0 0 0 1, 4 0 2, 7 9, 2 8, 9 18 ,8 16 ,2 44 ,0 60 ,6 57 ,1 74 ,4 48 ,0 49 ,6 1, 5 Ki d ne y, e xc e p t r e na l p e lv is Ž 8, 7 0 2, 2 0 0 0 0 1, 4 1, 4 5, 2 9, 2 6, 6 4, 9 18 ,5 28 ,8 33 ,4 35 ,0 21 ,8 0, 6 C 65 Le d vi čn i m eh M 1, 4 0 0 0 0 0 0 0 0 0 0 2, 5 0 4, 0 6, 8 5, 7 13 ,1 12 ,4 0, 1 Re na l p e lv is Ž 1, 4 0 0 0 0 0 0 0 0 0 0 1, 3 0 3, 7 7, 7 7, 9 0 6, 5 0, 1 C 66 Se če vo d M 0, 9 0 0 0 0 0 0 0 0 0 1, 3 3, 7 1, 6 0 4, 6 2, 9 4, 4 0 0, 1 U re te r Ž 0, 6 0 0 0 0 0 0 0 1, 4 0 0 0 0 0 0 3, 9 0 6, 5 0, 0 C 67 Se čn i m eh ur M 21 ,5 0 0 0 0 0 0 0 0 0 6, 3 23 ,7 39 ,1 44 ,4 75 ,3 12 8, 8 12 6, 6 21 0, 8 1, 6 Bl a d d e r Ž 6, 3 0 0 0 0 0 0 0 0 2, 6 5, 2 2, 7 9, 8 3, 7 13 ,4 13 ,7 37 ,3 39 ,2 0, 3 C 68 D ru g i i n ne o p re d el je ni se čn i o rg a ni M 0, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 9 4, 4 0 0, 0 O th e r a nd u ns p e ci fie d ur in a ry o rg a ns Ž 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 C 69 O ko in o če sn i a d ne ks i M 1, 4 2, 2 0 0 0 0 0 0 0 1, 3 2, 5 1, 2 1, 6 2, 0 4, 6 5, 7 8, 7 6, 2 0, 1 Ey e a nd a d ne xa Ž 0, 5 0 0 0 0 0 0 0 0 0 1, 3 0 1, 6 1, 9 0 0 0 4, 4 0, 0 C 70 M en in g e M 0, 1 0 0 0 0 0 0 0 0 0 0 1, 2 0 0 0 0 0 0 0, 0 M e ni ng e s Ž 0, 2 0 0 0 0 0 0 0 0 0 0 0 1, 6 1, 9 0 0 0 0 0, 0 C 71 M ož g a ni M 6, 7 4, 4 6, 3 1, 9 0 1, 4 1, 3 1, 3 2, 6 5, 1 7, 5 16 ,2 8, 2 12 ,1 27 ,4 11 ,4 13 ,1 12 ,4 0, 5 Br a in Ž 6, 3 4, 6 2, 2 0 0 1, 5 2, 7 0 2, 7 9, 1 5, 2 4, 0 4, 9 18 ,5 7, 7 23 ,6 11 ,7 17 ,4 0, 4 C 72 H rb tn i m o ze g , m ož g a ns ki ži vc i i n d ru g i d el i C ŽS M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 Sp in a l c o rd , c ra ni a l ne rv e s a nd o th e r p a rt s o f C N S Ž 0, 1 0 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 0 0 0 0, 0 C 73 Šč itn ic a M 3, 2 0 0 1, 9 1, 6 1, 4 2, 5 0 1, 3 1, 3 3, 8 10 ,0 8, 2 10 ,1 4, 6 2, 9 0 0 0, 2 Th yr o id g la nd Ž 11 ,5 0 0 0 1, 7 16 ,0 10 ,8 9, 9 14 ,9 17 ,1 14 ,4 21 ,2 11 ,5 26 9, 6 9, 8 7, 0 10 ,9 0, 8 C 74 N a d le d vi čn a ž le za M 0, 1 0 0 0 0 0 0 0 0 0 0 1, 2 0 0 0 0 0 0 0, 0 A d re na l g la nd Ž 0, 2 2, 3 0 0 0 0 0 0 0 0 0 0 0 0 1, 9 0 0 0 0, 0 C 75 D ru g e en d o kr in e žl ez e in so ro d ne s tru kt ur e M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 O th e r e nd o cr in e g la nd s a nd re la te d s tru ct ur e s Ž 0, 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 3 2, 2 0, 0 C 76 D ru g a in s la b o o p re d el je na m es ta M 0, 7 0 0 0 0 0 1, 3 0 0 0 1, 3 0 0 2, 0 2, 3 2, 9 8, 7 0 0, 0 O th e r a nd il l-d e fin e d s ite s Ž 2, 3 0 0 0 0 0 0 0 0 0 0 0 4, 9 1, 9 5, 8 9, 8 9, 3 15 ,2 0, 1 C 77 M et as ta za in n eo pr ed el je - na m al ig na n eo pl az m a be zg av k M 2, 4 0 0 0 0 0 0 1, 3 0 1, 3 0 6, 2 4, 9 8, 1 9, 1 8, 6 8, 7 6, 2 0, 2 M et a st a sis a nd u ns p e ci - fie d m a lig na nt n e o p la sm o f l ym p h no d e s Ž 1, 2 0 0 0 0 0 0 0 0 0 0 1, 3 2, 7 3, 3 1, 9 2, 0 2, 3 6, 5 0, 1 Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 Ta b el a 5 . – T a b le 5 . N a d a lje va nj e – C o nt in ue d na d a lje va nj e / c o nt ’d 4 52 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 Ta b el a 5 . – T a b le 5 . N a d a lje va nj e – C o nt in ue d na d a lje va nj e / c o nt ’d 4 C 78 M et as ta ze d ih al in p re ba vi l M 4, 4 0 0 0 0 0 0 0 0 0 1, 3 5, 0 4, 9 8, 1 18 ,3 17 ,2 39 ,3 49 ,6 0, 3 M et a st a se s o f r e sp ira to ry a nd d ig e st iv e o rg a ns Ž 5, 0 0 0 0 0 0 0 1, 4 0 0 0 2, 7 3, 3 1, 9 9, 6 17 ,7 16 ,3 52 ,3 0, 2 C 79 M et a st a ze , d ru g je M 2, 2 0 0 0 0 0 0 0 0 1, 3 0 2, 5 4, 9 12 ,1 4, 6 8, 6 13 ,1 12 ,4 0, 2 M et a st a se s o f o th e r s ite s Ž 0, 9 0 0 0 0 0 0 0 0 0 1, 3 1, 3 0 1, 9 5, 8 2, 0 2, 3 2, 2 0, 1 C 80 M a lig na n eo p la zm a b re z o p re d el je ne g a m es ta M 4, 4 0 0 0 0 0 0 0 1, 3 2, 5 6, 3 5, 0 1, 6 14 ,1 9, 1 22 ,9 21 ,8 37 ,2 0, 3 M a lig na nt n e o p la sm w ith - o ut s p e ci fic a tio n o f s ite Ž 3, 9 0 0 0 0 0 0 1, 4 0 2, 6 3, 9 2, 7 4, 9 5, 6 5, 8 15 ,7 9, 3 24 ,0 0, 2 C 81 H o d g ki no va b o le ze n M 2, 7 0 2, 1 3, 8 0 5, 5 3, 8 0 3, 9 2, 5 2, 5 1, 2 3, 3 2, 0 6, 8 2, 9 4, 4 0 0, 2 H o d g ki n’ s d ise a se Ž 1, 9 0 0 0 3, 3 2, 9 5, 4 1, 4 1, 4 0 0 1, 3 0 3, 7 1, 9 2, 0 2, 3 6, 5 0, 1 C 82 Fo lik ul a rn i n e- H o d g ki no v lim fo m M 2, 7 0 0 0 0 0 0 1, 3 3, 9 2, 5 0 6, 2 6, 5 4, 0 11 ,4 2, 9 8, 7 6, 2 0, 2 Fo lli cu la r n o n- H o d g ki n’ s ly m p ho m a Ž 3, 8 0 0 0 0 0 0 0 2, 7 1, 3 1, 3 5, 3 9, 8 5, 6 7, 7 9, 8 16 ,3 13 ,1 0, 2 C 83 D ifu zn i n e- H o d g ki no v lim fo m M 6, 9 0 0 1, 9 4, 7 1, 4 1, 3 1, 3 7, 9 2, 5 3, 8 6, 2 8, 2 12 ,1 25 ,1 22 ,9 43 ,6 31 ,0 0, 5 D iff us e n o n- H o d g ki n’ s ly m p ho m a Ž 7, 5 0 0 0 0 0 1, 3 2, 8 1, 4 0 7, 9 8, 0 11 ,5 18 ,5 13 ,4 29 ,5 23 ,3 26 ,1 0, 5 C 84 Li m fo m i c el ic T in k ož ni lim fo m c el ic T M 1, 5 0 0 0 0 1, 4 0 0 0 0 0 0 9, 8 4, 0 6, 8 2, 9 4, 4 6, 2 0, 1 Pe rip he ra l a nd c ut a ne - o us T -c e ll ly m p ho m a s Ž 1, 4 0 0 0 0 1, 5 2, 7 0 1, 4 0 1, 3 4, 0 3, 3 1, 9 1, 9 2, 0 2, 3 0 0, 1 C 85 D ru g e in n eo p re d el je ne vr st e ne -H o d g ki no ve g a lim fo m a M 0, 7 0 0 0 0 0 0 0 0 0 0 1, 2 0 2, 0 2, 3 2, 9 8, 7 6, 2 0, 0 O th e r a nd u ns p e ci fie d ty p e s o f n o n- H o d g ki n’ s ly m p ho m a Ž 0, 8 0 0 0 0 0 0 0 0 0 0 1, 3 0 0 0 2, 0 2, 3 10 ,9 0, 0 C 88 M a lig ne im un o p ro lif er a - tiv ne b o le zn i M 0, 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4, 4 0 0, 0 M a lig na nt im m un o p ro lif - e ra tiv e d ise a se s Ž 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 C 90 D ifu zn i p la zm o ci to m in m a lig ne n eo p la zm e p la zm o ci to v M 4, 6 0 0 0 0 0 0 0 0 3, 8 6, 3 3, 7 8, 2 4, 0 13 ,7 31 ,5 30 ,5 18 ,6 0, 4 M ul tip le m ye lo m a a nd m a lig na nt p la sm a c e ll ne o p la sm s Ž 5, 5 0 0 0 0 0 0 0 0 2, 6 2, 6 6, 6 6, 5 9, 3 9, 6 17 ,7 21 ,0 32 ,7 0, 3 C 91 .0 Li m fa tič na le vk em ija , a ku tn a M 0, 9 6, 5 4, 2 0 3, 2 0 0 1, 3 0 0 1, 3 0 0 0 0 0 0 0 0, 1 Ly m p ho b la st ic le uk a e - m ia , a cu te Ž 0, 8 2, 3 0 2, 0 0 0 0 0 0 0 0 0 1, 6 3, 7 0 3, 9 2, 3 0 0, 1 C 91 .1 – Li m fa tič na le vk em ija , d ru g a M 4, 7 0 0 0 0 0 0 0 0 2, 5 2, 5 6, 2 4, 9 16 ,1 27 ,4 8, 6 17 ,5 43 ,4 0, 3 C 91 .9 Ly m p ho id le uk a em ia , o th er Ž 3, 3 0 0 0 0 0 0 0 0 0 2, 6 2, 7 4, 9 9, 3 5, 8 3, 9 18 ,7 19 ,6 0, 1 Cancer incidence in Slovenia 2005 53 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C 92 M ie lo ič na le vk em ija M 3, 2 0 0 0 0 1, 4 1, 3 0 1, 3 1, 3 2, 5 0 1, 6 8, 1 13 ,7 14 ,3 8, 7 43 ,4 0, 2 M ye lo id le uk a e m ia Ž 4, 6 2, 3 0 0 3, 3 0 2, 7 2, 8 0 1, 3 1, 3 1, 3 8, 2 5, 6 13 ,4 9, 8 11 ,7 26 ,1 0, 3 C 93 M o no ci tn a le vk em ija M 0, 3 0 0 0 1, 6 0 0 0 0 0 1, 3 0 0 0 0 2, 9 0 0 0, 0 M o no cy tic le uk a e m ia Ž 0, 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1, 9 0 2, 3 2, 2 0, 0 C 94 D ru g e o p re d el je ne le vk em ije M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 O th e r l e uk a e m ia s o f sp e ci fie d c e lls Ž 0, 2 2, 3 0 0 0 0 0 0 0 0 0 0 0 0 1, 9 0 0 0 0, 0 C 95 Le vk em ija z n eo p re d e- lje ni m c el ič ni m ti p o m M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 Le uk a e m ia , u ns p e ci fie d ce ll ty p e Ž 0, 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2, 2 0, 0 C 96 D ru g e in n eo p re d el je ne m a lig ne n eo p la zm e lim fa tič ne g a , k rv o tv o rn e- g a a li so ro d ne g a tk iv a M 6, 7 0 0 0 0 0 1, 3 0 0 1, 3 3, 8 5, 0 9, 8 6, 1 27 ,4 37 ,2 48 ,0 74 ,4 0, 5 O th e r a nd u ns p e ci fie d m a lig na nt n e o p la sm s o f ly m p ho id , h a e m a to p o i- et ic a nd re la te d ti ss ue Ž 6, 3 0 0 0 0 1, 5 0 0 5, 4 1, 3 3, 9 4, 0 4, 9 11 ,1 9, 6 13 ,7 35 ,0 34 ,8 0, 3 Zg o ra j n eu p o št ev a ni N o t i nc lu d e d a b ov e D 03 M el a no m , i n si tu M 1, 6 0 0 0 0 0 0 0 0 1, 3 1, 3 1, 2 4, 9 6, 1 6, 8 11 ,4 0 0 0, 2 M e la no m a , i n sit u Ž 1, 3 0 0 0 0 0 2, 7 0 0 2, 6 1, 3 1, 3 0 3, 7 1, 9 3, 9 4, 7 0 0, 1 D 05 D o jk a , i n si tu M 0, 2 0 0 0 0 0 0 0 0 0 0 0 1, 6 2, 0 0 0 0 0 0, 0 Br e a st , i n sit u Ž 8, 8 0 0 0 0 0 0 0 2, 7 2, 6 17 ,1 23 ,9 24 ,6 14 ,8 15 ,4 25 ,5 16 ,3 8, 7 0, 6 D 06 M a te rn ič ni v ra t, C IN II I M – – – – – – – – – – – – – – – – – – – C e rv ix u te ri, in s itu Ž 10 7, 0 0 0 0 3, 3 12 7, 8 31 9, 9 33 8, 5 22 0, 3 20 6, 2 12 4, 6 53 ,0 54 ,0 29 ,7 17 ,3 15 ,7 4, 7 6, 5 7, 6 D 09 .0 Se čn i m eh ur , i n si tu M 10 ,9 0 0 0 0 0 0 0 1, 3 2, 5 10 15 ,0 16 ,3 24 ,2 32 ,0 65 ,8 61 ,1 68 ,2 0, 8 Bl a d d e r, in s itu Ž 3, 7 0 0 0 0 0 0 0 0 3, 9 0 10 ,6 8, 2 11 ,1 3, 8 11 ,8 11 ,7 6, 5 0, 2 D 32 .0 M en in g e, b en ig na ne o p la zm a M 2, 1 0 0 1, 9 0 0 2, 5 0 1, 3 0 0 3, 7 1, 6 6, 1 2, 3 14 ,3 13 ,1 6, 2 0, 2 Be ni g n ne o p la sm o f m e ni ng e s Ž 4, 2 0 0 0 0 1, 5 0 0 1, 4 3, 9 3, 9 5, 3 6, 5 9, 3 7, 7 11 ,8 16 ,3 10 ,9 0, 3 D 33 .0 – D 33 .2 M ož g a ni , b en ig na ne o p la zm a M 0, 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0, 0 Be ni g n ne o p a sm o f b ra in Ž 0, 1 0 0 0 0 0 0 0 0 1, 3 0 0 0 0 0 0 0 0 0, 0 D 39 .1 Ja jč ni k, n eo p l. ne g o to - ve g a z na ča ja M – – – – – – – – – – – – – – – – – – – O va ry , n e o p l. o f u nc e r- ta in b e ha vi o r Ž 2, 9 0 0 0 0 1, 5 1, 3 2, 8 6, 8 10 ,4 5, 2 4, 0 6, 5 3, 7 0 0 0 0 0, 2 D 43 .0 – M ož g a ni , n eo p re d el je no M 0, 6 0 0 0 0 0 1, 3 0 0 2, 5 0 0 0 2, 0 2, 3 0 4, 4 0 0, 0 D 43 .2 C N S, u nc e rta in o r u nk no w n Ž 1, 1 0 0 0 0 0 0 0 0 1, 3 0 1, 3 1, 6 0 3, 8 5, 9 2, 3 4, 4 0, 1 Ši fra M KB Pr im a rn a lo ka ci ja Sp o l V se st a ro st i S t a r o s t IC D Pr im a ry Se x A ll A g e co d e sit e a g e s 0– 5– 10 – 15 – 20 – 25 – 30 – 35 – 40 – 45 – 50 – 55 – 60 – 65 – 70 – 75 – 80 + 0– 74 Ta b el a 5 . – T a b le 5 . N a d a lje va nj e – C o nt in ue d na d a lje va nj e / c o nt ’d 4 54 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 6a. Incidenca najpogostejših lokacij raka po statističnih regijah in spolu – Slovenija 2005 Table 6a. Incidence of most frequent cancer sites by statistical regions and by sex – Slovenia 2005 Statistična regija Spol Sex Skupaj Lokacija (šifre MKB-10) Drugo Other C00–C96 C16 C18 C19 C20 C34 C44 C50 C53 C54 C61 D06* Statistical region All sites Site (ICD-10 codes) Slovenija, skupaj M 5455 296 381 67 236 846 773 9 – – 859 1988 – Slovenia, total Ž 5265 186 311 46 176 299 834 1082 180 326 – 1825 1093 Pomurska M 340 21 22 6 30 43 41 0 – – 65 112 – Ž 312 18 19 2 13 6 76 46 12 19 – 101 72 Podravska M 810 57 57 7 32 127 85 1 – – 140 304 – Ž 785 30 39 6 40 51 93 177 38 55 – 256 177 Koroška M 206 17 12 4 5 36 40 0 – – 24 68 – Ž 173 9 5 4 7 14 39 27 6 6 – 56 34 Savinjska M 623 36 42 8 35 98 58 1 – – 112 233 – Ž 620 24 41 4 24 38 69 129 26 45 – 220 188 Zasavska M 136 12 8 2 4 26 12 1 – – 18 53 – Ž 112 7 11 1 6 6 14 19 3 4 – 41 12 Spodnjeposavska M 185 11 12 2 18 31 11 1 – – 28 71 – Ž 144 5 4 1 3 7 6 30 6 12 – 70 34 Jugovzhodna Slovenija M 374 23 24 5 12 57 47 0 – – 56 150 – Ž 331 13 20 8 12 20 47 70 9 15 – 117 73 Osrednjeslovenska M 1475 55 103 22 57 217 271 4 – – 232 514 – Ž 1508 43 91 10 37 96 293 304 45 89 – 500 280 Gorenjska M 574 27 46 6 21 85 94 1 – – 106 188 – Ž 532 10 40 5 16 30 89 108 17 30 – 187 96 Notranjsko-kraška M 143 12 11 2 3 26 13 0 – – 17 59 – Ž 130 8 6 1 5 6 21 23 6 7 – 47 20 Goriška M 300 13 23 2 5 49 39 0 – – 44 125 – Ž 288 9 18 4 6 13 34 71 2 24 – 107 43 Obalno–kraška M 289 12 21 1 14 51 62 0 – – 17 111 – Ž 330 10 17 0 7 12 53 78 10 20 – 123 64 Opis šifer MKB Description of the ICD code C16 Želodec C44 Druge maligne neoplazme kože Stomach Skin, other malignomas C18 Debelo črevo C50 Dojka Colon Breast C19 Rektosigmoidna zveza C53 Maternični vrat Rectosigmoid junction Cervix uteri C20 Rektum C54 Maternično telo Rectum Corpus uteri C34 Sapnica in pljuča C61 Prostata Bronchus and lung Prostate D06 Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III) * Neupoštevano v skupnem številu: D06 – Maternični vrat, in situ (CIN III) Not included in All sites: D06 – Cervix uteri, in situ (CIN III) Cancer incidence in Slovenia 2005 55 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 6b. Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu – Slovenija 2005 Table 6b. Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex – Slovenia 2005 Opis šifer MKB Description of the ICD code C16 Želodec C44 Druge maligne neoplazme kože Stomach Skin, other malignomas C18 Debelo črevo C50 Dojka Colon Breast C19 Rektosigmoidna zveza C53 Maternični vrat Rectosigmoid junction Cervix uteri C20 Rektum C54 Maternično telo Rectum Corpus uteri C34 Sapnica in pljuča C61 Prostata Bronchus and lung Prostate D06 Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III) * Standard – prebivalstvo Slovenije po popisu 2002 Standard – population of Slovenia according to census 2002 ** Neupoštevano v skupnem številu: D06 – Maternični vrat, in situ (CIN III) Not included in All sites: D06 – Cervix uteri, in situ (CIN III) Statistična regija Spol Sex Skupaj Lokacija (šifre MKB-–10) Drugo Other C00–C96 C16 C18 C19 C20 C34 C44 C50 C53 C54 C61 D06** Statistical region All sites Site (ICD–10 codes) Slovenija, skupaj M 520,3 28,1 36,1 6,4 22,4 80,5 73,0 0,8 – – 81,4 191,6 – Slovenia, total Ž 492,0 17,1 28,7 4,3 16,2 27,9 76,9 102,2 17,4 30,6 – 170,7 107,2 Pomurska M 544,2 33,5 36,3 10,2 48,5 68,5 63,7 0,0 – – 105,9 177,6 – Ž 455,3 25,8 26,7 2,6 18,2 9,1 109,2 69,1 18,9 28,6 – 147,2 115,7 Podravska M 476,1 33,5 33,4 4,1 18,9 74,3 50,3 0,5 – – 81,7 179,3 – Ž 446,4 16,8 22,2 3,3 22,5 29,1 52,5 101,1 22,6 31,4 – 145,1 108,6 Koroška M 541,6 44,3 31,6 10,0 12,9 93,1 105,6 0,0 – – 62,8 181,2 – Ž 477,0 25,7 14,2 11,0 19,6 38,2 107,8 73,4 16,6 15,9 – 154,7 90,8 Savinjska M 484,9 28,2 32,5 6,3 27,1 76,3 45,1 0,7 – – 88,0 180,8 – Ž 473,1 18,3 31,4 3,1 18,5 29,0 52,8 98,1 19,6 34,6 – 167,7 142,3 Zasavska M 567,3 49,7 33,0 8,2 16,4 106,2 49,4 3,5 – – 76,8 224,0 – Ž 435,7 26,9 43,4 4,6 24,2 23,3 52,4 72,9 11,8 14,4 – 161,8 54,1 Spodnjeposavska M 493,2 28,3 32,3 5,1 47,2 82,1 28,0 2,3 – – 76,1 192,0 – Ž 379,2 12,0 9,8 2,9 7,3 18,4 16,3 80,3 16,2 33,4 – 182,6 99,2 Jugovzhodna Slovenija M 540,2 32,4 36,0 6,9 17,2 81,6 68,3 0,0 – – 80,1 217,7 – Ž 474,2 18,8 27,7 11,3 16,6 28,7 65,6 101,7 12,6 21,5 – 169,7 106,1 Osrednjeslovenska M 569,3 20,8 39,2 8,4 22,0 83,3 103,2 1,5 – – 88,2 202,8 – Ž 564,5 15,9 33,9 3,8 13,8 36,2 108,0 114,5 17,3 33,2 – 187,9 108,0 Gorenjska M 556,0 26,0 44,9 6,1 19,9 81,6 90,3 1,0 – – 101,5 184,8 – Ž 512,4 9,5 38,6 5,0 14,5 28,6 85,8 106,0 17,0 28,6 – 178,6 95,6 Notranjsko-kraška M 495,0 42,4 37,9 7,9 8,9 89,2 43,9 0,0 – – 55,6 209,2 – Ž 458,4 25,8 18,9 4,4 17,4 18,6 69,1 87,2 23,4 27,0 – 166,8 80,3 Goriška M 438,8 19,1 31,8 2,6 7,4 73,6 54,4 0,0 – – 64,4 185,6 – Ž 434,0 13,1 25,2 6,4 8,9 18,3 49,3 111,4 3,2 36,2 – 161,8 72,9 Obalno–kraška M 477,5 20,7 35,3 1,9 23,7 83,4 98,9 0,0 – – 28,5 185,1 – Ž 565,2 16,4 29,1 0,0 11,6 20,7 91,5 133,3 19,1 32,5 – 211,0 117,6 56 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 7. Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji – Slovenija 2005 Table 7. Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site – Slovenia 2005 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All types 9171 853 25 1 22 0 33 0 6 0 33 1 18 1 26 0 15 2 1 0 27 1 Small cell carcinoma 145 53 – – – – – – – – – – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 25 1 21 – 33 – 6 – 33 1 16 1 21 – 1 2 – – 25 – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 – – 1 – – – – – – – 1 – 1 – 8 – 1 – – – Other specified carcinomas 161 16 – – – – – – – – – – 1 – 2 – 5 – – – – – Carcinoma, unspecified 185 140 – – – – – – – – – – – – – – – – – – 2 1 Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – – – – – – – – – – – – – – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – 1 – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 – – – – – – – – – – – – 1 – 1 – – – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – – – – – – – – – – – – – – – – – – nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 57 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 50 1 7 0 23 0 27 0 0 0 81 3 455 3 26 2 661 4 109 0 Small cell carcinoma 145 53 – – – – – – – – – – 1 – 1 – – – 3 – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 46 1 6 – 23 – 26 – – – 66 1 3 – – – – – – – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 – – – – – – 1 – – – 11 – 423 1 14 1 636 1 107 – Other specified carcinomas 161 16 1 – 1 – – – – – – – 2 – 1 – – – 3 – – – Carcinoma, unspecified 185 140 3 – – – – – – – – – – 2 13 2 – – 14 3 2 – Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – – – – – – – – – – – – – – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – 1 – – – 1 – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – – – 1 – – – Malignant complex mixed and stromal tumors 58 0 – – – – – – – – – – – – 13 – 12 – 1 – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – – – – – – – 1 – – – – 1 2 – – – 58 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 393 4 18 0 57 17 54 4 49 7 134 26 3 0 8 0 9 0 87 1 Small cell carcinoma 145 53 1 – – – – – 3 – – – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 – – 13 – – – – – – – – – – – 3 – 5 – 84 – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 377 1 4 – 57 17 48 2 43 5 120 17 2 – 1 – 1 – – 1 Other specified carcinomas 161 16 3 – – – – – 3 – – – 5 – – – – – 2 – 1 – Carcinoma, unspecified 185 140 8 3 1 – – – – 2 4 – 9 8 – – – – 1 – 2 – Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 1 – – – – – – – – – – – – – 1 – – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – – – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – 1 – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 2 – – – – – – – 1 – – – 1 – – – – – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – – – – – – – – – 2 – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 1 – – – – – – – 1 2 – 1 – – – – – – – – Cancer incidence in Slovenia 2005 59 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C33 C34 C37 C38 C39 C40 C41 C43 C44 C45 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 3 2 774 275 4 0 5 0 0 0 2 0 8 1 304 3 1550 48 24 0 Small cell carcinoma 145 53 – – 126 51 – – – – – – – – – – – – – – – – Non-small cell carcinoma 42 40 1 1 41 39 – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 – – 273 56 – – – – – – – – – – – – 300 11 – – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – 1233 33 – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 1 – 243 92 – – – – – – – – – – – – 7 1 – – Other specified carcinomas 161 16 – – 78 14 – – – – – – – – – – – – 2 – – – Carcinoma, unspecified 185 140 1 – 9 19 – – – – – – – – – – – – 3 2 – – Malignant thymoma 4 0 – – – – 4 – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – – – – – – – – – – – 304 3 – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – 1 – – – 5 – – – Liposarcoma 9 0 – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – – – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – 1 – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – 1 – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – 1 – 3 – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – 1 – 1 – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – 2 1 – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – 1 – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 – – – – – – – – – – – – – – – – – – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – 24 – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – 1 – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – 1 – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – 1 – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – 1 – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – 1 3 4 – – – – – – – – – – – – – 1 – – 60 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 2 0 2 0 15 1 40 2 989 84 41 0 4 0 178 0 323 0 7 0 Small cell carcinoma 145 53 – – – – – – – – 1 – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 – – – – – – – – – – 34 – 3 – 153 – – – – – Basal cell carcinoma 1235 33 – – – – – – – – – – 2 – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 – – – – 8 1 – – 968 22 1 – 1 – 14 – 281 – – – Other specified carcinomas 161 16 – – – – – – – – 3 – – – – – 9 – 28 – – – Carcinoma, unspecified 185 140 – – – – – – – – 14 62 1 – – – 2 – 2 – – – Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – – – – – – – 2 – – – – – – – – – Fibrosarcoma 8 0 – – – – 1 – 6 – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – 4 – – – – – – – – – – – – – Liposarcoma 9 0 – – – – 2 – 5 – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – 2 – 9 1 1 – – – – – – – – – 4 – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – 3 – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – 1 – 1 – 1 – – – – – – – – – Kaposi sarcoma 2 0 2 – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – 1 – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – 8 1 – – – – – – – – – – 1 – Malignant complex mixed and stromal tumors 58 0 – – – – 1 – 1 – – – – – – – – – 12 – 2 – Malignat fibroepithelial tumors 1 0 – – – – – – – – 1 – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – 1 – – – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – 2 – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – 2 – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – – – – – – – – – – – – – – – – – – Cancer incidence in Slovenia 2005 61 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C56 C57 C58 C60 C61 C62 C63 C64 C65 C66 H C H C H C H C H C H C H C H C H C H C H C Vse vrste/All Types 9171 853 179 8 9 0 0 0 6 0 793 10 79 0 3 0 218 9 27 0 15 0 Small cell carcinoma 145 53 – – – – – – – – 1 – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 – – – – – – 5 – 1 – – – – – – – – – – – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – 2 – – – – – – – 27 – 13 – Adenocarcinoma 4681 214 162 6 9 – – – – – 712 4 1 – – – 216 9 – – 2 – Other specified carcinomas 161 16 5 – – – – – – – 1 – – – 1 – – – – – – – Carcinoma, unspecified 185 140 2 2 – – – – – – 76 6 – – – – 1 – – – – – Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – – – 1 – – – – – – – – – – – – – Fibrosarcoma 8 0 1 – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – 2 – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – – – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 5 – – – – – – – – – – – – – 1 – – – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 2 – – – – – – – – – 1 – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – – – 36 – – – – – – – – – Other malignant germ cell tumors 39 0 2 – – – – – – – – – 35 – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – 6 – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – – – – – – – – – – – – – – – – – – 62 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C67 C68 C69 C70 C71 C72 C73 C74 C75 C76 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 260 2 1 1 19 0 3 0 115 0 1 0 143 5 3 0 1 0 9 11 Small cell carcinoma 145 53 5 – – – – – – – – – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 6 – – – 3 – – – – – – – – – – – – – – – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 245 1 1 1 – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 3 – – – – – – – – – – – 140 3 1 – – – 3 4 Other specified carcinomas 161 16 – – – – – – – – – – – – 1 2 – – – – 1 – Carcinoma, unspecified 185 140 1 1 – – – – – – – – – – 1 – 1 – 1 – 1 7 Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – 15 – – – – – – – – – – – – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – – – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – 1 – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 – – – – – – – – – – – – – – – – – – 3 – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – 1 – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – – – – – 1 – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – 114 – 1 – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – 1 – – – – – – – – – 1 – – – – – Malignant meningioma 3 0 – – – – – – 3 – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – – – – – – – – – – – – – – – – – – Cancer incidence in Slovenia 2005 63 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 7. – Table 7. Nadaljevanje – Continued nadaljevanje / cont’d 4 Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites S i t e ( I C D - 1 0 c o d e s ) C00–C96 C77 C78 C79 C80 C81 C82 C83 C84 C85 C88 H C H C H C H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 27 7 24 24 11 4 36 21 41 4 56 9 121 24 28 1 8 7 0 1 Small cell carcinoma 145 53 – – – 2 2 – 1 – – – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 15 3 – – – 2 2 – – – – – – – – – – – – – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – – – – – – – Adenocarcinoma 4681 214 4 2 18 13 6 1 23 10 – – – – – – – – – – – – Other specified carcinomas 161 16 1 – – – – – 1 – – – – – – – – – – – – – Carcinoma, unspecified 185 140 4 1 3 8 – 1 3 10 – – – – – – – – – – – – Malignant thymoma 4 0 – – – – – – – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – – Malignant melanoma 335 5 2 1 2 – 3 – 4 1 – – – – – – – – – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – – – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 – – 1 – – – – – – – – – – – – – – – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 1 – – – – – – – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – – – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – 56 9 121 24 28 1 8 7 – 1 Hodgkin lymphoma 41 4 – – – – – – – – 41 4 – – – – – – – – – – Plasma cell tumors 71 29 – – – – – – – – – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – – – – – – – – – – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – – – – – – – – – – – – – – – – – – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – – – – – – – – – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – – – – – – – – – Myelodysplastic syndromes 23 48 – – – – – – – – – – – – – – – – – – – – Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – 1 – – 2 – – – – – – – – – – – – – 64 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 7. – Table 7. Nadaljevanje – Continued Histološka vrsta Skupaj L o k a c i j a ( š i f r e M K B - 1 0 ) Histological type All Sites Site (ICD - 10 codes) C00–C96 C90 C91 C92 C93 C94 C95 C96 H C H C H C H C H C H C H C H C Vse vrste / All Types 9171 853 71 29 50 47 45 33 6 0 2 0 0 1 29 101 Small cell carcinoma 145 53 – – – – – – – – – – – – – – Non-small cell carcinoma 42 40 – – – – – – – – – – – – – – Squamous cell carcinoma 1251 79 – – – – – – – – – – – – – – Basal cell carcinoma 1235 33 – – – – – – – – – – – – – – Transitional cell carcinoma 288 2 – – – – – – – – – – – – – – Adenocarcinoma 4681 214 – – – – – – – – – – – – – – Other specified carcinomas 161 16 – – – – – – – – – – – – – – Carcinoma, unspecified 185 140 – – – – – – – – – – – – – – Malignant thymoma 4 0 – – – – – – – – – – – – – – Malignant paraganglioma/ pheochromocytoma 0 0 – – – – – – – – – – – – – – Malignant melanoma 335 5 – – – – – – – – – – – – – – Fibrosarcoma 8 0 – – – – – – – – – – – – – – Fibrohistiocytic sarcoma 10 0 – – – – – – – – – – – – – – Liposarcoma 9 0 – – – – – – – – – – – – – – Leiomyosarcoma 19 1 – – – – – – – – – – – – – – Rhabdomyosarcoma 2 0 – – – – – – – – – – – – – – Synovial sarcoma 4 0 – – – – – – – – – – – – – – Angiosarcoma 4 0 – – – – – – – – – – – – – – Kaposi sarcoma 2 0 – – – – – – – – – – – – – – Osteosarcoma 4 0 – – – – – – – – – – – – – – Chondrosarcoma 2 0 – – – – – – – – – – – – – – Ewing sarcoma/PNET 3 1 – – – – – – – – – – – – – – Other specified sarcomas 0 0 – – – – – – – – – – – – – – Sarcoma, unspecified 11 1 – – – – – – – – – – – – – – Malignant complex mixed and stromal tumors 58 0 – – – – – – – – – – – – – – Malignat fibroepithelial tumors 1 0 – – – – – – – – – – – – – – Malignant mesothelioma 24 0 – – – – – – – – – – – – – – Malignant gonadal stromal tumors 3 0 – – – – – – – – – – – – – – Dysgerminoma and seminoma 39 0 – – – – – – – – – – – – – – Other malignant germ cell tumors 39 0 – – – – – – – – – – – – – – Malignant trophoblastic tumors 6 0 – – – – – – – – – – – – – – Malignant gliomas 115 0 – – – – – – – – – – – – – – Malignant neuroepithelial tumors 6 0 – – – – – – – – – – – – – – Malignant meningioma 3 0 – – – – – – – – – – – – – – Malignant nerve sheath tumors 3 0 – – – – – – – – – – – – – – Non Hodgkin lymphoma 213 42 – – – – – – – – – – – – – – Hodgkin lymphoma 41 4 – – – – – – – – – – – – – – Plasma cell tumors 71 29 71 29 – – – – – – – – – – – – Chronic lymphoid leukemia 33 39 – – 33 39 – – – – – – – – – – Leukemia except chronic lymphoid 70 42 – – 17 8 45 33 6 – 2 – – 1 – – Other lymphoreticular neoplasms 1 0 – – – – – – – – – – – – 1 – Chronic myeloproliferative diseases 5 53 – – – – – – – – – – – – 5 53 Myelodysplastic syndromes 23 48 – – – – – – – – – – – – 23 48 Other specified malignant tumors 2 0 – – – – – – – – – – – – – – Malignant tumor, unspecified 10 11 – – – – – – – – – – – – – – Cancer incidence in Slovenia 2005 65 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Šifra MKB–8 Lokacija Spol Vse starosti S t a r o s t ICD–8 Site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ Vse lokacije M + Ž 254 0 0 1 3 3 4 4 13 5 11 25 30 25 32 33 34 31 M 116 0 0 1 3 2 1 2 9 4 3 11 15 11 20 11 15 8 All sites Ž 138 0 0 0 0 1 3 2 4 1 8 14 15 14 12 22 19 23 Tabela 8. Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti – Slovenija 2005 Table 8. Incidence of non-Hodgkin´s malignant lymphomas* by site, by sex and by age – Slovenia 2005 141 Jezik M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 Tongue Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 142 Slinavke M 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Salivary glands Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 146 Orofarinks M 6 0 0 0 0 0 0 0 2 1 0 1 0 0 0 1 1 0 Oropharynx Ž 4 0 0 0 0 0 0 0 0 0 0 0 1 0 0 3 0 0 147 Epifarinks M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Epipharynx Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 148 Hipofarinks M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Hypopharynx Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 151 Želodec M 13 0 0 0 0 0 0 0 1 0 0 2 0 2 3 2 1 2 Stomach Ž 17 0 0 0 0 0 0 0 1 0 1 2 2 2 2 3 0 4 153 Debelo črevo M 4 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 1 0 Colon Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 155 Jetra M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liver Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 160 Nos, obnosne votline, drugo M 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 Nose, sinuses, etc. Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 162 Sapnik, sapnica, pljuča M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Trachea, bronchus, lung Ž 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 163 Plevra, mediastinum, drugo M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Pleura, mediastinum, etc. Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 170 Kosti M 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 Bone Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 171 Mehka tkiva M 2 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 Soft tissues Ž 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 173 Koža, drugi malignomi M 7 0 0 0 0 0 0 1 0 0 0 0 2 0 2 0 1 1 Skin, other malignancies Ž 5 0 0 0 0 0 2 0 0 0 0 1 0 0 0 0 2 0 174 Dojka M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Breast Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 1 186 Modo M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 Testis Ž – – – – – – – – – – – – – – – – – – 188 Mehur M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Bladder Ž 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 189 Ledvica, sečevod, drugo M 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 Kidney, ureter, etc. Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 190 Oko M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Eye Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 191 Možgani M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 Brain Ž 7 0 0 0 0 0 0 0 0 0 1 2 0 3 0 1 0 0 193 Ščitnica M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Thyroid Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 194 Endokrine žleze, druge M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Endocrine glands, other Ž 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 202 Bezgavke M 70 0 0 1 2 1 1 1 4 3 2 8 12 6 11 4 10 4 Lymph nodes Ž 84 0 0 0 0 1 0 2 2 1 6 9 10 7 9 13 13 11 * Vključeni so samo citološko in histološko potrjeni primeri All cases included have been verified citologically and histologically 66 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 9. Incidenca raka po bolnišnicah ugotovitve diagnoze ter število in odstotek* primerov, napotenih na Onkološki inštitut Ljubljana (OI) – Slovenija 2005 Table 9. Cancer incidence by reporting hospitals, and number and percentage* of cases referred to the Institute of Oncology Ljubljana (IO) – Slovenia 2005 nadaljevanje / cont’d 4 Bolnišnice Število novih primerov Napoteni na OI Število %* Hospitals Number of new cases Referred to the IO %* Skupaj 10648 5088 47,8 Total Onkološki inštitut Ljubljana 617 617 100,0 Institute of Oncology Ljubljana Univerzitetni klinični center Ljubljana 3363 1362 40,5 University Medical Centre Ljubljana SPS Interna klinika 820 287 35,0 Klinični oddelek za gastroenterologijo 391 158 40,4 Drugi klinični oddelki 429 129 30,1 SPS Kirurška klinika 1882 619 32,9 Klinični oddelek za abdominalno kirurgijo 384 176 45,8 Klinični oddelek za nevrokirurgijo 95 75 78,9 Klinični oddelek za maksilofacialno in oralno kirurgijo 56 49 87,5 Klinični oddelek za plastično kirurgijo in opekline 658 74 11,2 Klinični oddelek za torakalno kirurgijo 98 51 52,0 Klinični oddelek za urologijo 539 164 30,4 Drugi klinični oddelki 52 30 57,7 SPS Ginekološka klinika 240 141 58,8 SPS Nevrološka klinika 48 35 72,9 SPS Pediatrična klinika 23 19 82,6 Dermatovenerološka klinika 34 22 64,7 Klinika za infekcijske bolezni in vročinska stanja 24 11 45,8 Klinika za otorinolaringologijo in cervikofacialno kirurgijo 221 184 83,3 Očesna klinika 33 7 21,2 Ortopedska klinika 13 13 – Drugi klinični oddelki 25 24 96,0 Number Cancer incidence in Slovenia 2005 67 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Splošne in specialistične bolnišnice 5800 2671 46,1 General and special hospitals Splošna bolnišnica Brežice 94 47 50,0 Splošna bolnišnica Celje 827 346 41,8 Bolnišnica Golnik 507 323 63,7 Splošna bolnišnica Jesenice 267 126 47,2 Splošna bolnišnica Izola 315 159 50,5 Univerzitetni klinični center Maribor 1594 645 40,5 Splošna bolnišnica Murska Sobota 497 184 37,0 Splošna bolnišnica dr. Franc Derganc Nova Gorica 386 156 40,4 Splošna bolnišnica Novo mesto 468 245 52,4 Splošna bolnišnica dr. Jožeta Potrča Ptuj 101 59 58,4 Splošna bolnišnica Slovenj Gradec 434 159 36,6 Splošna bolnišnica Trbovlje 70 47 67,1 Bolnišnica za ginekologijo in porodništvo Kranj 34 29 85,3 Bolnišnica Topolšica 144 107 74,3 Bolnišnica za ginekologijo in porodništvo Postojna 32 21 65,6 Bolnica Sežana 24 13 54,2 Ortopedska bolnica Valdoltra 4 4 – Psihiatrična klinika Ljubljana 0 0 – Psihiatrična bolnišnica Begunje 0 0 – Psihiatrična bolnišnica Idrija 2 1 – Zasebne ordinacije 627 245 39,1 Private clinics Drugi zdravstveni zavodi 241 193 80,1 Other health institutions * Odstotki niso računani, če je število novih primerov manjše od 15 * Percentages are not calculated for less than 15 new cases Bolnišnice Število novih primerov Napoteni na OI Število %* Hospitals Number of new cases Referred to the IO Number %* Tabela 9. – Table 9. Nadaljevanje – Continued 68 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 10. Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu – Slovenija 2005 Table 10. Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex – Slovenia 2005 nadaljevanje / cont’d 4 S t a d i j Šifra MKB Primarna lokacija Spol Število novih primerov Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* S t a g e ICD code Primary site Sex Number of new cases Localized Regional Distant Unknown Number %* Number %* Number %* Number %* C00 Vse lokacije M+Ž 10648 4694 44,1 2954 27,7 2509 23,6 491 4,6 – All sites M 5431 2279 42,0 1518 27,9 1356 25,0 278 5,1 C96 Ž 5217 2415 46,3 1436 27,5 1153 22,1 213 4,1 C00 Ustnica M 14 11 – 3 – 0 – 0 – Lip Ž 12 10 – 1 – 0 – 1 – C01 Baza jezika M 21 3 14,3 16 76,2 2 9,5 0 0,0 Base of tongue Ž 1 0 – 1 – 0 – 0 – C02 Jezik, drugi deli M 27 8 29,6 18 66,7 0 0,0 1 3,7 Tongue, other & unspecified parts Ž 6 4 – 2 – 0 – 0 – C03 Dlesen M 2 1 – 1 – 0 – 0 – Gum Ž 4 2 – 2 – 0 – 0 – C04 Ustno dno M 28 7 25,0 19 67,9 2 7,1 0 0,0 Floor of mouth Ž 6 1 – 5 – 0 – 0 – C05 Nebo M 15 5 33,3 9 60,0 1 6,7 0 0,0 Palate Ž 4 1 – 3 – 0 – 0 – C06 Usta, drugi deli M 13 6 – 7 – 0 – 0 – Mouth, other & unspecified parts Ž 13 9 – 4 – 0 – 0 – C07 Parotidna žleza M 9 3 – 3 – 2 – 1 – Parotid gland Ž 8 4 – 3 – 0 – 1 – C08 Druge in neopredeljene velike žleze slinavke M 0 0 – 0 – 0 – 0 – Other & unspecified major salivary glands Ž 1 1 – 0 – 0 – 0 – C09 Tonzila M 23 6 26,1 16 69,6 1 4,3 0 0,0 Tonsil Ž 5 1 – 3 – 1 – 0 – C10 Orofarinks M 46 5 10,9 39 84,8 2 4,3 0 0,0 Oropharynx Ž 5 0 – 5 – 0 – 0 – C11 Nazofarinks M 3 2 – 1 – 0 – 0 – Nasopharynx Ž 4 2 – 2 – 0 – 0 – C12 Piriformni sinus M 21 1 4,8 19 90,5 1 4,8 0 0,0 Pyriform sinus Ž 3 1 – 2 – 0 – 0 – C13 Hipofarinks M 26 5 19,2 20 76,9 1 3,8 0 0,0 Hypopharynx Ž 3 0 – 3 – 0 – 0 – C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu M 0 0 – 0 – 0 – 0 – Other and ill-defined sites in the lip, oral cavity and pharynx Ž 0 0 – 0 – 0 – 0 – C15 Požiralnik M 73 11 15,1 32 43,8 17 23,3 13 17,8 Oesophagus Ž 17 4 23,5 6 35,3 4 23,5 3 17,6 C16 Želodec M 295 62 21,0 122 41,4 94 31,9 17 5,8 Stomach Ž 180 43 23,9 61 33,9 54 30,0 22 12,2 C17 Tanko črevo M 14 4 – 8 – 1 – 1 – Small intestine Ž 15 2 13,3 3 20,0 8 53,3 2 13,3 C18 Debelo črevo M 378 45 11,9 217 57,4 105 27,8 11 2,9 Colon Ž 308 35 11,4 189 61,4 75 24,4 9 2,9 C19 Rektosigmoidna zveza M 65 5 7,7 38 58,5 20 30,8 2 3,1 Rectosigmoid junction Ž 45 6 13,3 29 64,4 10 22,2 0 0,0 Cancer incidence in Slovenia 2005 69 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C20 Rektum M 234 28 12,0 152 65,0 47 20,1 7 3,0 Rectum Ž 172 27 15,7 99 57,6 38 22,1 8 4,7 C21 Anus in analni kanal M 12 4 – 6 – 2 – 0 – Anus and anal canal Ž 6 1 – 3 – 1 – 1 – C22 Jetra in intrahepatični vodi M 98 32 32,7 12 12,2 33 33,7 21 21,4 Liver and intrahepatic bile ducts Ž 28 6 21,4 4 14,3 11 39,3 7 25,0 C23 Žolčnik M 21 0 0,0 3 14,3 16 76,2 2 9,5 Gallbladder Ž 70 6 8,6 22 31,4 36 51,4 6 8,6 C24 Drugi in neopredeljeni deli bili- arnega trakta M 38 6 15,8 16 42,1 12 31,6 4 10,5 Billiary tract, other and unspeci- fied parts Ž 46 8 17,4 14 30,4 11 23,9 13 28,3 C25 Trebušna slinavka M 114 10 8,8 37 32,5 56 49,1 11 9,6 Pancreas Ž 166 12 7,2 60 36,1 75 45,2 19 11,4 C26 Druga in slabo opredeljena mesta v prebavnih organih M 2 0 – 0 – 2 – 0 – Other and ill-defined digestive organs Ž 4 0 – 0 – 3 – 1 – C30 Nosna votlina in srednje uho M 5 2 – 2 – 0 – 1 – Nasal cavity and middle ear Ž 3 2 – 0 – 1 – 0 – C31 Obnosni sinusi M 5 0 – 3 – 2 – 0 – Accessory sinuses Ž 4 1 – 3 – 0 – 0 – C32 Grlo M 76 31 40,8 43 56,6 1 1,3 1 1,3 Larynx Ž 13 5 – 7 – 0 – 1 – C33 Sapnik M 1 0 – 0 – 1 – 0 – Trachea Ž 4 0 – 4 – 0 – 0 – C34 Sapnica in pljuča M 841 113 13,4 291 34,6 400 47,6 37 4,4 Bronchus and lung Ž 296 51 17,2 98 33,1 125 42,2 22 7,4 C37 Timus M 3 1 – 2 – 0 – 0 – Thymus Ž 1 0 – 1 – 0 – 0 – C38 Srce, mediastinum, plevra M 6 1 – 2 – 1 – 2 – Heart, mediastinum, pleura Ž 1 0 – 0 – 1 – 0 – C39 Druga in slabo opredeljena mesta v dihalih in prsnih organih M 0 0 – 0 – 0 – 0 – Other and ill–defined sites in the respiratory system and intratho- racic organs Ž 0 0 – 0 – 0 – 0 – C40 Kosti, sklepni hrustanec udov M 0 0 – 0 – 0 – 0 – Bone and articular cartilage of limbs Ž 2 0 – 1 – 1 – 0 – C41 Kosti, sklepni hrustanec, drugje M 3 0 – 0 – 0 – 3 – Bone and articular cartilage of other and unspecified parts Ž 6 2 – 3 – 1 – 0 – C43 Maligni melanom kože M 126 93 73,8 25 19,8 4 3,2 4 3,2 Malignant melanoma of skin Ž 181 140 77,3 27 14,9 5 2,8 9 5,0 C44 Druge maligne neoplazme kože M 773 760 98,3 11 1,4 1 0,1 1 0,1 Skin, other malignomas Ž 832 817 98,2 12 1,4 1 0,1 2 0,2 C45 Mezoteliom M 20 7 35,0 9 45,0 2 10,0 2 10,0 Mesothelioma Ž 4 1 – 2 – 0 – 1 – C46 Kaposijev sarkom M 2 2 – 0 – 0 – 0 – Kaposi’s sarcoma Ž 0 0 – 0 – 0 – 0 – Tabela 10. – Table 10. Nadaljevanje – Continued nadaljevanje / cont’d 4 S t a d i j Šifra MKB Primarna lokacija Spol Število novih primerov Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* S t a g e ICD code Primary site Sex Number of new cases Localized Regional Distant Unknown Number %* Number %* Number %* Number %* 70 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 10. – Table 10. Nadaljevanje – Continued nadaljevanje / cont’d 4 C47 Periferni živci in avtonomno živčevje M 1 0 – 1 – 0 – 0 – Peripheral nerves and autonomic nervous system Ž 1 0 – 1 – 0 – 0 – C48 Peritonej in retroperitonej M 3 0 – 2 – 1 – 0 – Retroperitoneum and peritoneum Ž 13 0 – 3 – 9 – 1 – C49 Drugo vezivno in mehko tkivo M 22 9 40,9 7 31,8 2 9,1 4 18,2 Other connective and soft tissue Ž 21 7 33,3 11 52,4 2 9,5 1 4,8 C50 Dojka M 9 3 – 5 – 1 – 0 – Breast Ž 1076 531 49,3 460 42,8 73 6,8 12 1,1 C51 Žensko zunanje spolovilo M – – – – – – – – – Vulva Ž 41 25 61,0 11 26,8 4 9,8 1 2,4 C52 Nožnica M – – – – – – – – – Vagina Ž 4 2 – 2 – 0 – 0 – C53 Maternični vrat M – – – – – – – – – Cervix uteri Ž 180 102 56,7 72 40,0 5 2,8 1 0,6 C54 Maternično telo M – – – – – – – – – Corpus uteri Ž 326 230 70,6 65 19,9 27 8,3 4 1,2 C55 Maternica, neopredeljeno M – – – – – – – – – Uterus, unspecified Ž 8 3 – 0 – 3 – 2 – C56 Jajčnik M – – – – – – – – – Ovary Ž 194 21 10,8 16 8,2 149 76,8 8 4,1 C57 Drugi in neopredeljeni ženski spolni organi M – – – – – – – – – Other and unspecified parts of female genital organs Ž 9 2 – 2 – 5 – 0 – C58 Posteljica M – – – – – – – – – Placenta Ž 0 0 – 0 – 0 – 0 – C60 Penis M 6 5 – 0 – 1 – 0 – Penis Ž – – – – – – – – – C61 Prostata M 855 535 62,6 163 19,1 89 10,4 68 8,0 Prostate Ž – – – – – – – – – C62 Modo M 79 48 60,8 22 27,8 9 11,4 0 0,0 Testis Ž – – – – – – – – – C63 Drugi in neopredeljeni moški spolni organi M 3 3 – 0 – 0 – 0 – Other and unspecified male genital organs Ž – – – – – – – – – C64 Ledvica razen meha M 172 91 52,9 25 14,5 47 27,3 9 5,2 Kidney, except renal pelvis Ž 89 54 60,7 13 14,6 17 19,1 5 5,6 C65 Ledvični meh M 14 11 – 0 – 3 – 0 – Renal pelvis Ž 14 4 – 7 – 2 – 1 – C66 Sečevod M 9 6 – 3 – 0 – 0 – Ureter Ž 6 4 – 1 – 1 – 0 – C67 Sečni mehur M 211 154 73,0 40 19,0 12 5,7 5 2,4 Bladder Ž 64 41 64,1 15 23,4 4 6,3 4 6,3 C68 Drugi in neopredeljeni sečni organi M 2 0 – 1 – 1 – 0 – Other and unspecified urinary organs Ž 0 0 – 0 – 0 – 0 – C69 Oko in očesni adneksi M 14 11 – 2 – 1 – 0 – Eye and adnexa Ž 5 2 – 3 – 0 – 0 – C70 Meninge M 1 0 – 1 – 0 – 0 – Meninges Ž 2 2 – 0 – 0 – 0 – C71 Možgani M 66 65 98,5 1 1,5 0 0,0 0 0,0 Brain Ž 63 62 98,4 0 0,0 0 0,0 1 1,6 S t a d i j Šifra MKB Primarna lokacija Spol Število novih primerov Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* S t a g e ICD code Primary site Sex Number of new cases Localized Regional Distant Unknown Number %* Number %* Number %* Number %* Cancer incidence in Slovenia 2005 71 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C72 Hrbtni mozeg, možganski živci in drugi deli CŽS M 0 0 – 0 – 0 – 0 – Spinal cord, cranial nerves and other parts of CNS Ž 1 1 – 0 – 0 – 0 – C73 Ščitnica M 31 21 67,7 8 25,8 2 6,5 0 0,0 Thyroid gland Ž 117 79 67,5 30 25,6 7 6,0 1 0,9 C74 Nadledvična žleza M 1 1 – 0 – 0 – 0 – Adrenal gland Ž 2 0 – 2 – 0 – 0 – C75 Druge endokrine žleze in sorodne strukture M 0 0 – 0 – 0 – 0 – Other endocrine glands and related structures Ž 2 0 – 1 – 1 – 0 – C76 Druga in slabo opredeljena mesta M 7 0 – 1 – 3 – 3 – Other and ill-defined sites Ž 21 1 4,8 6 28,6 8 38,1 6 28,6 C77 Metastaza in neopredeljena ma- ligna neoplazma bezgavk M 24 0 0,0 0 0,0 0 0,0 24 Metastasis and unspecified malig- nant neoplasm of lymph nodes Ž 12 0 – 0 – 0 – 12 – C78 Metastaze dihal in prebavil M 41 0 0,0 0 0,0 41 100,0 0 0,0 Metastases of respiratory and digestive organs Ž 49 0 0,0 0 0,0 49 100,0 0 0,0 C79 Metastaze, drugje M 22 0 0,0 0 0,0 22 100,0 0 0,0 Metastases of other sites Ž 9 0 – 0 – 9 – 0 – C80 Maligna neoplazma brez opre- deljenega mesta M 42 0 0,0 0 0,0 42 100,0 0 0,0 Malignant neoplasm without specification of site Ž 37 0 0,0 0 0,0 37 100,0 0 0,0 S t a d i j ( A n n – A r b o r ) Šifra MKB Primarna lokacija Spol Število novih I II III+IV Neznan primerov Število %* Število % Število %* Število %* S t a g e ( A n n – A r b o r ) ICD code Primary site Sex Number of new cases Number % I Number % III+IV Number % Unknown Number % C81 Hodgkinova bolezen M 26 4 15,4 11 42,3 10 38,5 1 3,8 Hodgkin’s disease Ž 19 2 10,5 8 42,1 8 42,1 1 5,3 C82– Ne-Hodgkinov limfom M 116 30 25,9 22 19,0 44 37,9 20 17,2 C85 Non-Hodgkin’s lymphoma Ž 138 34 24,6 23 16,7 57 41,3 24 17,4 * Odstotki niso računani, če je število novih primerov manjše od 15 * Percentages are not calculated for less than 15 new cases Tabela 10. – Table 10. Nadaljevanje – Continued S t a d i j Šifra MKB Primarna lokacija Spol Število novih primerov Omejen Razširjen Razsejan Neznan Število %* Število %* Število %* Število %* S t a g e ICD code Primary site Sex Number of new cases Localized Regional Distant Unknown Number %* Number %* Number %* Number %* 72 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 11. Umrljivost za rakom po lokaciji, spolu in starosti – Slovenija 2005* Table 11. Mortality by site, by sex and by age – Slovenia 2005* C00 Ustnica M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Lip Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C01 Baza jezika M 4 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 Base of tongue Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C02 Jezik, drugi deli M 9 0 0 0 0 0 0 0 0 1 0 2 0 2 0 1 2 1 Tongue, other & unspeci- fied parts Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 C03 Dlesen M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Gum Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C04 Ustno dno M 3 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 Floor of mouth Ž 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 C05 Nebo M 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Palate Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 C06 Usta, drugi deli M 9 0 0 0 0 0 0 0 0 1 0 4 0 0 1 1 2 0 Mouth, other & unspeci- fied parts Ž 4 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 C07 Parotidna žleza M 4 0 0 0 0 0 0 0 0 0 1 0 0 2 0 0 0 1 Parotid gland Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 C08 Druge in neopredeljene velike žleze slinavke M 2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 Other & unspecified major salivary glands Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C09 Tonzila M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Tonsil Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C10 Orofarinks M 49 0 0 0 0 0 0 0 1 3 6 3 8 7 6 6 4 5 Oropharynx Ž 5 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 1 0 C11 Nazofarinks M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Nasopharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C12 Piriformni sinus M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Pyriform sinus Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C13 Hipofarinks M 25 0 0 0 0 0 0 0 0 0 4 1 5 1 7 4 3 0 Hypopharynx Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C14 Druga in slabo opre- deljena mesta na ustnici, v ustni votlini in farinksu M 4 0 0 0 0 0 0 0 0 1 0 1 0 0 2 0 0 0 Other and ill-defined sites in the lip, oral cavity and pharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C15 Požiralnik M 74 0 0 0 0 0 0 0 0 2 3 3 12 18 6 14 12 4 Oesophagus Ž 14 0 0 0 0 0 0 0 0 0 0 2 0 0 2 3 1 6 C16 Želodec M 210 0 0 0 0 0 0 2 0 2 2 13 14 16 41 31 42 47 Stomach Ž 148 0 0 0 0 0 0 3 2 2 5 3 7 5 16 22 29 54 C17 Tanko črevo M 9 0 0 0 0 0 0 0 0 0 0 0 0 2 1 3 1 2 Small intestine Ž 8 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 2 3 C18 Debelo črevo M 178 0 0 0 0 0 0 0 0 1 2 5 10 22 38 29 33 38 Colon Ž 181 0 0 0 0 0 0 0 1 0 0 5 7 11 26 29 30 72 C19 Rektosigmoidna zveza M 27 0 0 0 0 0 0 0 0 0 0 0 4 2 6 6 3 6 Rectosigmoid junction Ž 26 0 0 0 0 0 0 0 0 0 0 0 0 2 5 4 5 10 C20 Rektum M 129 0 0 0 0 0 0 0 0 1 3 6 11 14 19 40 22 13 Rectum Ž 103 0 0 0 0 0 0 0 0 0 2 1 9 4 9 19 22 37 C21 Anus in analni kanal M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 Anus and anal canal Ž 7 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 3 Šifra MKB Primarna lokacija Spol Vse starosti S t a r o s t ICD Primary site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ C00 Vse lokacije M + Ž 5119 3 2 3 5 4 12 20 25 79 150 300 414 480 650 892 8921188 – M 2814 2 1 1 4 4 8 8 9 44 84 187 247 315 397 520 511 472 C97 All sites Ž 2305 1 1 2 1 0 4 12 16 35 66 113 167 165 253 372 381 716 nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 73 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C22 Jetra in intrahepatični vodi M 93 0 0 0 0 0 0 1 0 0 2 10 7 11 20 17 16 9 Liver and intrahepatic bile ducts Ž 40 0 0 0 0 0 0 0 0 1 0 1 2 1 5 8 5 17 C23 Žolčnik M 16 0 0 0 0 0 0 0 1 0 0 0 1 2 2 3 4 3 Gallbladder Ž 43 0 0 0 0 0 0 0 0 0 0 2 3 2 3 8 12 13 C24 Drugi in neopredeljeni deli biliarnega trakta M 25 0 0 0 0 0 0 0 0 1 0 0 1 3 3 8 4 5 Billiary tract, other and unspecified parts Ž 29 0 0 0 0 0 0 0 0 0 1 0 4 2 2 1 7 12 C25 Trebušna slinavka M 106 0 0 0 0 0 0 0 0 6 2 8 10 19 16 20 16 9 Pancreas Ž 155 0 0 0 0 0 0 0 0 0 3 10 4 10 21 30 24 53 C26 Druga in slabo opredelje- na mesta v prebavnih organih M 7 0 0 0 0 0 0 0 0 0 0 1 0 1 1 2 0 2 Other and ill–defined digestive organs Ž 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 4 7 C30 Nosna votlina in srednje uho M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Nasal cavity and middle ear Ž 2 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 C31 Obnosni sinusi M 3 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 Accessory sinuses Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 C32 Grlo M 50 0 0 0 0 0 0 0 0 2 1 4 8 5 7 11 6 6 Larynx Ž 5 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 1 C33 Sapnik M 4 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 Trachea Ž 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 C34 Sapnica in pljuča M 805 0 0 0 0 0 1 0 1 8 32 76 91 101 110 161 152 72 Bronchus and lung Ž 273 0 0 0 0 0 0 0 1 7 14 23 26 24 32 50 40 56 C37 Timus M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Thymus Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 C38 Srce, mediastinum, plevra M 10 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 3 3 Heart, mediastinum, pleura Ž 8 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 4 C39 Druga in slabo oprede- ljena mesta v dihalih in prsnih organih M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 C40 Kosti, sklepni hrustanec udov M 5 0 0 0 0 0 0 0 0 0 1 1 1 0 0 2 0 0 Bone and articular carti- lage of limbs Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 C41 Kosti, sklepni hrustanec, drugje M 6 0 0 0 0 0 0 0 0 1 0 0 1 0 1 2 0 1 Bone and articular cartilage of other and unspecified parts Ž 6 0 0 0 0 0 0 0 0 0 1 0 2 1 1 0 0 1 C43 Maligni melanom kože M 43 0 0 0 0 0 0 0 0 2 4 4 5 3 7 10 5 3 Malignant melanoma of skin Ž 54 0 0 0 0 0 1 2 4 2 4 3 8 2 1 8 7 12 C44 Druge maligne neoplaz- me kože M 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 5 Skin, other malignomas Ž 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 8 C45 Mezoteliom M 8 0 0 0 0 0 0 0 0 0 1 0 2 1 1 2 0 1 Mesothelioma Ž 7 0 0 0 0 0 0 0 0 0 1 0 0 0 3 1 0 2 C46 Kaposijev sarkom M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Kaposi’s sarcoma Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C47 Periferni živci in avtonom- no živčevje M 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Peripheral and authono- mic nervous system Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C48 Peritonej in retroperitonej M 9 0 0 0 0 0 0 0 1 0 0 1 1 0 2 1 0 3 Retroperitoneum and peritoneum Ž 10 0 0 0 0 0 0 0 0 0 0 0 1 0 3 2 1 3 C49 Drugo vezivno in mehko tkivo M 10 0 0 0 0 1 2 0 0 0 0 1 1 3 1 0 0 1 Other connective and soft tissue Ž 9 0 0 0 0 0 0 0 0 0 0 1 1 1 2 0 1 3 C50 Dojka M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Breast Ž 390 0 0 0 0 0 1 4 1 10 20 31 39 35 41 49 61 98 C51 Žensko zunajnje spolovilo M – – – – – – – – – – – – – – – – – – Vulva Ž 17 0 0 0 0 0 0 0 0 0 0 0 1 1 2 1 3 9 Tabela 11. – Table 11. Nadaljevanje – Continued Šifra MKB Primarna lokacija Spol Vse starosti S t a r o s t ICD Primary site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 74 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo C52 Nožnica M – – – – – – – – – – – – – – – – – – Vagina Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 2 C53 Maternični vrat M – – – – – – – – – – – – – – – – – – Cervix uteri Ž 39 0 0 0 0 0 0 0 1 3 1 2 5 4 3 6 4 10 C54 Maternično telo M – – – – – – – – – – – – – – – – – – Corpus uteri Ž 67 0 0 0 0 0 0 0 1 0 1 2 1 6 9 17 12 18 C55 Maternica, neopredel- jeno M – – – – – – – – – – – – – – – – – – Uterus, unspecified Ž 29 0 0 0 0 0 0 0 0 0 0 2 2 1 4 7 4 9 C56 Jajčnik M – – – – – – – – – – – – – – – – – – Ovary Ž 117 0 0 0 0 0 0 0 1 1 6 8 11 13 13 22 18 24 C57 Drugi in neopredeljeni ženski spolni organi M – – – – – – – – – – – – – – – – – – Other and unspecified parts of female genital organs Ž 5 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 3 C58 Posteljica M – – – – – – – – – – – – – – – – – – Placenta Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C60 Penis M 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 Penis Ž – – – – – – – – – – – – – – – – – – C61 Prostata M 305 1 0 0 0 1 0 0 0 0 0 1 2 20 30 49 77 124 Prostate Ž – – – – – – – – – – – – – – – – – – C62 Modo M 6 0 0 0 0 1 1 3 0 0 1 0 0 0 0 0 0 0 Testis Ž – – – – – – – – – – – – – – – – – – C63 Drugi in neopredeljeni moški spolni organi M 4 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 2 Other and unspecified male genital organs Ž – – – – – – – – – – – – – – – – – – C64 Ledvica razen meha M 86 0 0 0 0 0 0 0 0 3 1 3 9 15 11 18 15 11 Kidney, except renal pelvis Ž 49 0 0 0 0 0 0 0 0 0 2 3 4 2 8 8 10 12 C65 Ledvični meh M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Renal pelvis Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 0 C66 Sečevod M 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Ureter Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C67 Sečni mehur M 107 0 0 0 0 0 0 0 1 0 2 3 5 10 13 13 28 32 Bladder Ž 49 0 0 0 0 0 0 0 0 0 0 0 3 1 3 8 11 23 C68 Drugi in neopredeljeni sečni organi M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Other and unspecified urinary organs Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C69 Oko in očesni adneksi M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Eye and adnexa Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C70 Meninge M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 Meninges Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 C71 Možgani M 58 1 0 1 1 0 1 0 1 3 5 11 6 6 7 8 7 0 Brain Ž 60 1 0 0 0 0 0 1 0 4 2 3 8 8 5 12 10 6 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS M 3 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 Spinal cord, cranial nerves and other parts of CNS Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 C73 Ščitnica M 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 Thyroid gland Ž 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 2 3 C74 Nadledvična žleza M 7 0 0 0 0 0 0 0 1 0 0 1 1 1 1 2 0 0 Adrenal gland Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 C75 Druge endokrine žleze in sorodne strukture M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other endocrine glands and related structures Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 C76 Druga in slabo opredelje- na mesta M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Other and ill-defined sites Ž 15 0 0 0 0 0 0 0 0 0 1 1 0 0 0 3 2 8 Tabela 11. – Table 11. Nadaljevanje – Continued Šifra MKB Primarna lokacija Spol Vse starosti S t a r o s t ICD Primary site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 Cancer incidence in Slovenia 2005 75 Institute of Oncology Ljubljana, Cancer Registry of Slovenia C77 Metastaza in neoprede- ljena maligna neoplaz- ma bezgavk M 4 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 Metastasis and unspeci- fied malignant neoplasm of lymph nodes Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C78 Metastaze dihal in prebavil M 28 0 0 0 0 0 0 0 0 0 1 2 4 0 3 4 7 7 Metastases of respiratory and digestive organs Ž 32 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 6 22 C79 Metastaze, drugje M 5 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 0 Metastases of other sites Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 C80 Maligna neoplazma brez opredeljenega mesta M 45 0 0 0 0 0 0 0 1 1 2 2 7 7 8 5 7 5 Malignant neoplasm with- out specification of site Ž 49 0 0 0 0 0 0 1 0 1 0 4 3 3 4 7 6 20 C81 Hodgkinova bolezen M 4 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 1 Hodgkin’s disease Ž 6 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 1 2 C82 Folikularni ne-Hodgkinov limfom M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 Follicular non-Hodgkin’s lymphoma Ž 5 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 1 1 C83 Difuzni ne-Hodgkinov limfom M 7 0 0 0 1 0 0 0 0 0 0 0 1 0 1 2 2 0 Diffuse non-Hodgkin’s lymphoma Ž 10 0 0 0 0 0 0 0 1 0 0 0 0 3 0 1 3 2 C84 Limfomi celic T in kožni limfom celic T M 3 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 0 Peripheral and cutane- ous T-cell lymphomas Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma M 48 0 0 0 1 0 0 0 0 1 1 2 8 2 4 8 9 12 Other and unspecified types of non-Hodgkin’s lymphoma Ž 37 0 0 0 0 0 0 0 1 0 0 1 4 4 6 4 1 16 C88 Maligne imunoprolife-ra- tivne bolezni M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant immunoproli- ferative diseases Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 C90 Difuzni plazmocitom in maligne neoplazme plazmocitov M 35 0 0 0 0 0 0 0 0 1 2 1 1 2 2 9 8 9 Multiple myeloma and malignant plasma cell neoplasms Ž 40 0 0 0 0 0 0 0 0 0 1 2 3 1 2 9 8 14 C91 Limfatična levkemija M 27 0 0 0 0 0 1 0 0 0 0 2 3 3 3 3 7 5 Lymphoid leukaemia Ž 22 0 1 2 0 0 1 0 0 0 0 0 0 3 3 2 1 9 C92 Mieloična levkemija M 36 0 0 0 1 0 1 2 1 2 1 3 0 4 7 7 1 6 Myeloid leukaemia Ž 26 0 0 0 1 0 0 0 1 0 0 1 2 2 4 4 5 6 C93 Monocitna levkemija M 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 Monocytic leukaemia Ž 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 C94 Druge opredeljene levkemije M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Other leukaemias of specified cells Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C95 Levkemija z neoprede- ljenim celičnim tipom M 4 0 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 1 Leukaemia, unspecified cell type Ž 9 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 6 Tabela 11. – Table 11. Nadaljevanje – Continued Šifra MKB Primarna lokacija Spol Vse starosti S t a r o s t ICD Primary site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ nadaljevanje / cont’d 4 76 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo Tabela 11. – Table 11. Nadaljevanje – Continued Šifra MKB Primarna lokacija Spol Vse starosti S t a r o s t ICD Primary site Sex All A g e code ages 0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+ C96 Druge in neopredeljene maligne neoplazme limfatičnega, krvotvorne- ga in sorodnega tkiva M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other & unspecified malignant neoplasms of lymphoid, haemopoetic & related tissues Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 C97 Maligne neoplazme na več neodvisnih (primarnih) mestih M 22 0 0 0 0 0 0 0 0 0 1 2 0 1 1 4 6 7 Malignant neoplasms of independant (primary) multiple sites Ž 17 0 0 0 0 0 0 0 0 1 1 0 1 2 1 4 2 5 Zgoraj neupoštevani Not includede above D32 Meninge, benigna neopalzma M 3 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0 Benign neoplasm of meninges Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 D33 CŽS, benigna neoplazma M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Benign neoplasm of brain and other parts of CNS Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 D43 CŽS, neopredeljeno M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 CNS, uncertain or un- known Ž 7 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 2 2 * Vir: Inštitut za varovanje zdravja * Source: Institute of Public Health Cancer incidence in Slovenia 2005 77 Institute of Oncology Ljubljana, Cancer Registry of Slovenia Tabela 12. Prevalenca po spolu in izbrani primarni lokaciji – Slovenija, 31. 12. 2005 Table 12. Prevalence of cancer patients by sex and by selected primary site – Slovenia, December 31, 2005 Šifra MKB Primarna lokacija Skupaj Moški Ženske ICD code Primary site Total Males Females C00 – C96 Vse lokacije All sites 63561 25550 38011 C00– C14 Usta in žrelo Mouth and pharynx 1778 1326 452 C15 Požiralnik 125 100 25Oesophagus C16 Želodec 1623 937 686Stomach C18 Debelo črevo 3383 1718 1665Colon C19– C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 2824 1562 1262 C22 Jetra in intrahepatični vodi 110 78 32Liver and intrahepatic bile ducts C23– Žolčnik in žolčevodi 181 84 97C24 Gallbladder and billiary tract C25 Trebušna slinavka 203 95 108Pancreas C32 Grlo 882 785 97Larynx C33– Sapnik, sapnici in pljuča 1878 1409 469C34 Trachea, bronchus and lung C43 Maligni melanom kože 2688 1063 1625Malignant melanoma of skin C44 Druge maligne neoplazme kože 13266 6010 7256Skin, other malignomas C48– Vezivno in mehko tkivo 558 260 298C49 Connective and soft tissue C50 Dojka 10370 73 10297Breast C53 Maternični vrat 3532 – 3532Cervix uteri C54 Maternično telo 3465 – 3465Corpus uteri C56 Jajčnik 1319 – 1319Ovary C61 Prostata 3443 3443 –Prostate C62 Modo 1433 1433 –Testis C64– Ledvica z ledvičnim mehom 1538 889 649 C65 Kidney with renal pelvis C67 Sečni mehur 1191 905 286 Bladder C70– Centralni in avtonomni živčni sistem 532 301 231 C72 Central and autonomic nervous system C73 Ščitnica 1232 268 964 Thyroid gland C81 Hodgkinova bolezen 788 420 368 Hodgkin’s disease C82– ne-Hodgkinovi limfomi 1600 790 810 C85 non-Hodgkin’s lymphoma C90 Difuzni plazmocitom in maligne neoplazme plazmocitov 285 134 151 Multiple myeloma and malignant plasma cell neoplasms C91– Levkemije 1028 535 493 C95 Leukaemias 78 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci) SELECTED PUBLICATIONS, published by the members of Epidemiology and Can- cer Registry in the last five years (also in cooperation with other researchers) 2003 – Benedičič Pilih A, Pompe Kirn V, Kokol P, Povalej P, Arzenšek J. Kožni melanom v Sloveniji in potreba po preventivi. In: Miljković J ed. Dermatološki dnevi. Stro- kovno izpopolnjevanje iz dermatologije z medna- rodno udeležbo, Maribor 2003. Maribor: Splošna bolnišnica, 2003: 27–37. – Berrino F, Capocaccia R, Gatta G, et al, eds. Survi- val of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003; 14(5). – Lutz JM, Francisci S, Pompe-Kirn V, et al and EU- ROPREVAL Working Group. Cancer prevalence in Central Europe: the EUROPREVAL study. Ann Oncol 2003; 14(2): 313–22. – Pompe-Kirn V. Rak v številkah : da bi ga bolje razu- meli in lažje obvladovali. Okno 2003; 17(1): 27–9. – Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997. Ljubljana: Onkološki inšti tut, Register raka za Slovenijo, 2003. – Primic Žakelj M, Arko D, Rener M, Žgajnar J. Rak dojk v Sloveniji: epidemiologija in presejanje. Zdrav Vestn 2003; 72: Suppl 2: II–179–II–181. – Primic Žakelj M, Zadnik V. Epidemiologija raka dojk. In: Takač I, Arko D eds. 30 let Centra za bolezni dojk v Mariboru. Simpozij z mednarodno udeležbo, Maribor 2003. Zbornik predavanj. Maribor: Splošna bolnišnica, 2003: 15–27. – Primic Žakelj M, Zadnik V. Rak dojk: razširjenost in nevarnostni dejavniki.In: Štabuc B, ed. Več znanja o raku, manj smrti. Seminar, Strunjan 2003. Ljubljana; Koper: Zveza slovenskih društev za boj proti raku; Obalno društvo za boj proti raku, 2003: 55–63. – Primic Žakelj M, Zadnik V. Staranje prebivalstva in rak. In: Skela Savič B ed. Starost in rak. 30 strokovni seminar, Ljubljana 2003. Ljubljana: Sekcija medicin- skih sester v onkologiji pri Zbornici zdravstvene nege – Zvezi društev medicinskih sester in zdravstvenih tehnikov Slovenije, 2003: 5–11. – Uršič Vrščaj M, Primic Žakelj M, Kirar Fazarinc I. Epidemiologija raka materničnega vratu v Sloveniji in v svetu ter nacionalni program ZORA. In: Možina A, ed. Zgodnja detekcija raka materničnega vratu in kolposkopski tečaj in Praktična kolposkopija in ambulantno zdravljenje prekanceroze, Ljubljana 2003. Zbornik predavanj. Ljubljana: Klinični center; Ginekološka klinika; Združenje za ginekološko onko- logijo, kolposkopijo in cervikalno patologijo, 2003: 92–5. – Zadnik V, Šelb J: Osnovni vzroki smrti s kazalniki umrljivosti v Sloveniji v letu 2001. Zdrav Vestn 2003; 72(7–8): 429–4. 2004 – de Vries E, Boniol M, Dore JF, Coebergh JW, Pompe- Kirn V and Eurocare Working Group. Lower inciden- ce rates but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe. Eur J Cancer 2004; 40: 1045–52. – Norčič G, Repše S, Pompe-Kirn V. Rezultati zdravljenja raka debelega črevesa in danke v Sloveniji – analiza leta 1997. Gastroenterolog 2004; 8: Suppl 2: 287–9. – Primic Žakelj M, Kirar Fazarinc I. Cervical cancer screening – a Slovenian experience. In: Better healt h outcomes through public health approaches in primary health care. Fourth international forum on common access to health care. Brdo pri Kranju: Mi- nistry of Health, 2004: 1–5. – Primic Žakelj M, Ravnihar B and Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007–16. – Primic Žakelj M, Zadnik V. Kajenje in rak v Sloveniji. In: Štabuc B, Primic Žakelj M, Zdešar A eds. Kajenje in rak. 12. seminar »In memoriam dr. Dušana Reje«. Ljubljana: Zveza slovenskih društev za boj proti raku, Onkološki inštitut, Inštitut za varovanje zdravja RS, Rdeči križ Slovenije, 2004: 36–42. – Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v svetu in v Sloveniji. Radiol Oncol 2004; 38: Suppl 1: S1–S7. – Primic Žakelj M, Zadnik V, Škrlec F. Nekaj osnovnih podatkov in zanimivosti iz novega letnega poročila Registra raka za Slovenijo. Onkologija 2004; 8: 22–4. – Tyczynski JE, Bray F, Pompe-Kirn V, et al. Lung cancer mortality patterns in selected Central Eastern and Southern European countries. Int J Cancer 2004; 109: 598–610. Cancer incidence in Slovenia 2005 79 Institute of Oncology Ljubljana, Cancer Registry of Slovenia – Tyczynski JE, Pleško I, Primic Žakelj M, et al. Breast can- cer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer 2004; 112: 1056–64. – Zadnik V, Primic Žakelj M. Vpliv dejavnikov tveganja in genetske nagnjenosti na pojavljanje raka dojk pri mladih ženskah. In: Bešić N, Anderluh F, Benedik J et al eds. Novosti v onkologiji in smernice za obravna- vo bolnic z rakom dojk in bolnikov z malignim mela- nomom. 17. onkološki vikend. Laško: Kancerološko združenje Slovenskega zdravniškega društva, 2004: 114–5. 2005 – Bray F, Carstensen B, Moller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence trends of adenocarci- noma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005; 14: 2191–9. – Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tra- cey E, Pompe-Kirn V, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93: 159–66. – Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tra- cey E, AndersenA, Pompe-Kirn V, et al. Second pri- mary malignancies in patients with male breast can- cer. Br J Cancer 2005; 92: 1288–92. – Kobal AB, Horvat M, Prezelj M, Pompe-Kirn V, Zadnik V, Osredkar J, et al. Vpliv elementarnega živega sre- bra na peroksidacijo lipidov in funkcijsko sposobnost posameznih tarčnih organov pri prebivalcih mesta Idrija in delavcih rudnika : zaključno poročilo razisko- valnega projekta (skrajšana verzija). Idrij Razgl 2005; 50: 20–30. – Norčič G, Repše S, Pompe-Kirn V. Rak debelega črevesa in danke v Sloveniji – razlike v kirurškem zdrav ljenju in preživetju bolnikov. Zdrav vestn 2005; 74: št. 12, 767–70. – Pompe-Kirn V. Podrobnejši pregled trenda incidence raka ščitnice v obdobju 1983–2002 v Sloveniji. Onko- logija 2005; 9: 12–4. – Primic Žakelj M. Epidemiology of breast cancer: inci- dence and mortality trends, prevention and control. 3rd Sarajevo breast cancer conference. Sarajevo: ESO, 2005: 15–27. – Primic Žakelj M. Prenovljeni evropski kodeks proti raku. In: Štabuc B, ed. Poročilo Zveze in regijskih društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 6–11. – Primic Žakelj M. Zgodnje odkrivanje pogostejših rakov pri starejših. In: Turk J, ed. Zdrava poznejša leta. Ljubljana: Društvo za zdravje srca in ožilja Slovenije, 2005: 97–110. – Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v Sloveniji in v svetu. In: Štabuc B, ed. Poročilo Zveze in regijskih društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 13–6. – Primic Žakelj M, Zadnik V. Presejanje in zgodnje odkri- vanje raka. In: Štabuc B, ed. Zgodnje odkrivanje raka – izzivi za prihodnost. XIII. seminar »In memoriam dr. Dušana Reje«, Zbornik. Ljubljana: Zveza slovenskih društev za boj proti raku, 2005: 8–13. – Primic Žakelj, Zadnik V. Raziskovalno delo službe epi- demiologija in registri raka na Onkološkem inštitutu. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 125–34. – Primic Žakelj, Zadnik V, Žagar T. Epidemiološki podat- ki o raku materničnega vratu v Sloveniji. In: Takač I, ed. 50 let laboratorija za ginekološko citologijo v Mariboru. Mednarodni znanstveni simpozij. Maribor: Splošna bolnišnica, 2005: 151–60. – Primic-Žakelj M, Zadnik V, Žagar T. Is cancer epide- miology different in Western Europe to that in Eastern Europe? Ann Oncol 2005; 16 Suppl 2: ii 27–9. – Zadnik V: Evropska raziskava vplivov dejavnikov tveganja na zbolevanje za rakom dojk pri mla- dih ženskah: podatki za Slovenijo. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 135–49. – Zadnik V, Primic Žakelj M. Epidemiologija želodčnega raka. In: Omejc M, Repše S, eds: Kirurgija želodca – standardi in novosti. Simpozij. Ljubljana: Klinični od- delek za abdominalno kirurgijo, SPS Kirurška klinika, Klinični center, 2005: 122–7. – Žagar T, Primic Žakelj, Zadnik V. Povezovanje Registra raka za Slovenijo s sorodnimi državnimi podatkov- nimi zbirkami. In: Tkačik B, Urbas M, eds. Komunici- ranje z dajalci in uporabniki statističnih podatkov ter podpora EMU in Lizbonski strategiji. 15. statistični dnevi. Ljubljana: Statistični urad Republike Slovenije, Statistično društvo Slovenije, 2005: 268–77. – Žagar T. Lifetables for Slovenia 1982–2004. Rostock: Max Planck, 2005: 1–94. http://www.lifetable.de/cgi- bin/country.plx?country=Slovenia. 2006 – Hertl K, Primic Žakelj M, Žgajnar J, Kocijančič I. Perfor- mance of opportunistic breast cancer screening in Slovenia. Neoplasma 2006; 53: 237–41. 80 Incidenca raka v Sloveniji 2005 Onkološki inštitut Ljubljana, Register raka za Slovenijo – Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second can- cer among women with breast cancer. Int J Cancer 2006; 118: 2285–92. – Pompe-Kirn V, Primic Žakelj M. Ali vemo, koliko je raka prostate v Sloveniji in kaj vpliva na razvoj te bolezni? Onkologija 2006; 10: 9–13. – Pompe-Kirn V. Obolevnost za rakom dojk med žen- skami, vključenimi v pilotno študijo. Onkologija 2006; 10: 96–8. – Primic Žakelj M, Zadnik V, Žagar T. Breast cancer risk factors. Liječ Vjesn 2006; 128, Suppl 3: 49–50. – Primic Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke (Epidemiology of colorectal cancer. In: Repše S, Štor Z eds. Kirurgija raka debelega črevesa in danke: standardi in novo- sti. Zbornik simpozija (Standards & novelties: proceed- ings of the symposium, Ljubljana 2006. Ljubljana: Kirurška šola, Klinični oddelek za abdominalno kirur- gijo, Kirurška klinika, Klinični center, 2006: 14–20. – Primic Žakelj M, Zadnik V, Žagar T. Ali se učinki pro- grama ZORA že kažejo v incidenci invazijskega raka materničnega vratu. In: Možina A ed. Dan ginekološke onkologije: rak jajčnikov. Zbornik. Ljub- ljana: Združenje za ginekološko onkologijo, kolpo- skopijo in cervikalno patologijo: Ginekološka klinika, Klinični center, 2006: 55–6. – Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Pompe-Kirn V, et al. Second primary cancers in thyroid cancer patients : a multi- national record linkage study. J Clin Endocrinol Me- tab 2006; 91: 1819 25. – Scélo G, Boffetta P, Hemminki K, Pukala E, Olsen JH, Andersen A, Pompe-Kirn V, et al. Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer 2006; 118: 189–96. – Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, Pompe-Kirn V, et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 2006; 163: 502 11. – Snoj M, Zadnik V. Starostnik z rakom – kirurški bolnik. In: Smrkolj V ed. Kirurgija v starostnem obdobju : zbor- nik povzetkov. Ljubljana: Združenje kirurgov Slovenije, 2006: 28–36. – Strojan P, Šmid A, Čizmarevič B, Žagar T, Auersperg M. Verrucous carcinoma of the larynx : determining the best treatment option. Eur J Surg Oncol 2006; 32: 984–8. – Steliarova-Foucher E, Kaatsch P, Lacour B, Pompe-Kirn V, Eser S, Miranda A, et al. Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978–1997) : report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42: 1915–51. – Zadnik V, Primic Žakelj M. Breme želodčnega raka v svetu in Sloveniji (The burden of stomach cancer worldwide and in Slovenia). In: Zbornik predavanj XII. podiplomskega tečaja kirurgije, 10.–11. februar 2006. Ljubljana: Kirurška klinika, Klinični center, 2006: 77–80. – Zadnik V, Reich BJ. Analysis of the relationship between socioeconomic factors and stomach cancer inci- dence in Slovenia. Neoplasma 2006; 53: 103–10. – Zadnik V. Geografska analiza razporejanja inciden- ce raka. Onkologija 2006; 10: 92–5. – Zadnik V, Žagar T, Primic Žakelj M. Pojavljanje raka v občini Brežice v primerjavi z ostalo Slovenijo : geo- grafska analiza incidence raka v občini Brežice na podlagi podatkov Registra raka za Slovenijo : zaključno poročilo. Ljubljana: Onkološki inštitut, 2006. – Zadnik V, Žagar T, Primic Žakelj M. The geographical variation of cervical cancer screening efficiency in Slovenia. In: Batagelj V, Ferligoj A, Žiberna A eds. Data science and classification : program and abstracts. Ljubljana: Center of Methodology and Informatics, Institute of Social Sciences at Faculty of Social Scien- ces, 2006: 173. – Žagar T, Primic Žakelj M, Zadnik V. Pretok in uporaba informacij v Registru raka – najstarejšem zdravstve- nem registru v Sloveniji. Bilt ekon organ inform zdrav 2006; 22: 6. – Žagar T, Zadnik V, Pohar M, Primic Žakelj M. Complete yearly life tables by sex for Slovenia, 1982–2004, and their use in public health [Popolne letne tablice umr- ljivosti za Slovenijo po spolu, 1982–2004, in možnosti uporabe v javnem zdravju]. Radiol Oncol 2006; 40: 115–24. 2007 – Arbyn M, Primic-Žakelj M, Raifu AO, Grce M, Paraske- vaidis E, Diakomanolis E, et al. The burden of cervical cancer in South-East Europe at the beginning of the 21st century. Coll Antropol 2007; 31 Suppl 2: 7–10. – Bidoli E, Zadnik V, De Dottori M, Zanier L, Serraino D. Prostate cancer pattern in the bordering areas of Friuli-Venezia Giulia, Italy, and Slovenia, 1995–2003. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At the cros- sroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control : programme and book of abstracts. Ljublja- na: Institute of Oncology, 2007. Cancer incidence in Slovenia 2005 81 Institute of Oncology Ljubljana, Cancer Registry of Slovenia – Bizjak-Ogrinc U, Čufer T, Pompe-Kirn V. Survival of pa- tients with invasive urinary bladder cancer in Slove- nia regarding to stage of disease and treatment in years 1987–1997. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At the crossroad of tradition and new tech- nologies in cancer registration. The role of cancer registries in cancer control : programme and book of abstracts. Ljubljana: Institute of Oncology, 2007. – Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second ma- lignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst 2007; 10: 790–800. – Primic-Žakelj M. Epidemiologija raka pri moških in ženskah. In: Mlakar-Mastnak D, Lokar K, eds. Ženske, moški in rak. Ljubljana: Sekcija medicinskih sester in zdra- vstvenih tehnikov v onkologiji pri Zbornici zdrav stvene in babiške nege Slovenije – Zvezi društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije; 2007. – Primic-Žakelj M. Obvladovanje raka v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. sloven- ski kongres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju : knjiga izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007. – Primic-Žakelj M. Rak materničnega vratu v Sloveniji in program ZORA. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju : knjiga izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007. – Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. Zdrav Vest 2007; 76: 775–80. – Primic-Žakelj M, Žagar T. Breast cancer epidemiolo- gy in Slovenia. Senologie 2007; 4: 205. – Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija malignega melanoma. Radiol Oncol 2007; 41 Suppl 1: S1–S12. – Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija pljučnega raka. In: Rott T, Luzar B, eds. Pljučni rak – današnje stanje in perspektive. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2007. – Ravnik M, Arko D, Žagar T, Primic-Žakelj M, Čufer T. Breast cancer and second malignancies. Senologie 2007; 4: 209. – Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V, et al. Second malignan- cies among survivors of germ-cell testicular cancer : a pooled analysis between 13 cancer registries. Int J Cancer 2007; 120: 623–31. – Riska A, Pukkala E, Scélo G, Mellemkjaer L, Hemminki K, Weiderpass E, Pompe-Kirn V, et al. Second primary malignancies in females with primary fallopian tube cancer. Int J Cancer 2007; 120: 2047–51. – Scélo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V. Associations between ocu- lar melanoma and other primary cancers : an inter- national population-based study. Int J Cancer 2007; 120: 152–9. – Scélo G, Boffetta P, Corbex M, Chia KS, Hemminki K, Friis S, Pompe-Kirn V, et al. Second primary cancers in patients with nasopharyngeal carcinoma : a pooled analysis of 13 cancer registries. Cancer Causes Con- trol 2007; 18: 269–78. – Tuohimaa P, Pukkala E, Scélo G, Olsen JH, Brewster DH, Hemminki K, Pompe-Kirn V, et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer 2007; 43: 1701–12. – Zadnik V, Pompe-Kirn V. Effects of 500-year mercury mining and milling on cancer incidence in the re- gion of Idrija, Slovenia. Coll Antropol 2007; 31: 897– 903. – Zver S, Zadnik V, Bunc M, Rogel P, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autolo- gous hematopoietic stem cell transplantation. Int J Hematol 2007; 85: 408–14. – Žagar T, Droljc A. Connection of Cancer Registry of Slovenia to other state databases. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control : program- me and book of abstracts. Ljubljana: Institute of On- cology, 2007. – Žagar T, Zadnik V, Primic-Žakelj M. Različne možnosti prikazovanja geografskega razporejanja incidence raka na materničnem vratu v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kon- gres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju : knjiga izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.